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Abstract 
Psittacine beak and feather disease (PBFD), the most prevalent viral disease affecting psittacines, is 
caused by beak and feather disease virus (BFDV). An outbreak of the disease has been reported in 
wild endangered Cape parrots (Poicephalus robustus), which is endemic to South Africa. No 
treatment or vaccine is commercially available. In this study, an investigation into the outbreak was 
undertaken. BFDV diversity was assessed and viral load and clinical signs correlated. A plant-
produced BFDV subunit vaccine was produced in parallel with a corresponding challenge model. 
Cape parrots were assessed and 53 blood samples collected. Viral load was determined using 
quantitative real-time PCR (qPCR), and 22 BFDV full-length genome sequences acquired to infer 
phylogenetic relatedness. The capsid gene (cp) was optimised for transient Agrobacterium-mediated 
expression in whole-plant Nicotiana benthamiana (N. benthamiana). Virus-like particles (VLPs) were 
purified and analysed using transmission electron microscopy. Virions from a Palm cockatoo 
(Probosciger aterrimus) were purified and a BFDV dsDNA molecular clone was synthesised and 
replication assessed in 293TT mammalian cells and N. benthamiana using rolling circle replication 
and qPCR. 
Two distinct BFDV phylogenetic clusters were reported for Cape parrots, and a direct correlation was 
seen between viral load in the blood and clinical signs in PBFD-afflicted birds. The CP was 
successfully expressed in N. benthamiana, and increased through optimisation of Agrobacterium 
infiltration density and the inclusion of the NSs silencing suppressor. The CP formed VLPs, which 
were shown to be morphologically similar to infectious virions. The dsDNA molecular clone was 
shown to replicate autonomously in mammalian 293TT cells, and in plants with the assistance of the 
Bean yellow dwarf virus replication associated protein (Rep). 
BFDV genetic diversity in Cape parrots highlights the importance of ensuring new strains are not 
inadvertently introduced into the wild. This is the first systematic investigation of virus diversity in 
Cape parrots and assessment of BFDV viral load in a wild psittacine population. The CP was 
successfully produced in planta and presence of VLPs suggests the possibility of developing 
pseudovirions. This is the first reported replication of BFDV in tissue culture, and will greatly expand 
the scope of available research. 
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Chapter 1: Literature Review 
1.1. Introduction 
Psittacines, which are more commonly known as parrots, belong to the family Psittacidae, which 
consists of 85 genera and 356 species. At present almost 30% of psittacine species are threatened 
with extinction due to the loss of habitat, persecution as crop pests and illegal capture for the wild-
caught bird trade; this is further exacerbated by disease (BirdLife International, 2013; Boyes, 2011). 
Population decline as a result of genetic bottlenecks decreases the immunocompetence of the 
population, thus increasing the risk of infection (Varsani et al., 2010). A four year study of wild 
Sulphur-crested cockatoos (Cacatua galerita) in Australia showed a decline in population which was 
in part caused by disease (McOrist et al., 1984). Infectious disease can result in extinction if it is 
introduced to a naive host species, if the pre-epidemic population is small, or the pathogen has 
abiotic or biotic reservoirs (Peters et al., 2014). 
Beak and feather disease virus (BFDV; family Circoviridae, genus Circovirus) is one of the most 
common disease organisms to infect psittacines. The virus infects both wild and captive birds, and 
has been detected in at least 10% of species (Ortiz-Catedral et al., 2009; Rahaus and Wolff, 2003). 
The earliest description of the disease was reported in 1907, affecting Psephotus melanogaster in 
Australia (De Kloet and De Kloet, 2004). 
Since then, BFDV has been rapidly disseminated around the world through the international trade in 
wild-caught birds (Doneley, 2003; Hsu et al., 2006). Of particular concern to breeders is the spread of 
disease amongst captive birds, as aviaries often experience a high turnover and more than one 
species can share a small enclosure, which is an ideal environment for viral transmission (Bert et al., 
2005; Rahaus and Wolff, 2003; Shearer et al., 2008a). It has also threatened conservation efforts of 
wild psittacines (Kundu et al., 2012; Peters et al., 2014). It has been postulated that the convergence 
of multiple species and virus strains in breeding facilities could result in the emergence of high 
virulence genotypes (Varsani et al., 2010). 
In South Africa the virus is a significant cause of mortality and has resulted in an annual loss of 
between 10-20% of psittacine breeding stocks (Albertyn et al., 2004; Heath et al., 2004). The virus 
also threatens indigenous African wild populations such as the endangered South African Cape 
parrot and the vulnerable Zambian Black-cheeked lovebirds (Agapornis nigrigenis) (Heath et al., 
2004).  
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1.2. Beak and feather disease virus 
The prevalence of BFDV is widespread and can be detected anywhere psittacines are traded 
(Albertyn et al., 2004; Kiatipattanasakul-Banlunara et al., 2002; Varsani et al., 2010) (Table 1.1). 
Table 1.1: Reported prevalence of BFDV. 
Africa Cameroon Bert et al. (2005) 
 Ivory Coast Bert et al. (2005) 
 Mauritius Kundu et al. (2012) 
 South Africa Heath et al. (2004) 
 Zambia Warburton and Perrin (2002) 
 Zimbabwe Kock (1990) 
Americas Costa Rica Dolz et al. (2013) 
 United States of America Bert et al. (2005) 
Asia-Pacific Australia Shearer et al. (2008a) 
 Indonesia Stewart et al. (2007) 
 Japan Sanada et al. (1999) 
 New Caledonia Julian et al. (2012) 
 New Zealand Ha et al. (2007) 
 Papua New Guinea Shearer et al. (2008a) 
 Thailand Katoh et al. (2010a) 
 Taiwan Hsu et al. (2006) 
Europe and the Middle East Germany Rahaus and Wolff (2003) 
 Israel Bendheim et al. (2006) 
 Italy Bert et al. (2005) 
 Netherlands Tomasek and Tukac (2007) 
 Poland Julian et al. (2013) 
 Portugal Henriques et al. (2010) 
 Qatar Raue et al. (2004) 
 Spain Raue et al. (2004) 
 United Kingdom Sa et al. (2014) 
 
1.2.1. Circoviridae 
The species Beak and feather disease virus belongs to the family Circoviridae, which consists of three 
genera: these are Gyrovirus, Circovirus and the proposed Cyclovirus (Li et al., 2011; Rahaus et al., 
2008; Todd et al., 2001). A novel circo-like genus tentatively called Krikovirus has recently been 
described (Garigliany et al., 2014). Viruses within the family are the smallest known animal viruses 
and are characterised by having small isometric virions, consisting of a single capsid protein, 
containing circular ssDNA genomes which replicate via intermediate dsDNA forms (Cheung, 2006; 
Studdert, 1993). Genera are differentiated according to their genome organisation (Crowther et al., 
2003). Viruses in the genus Gyrovirus are represented by the type species Chicken anaemia virus. 
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They differ from generic circoviruses in having a negative sense circular ssDNA genome which 
produces a single polycistronic unspliced transcript and a virion that is different in size and 
morphology (Mahé et al., 2000; Todd et al., 2007). Viruses in genus Circovirus have non-enveloped 
icosahedral virions which protect an ambisense circular ssDNA genome (Scott et al., 2006). Viral 
replication is initiated within a conserved nonanucleotide motif (5ʹ-TAGTATTAC-3ʹ) situated on a 
stem-loop within the origin of replication (ori)(Mankertz et al., 1998). Adjacent and within this stem-
loop structure are direct repeat sequences which are potential binding sites for the replication-
associated protein (Rep)(Todd et al., 2001). The numbering of the genome is based on that agreed 
for geminiviruses, in which the first nucleotide position of the genome is the adenine residue at the 
eighth position of the nonanucleotide motif (5ʹ-TAGTATT/AC-3ʹ)(Meehan et al., 1997; Todd et al., 
1991). 
Circoviruses have restricted host ranges and it has been suggested that this may be due to the lack 
of transmission vectors (Niagro et al., 1998; Todd, 2004). The viruses are associated with major 
diseases and often target the lymphoreticular tissue resulting in immunosuppression (Hattermann et 
al., 2002). It is within this genus that the smallest known autonomously replicating virus resides 
(Duchatel et al., 2006). The type species is Porcine circovirus and was first identified as a 
contaminant in a porcine kidney 15 (PK-15) cell line (Karuppannan and Kwang, 2011; Mahé et al., 
2000). Two types have been identified: these are porcine circovirus 1 (PCV-1), which is non-
pathogenic, and PCV-2, which is associated with postweaning multisystemic wasting syndrome in 
piglets (Karuppannan and Kwang, 2011; Studdert, 1993). A third type, PCV-1/2a, which is a 
recombinant between PCV-1 and PCV-2 has also been described (Gagnon et al., 2010). The disease is 
of significant economic importance and can be linked to a greater than 50% mortality in piglets 
(Gillespie et al., 2008). 
The PCV virion is approximately 17 nm in diameter and contains a 1.76-kb genome (Gillespie et al., 
2008; Mankertz et al., 2000a). In addition to Rep, replication is furthermore dependent on splicing of 
the rep to produce Repʹ which is essential in mammalian cells; replication in bacteria however does 
not require Repʹ and suggests that the virus possibly evolved from bacterial episomal replicons 
(Cheung, 2006). New sequencing technologies and enrichment techniques have increased the rate of 
discovery of these viruses, with Li et al. (2013) for example having recently described a dog 
circovirus. Numerous circoviruses have been discovered affecting non-psittacine avian species; these 
cluster into a monophyletic group (Hughes and Piontkivska, 2008)(Table 1.2). Recently symptoms 
similar to those described for BFDV have been reported in Antarctic penguins; however, the 
causative agent has yet to be identified (Barbosa et al., 2015). 
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A number of circoviruses and circo-like viruses have been identified in humans, though there is as 
yet very little known about them as they were largely identified by metagenomic screening methods 
(Li et al., 2010). A better characterised group are the anelloviruses (family Anelloviridae, 11 genera) 
such as the human torque teno virus 1a (TTV-1a) and swine torque teno sus virus (TTSuV) (Jiménez-
Melsió et al., 2013). 
Table 1.2 Circoviruses infecting non-psittacine avian species and reported potential hosts. 
Budgerigar circovirus Varsani et al. (2011) 
Canary circovirus Phenix et al. (2001) 
Duck circovirus Hattermann et al. (2003) 
Finch circovirus Todd et al. (2007) 
Goose circovirus Soike et al. (1999) 
Gull circovirus Todd et al. (2007) 
Pigeon circovirus Mankertz et al. (2000b), Todd et al. (2001) 
Raven circovirus Todd et al. (2007) 
Starling circovirus Johne et al. (2006) 
Swan circovirus Studdert (1993) 
Ostrich Eisenberg et al. (2003) 
Penguin Barbosa et al. (2015) 
 
Three plant virus species were originally included in genus Circovirus: these were Banana bunchy top 
virus, Coconut foliar decay virus and Subterranean clover stunt virus (Fenaux et al., 2003). However, 
these viruses have previously been described as having multipartite genomes and were reclassified 
as members of the family Nanoviridae on the master species list of 2012 by the International 
Committee on Taxonomy of Viruses (ICTV). The geographic distribution of these plant viruses 
compared to that of circoviruses suggest a possible common ancestor (Niagro et al., 1998). The 
origin of circoviruses has been speculated to be through recombination between a ssRNA calicivirus 
and a ssDNA nanovirus, as circoviruses have distant sequence similarities to nanoviruses and 
geminiviruses (Gibbs and Weiller, 1999). 
1.2.2. Virus structure 
BFDV was the first avian Circovirus to be characterised (Ritchie et al., 1989b). The BFDV virion is a 
non-enveloped icosahedral particle of T = 1 symmetry that consists of 60 subunits arranged into 12 
pentameric units (Crowther et al., 2003; Ritchie et al., 1990)(Figure 1.1). When viewed using an 
electron microscope the virion lacks any surface structure, and its appearance is smooth and 
spherical (Crowther et al., 2003; Todd et al., 1991). The virus particles can vary in size depending on 
the staining technique, and Todd et al. (1991) reported that virions stained with uranyl acetate were 
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20% larger than those stained with phosphotungstic acid. The literature reports the size of the virion 
to be on average between 14-20 nm in diameter, with the smallest reported size being 10 nm and 
the largest being 22 nm (Figure 1.2). The range of virion sizes appeared to be independent of 
whether uranyl acetate or phosphotungstic acid was used during the staining procedure. The size 
range of 14-20 nm is similar to the 20.5 nm determined using the three dimensional structure 
determined by cryoelectron microscopy (Crowther et al., 2003). The BFDV virion is small in 
comparison to other psittacine viruses such as avian polyomavirus (40 nm), papovavirus (40-50 nm), 
avian reovirus (75-80 nm), adenovirus (70-90 nm) and herpesvirus (120-200 nm) which are all 
considerably larger (Davis et al., 1981; Gaskin, 1989; Johne and Müller, 1998; Pass, 1987; van den 
Brand et al., 2007). As with other circoviruses, the virion is extremely stable and is capable of 
withstanding heating for 30 minutes at 80 °C, which has important consequences for disinfection 
control (Davidson et al., 2008; Raidal and Cross, 1994b). 
Enclosed within the virion is a circular ssDNA genome of approximately 2 000 nucleotides (Bassami 
et al., 1998)(Figure 1.3A). The genome is ambisense and consists of as many as seven putative open 
reading frames (ORFs); however, only three ORFs have been consistently identified among isolates 
(Bassami et al., 2001; Hsu et al., 2006; Niagro et al., 1998). 
The first ORF found on the virion strand encodes the Rep; however, unlike PCV the alternatively 
spliced Repʹ has not been identified (Bassami et al., 2001; Heath et al., 2006). The Rep is involved in 
the initiation of rolling circle replication (RCR) of the genome, and the gene contains motifs I, II and 
III involved in RCR and common to all Rep (Bassami et al., 1998; Bassami et al., 2001; Todd et al., 
2007). The protein has a specific nucleotide binding motif, which is believed to have helicase and 
topoisomerase activity, that recognises and binds genomic DNA (Niagro et al., 1998). 
 
Figure 1.1: Three dimensional structure for BFDV virions, determined by cryoelectron microscopy from 
Crowther et al. (2003). Reprinted with permission from Dr. RA Crowther. 
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Figure 1.2: Summary of the BFDV virion size as reported by various authors. Sizes were determined from 
electron micrographs of particles stained with either uranyl acetate (black) or phosphotungstic acid (grey). 
The second ORF is found on the complementary strand and encodes the capsid protein (CP) 
(Bassami et al., 2001; Heath et al., 2006). This ORF is unusual in that it has an alternative start codon 
of either TCT or CTG (Bassami et al., 2001; Niagro et al., 1998). Similar alternative start codons have 
been detected in the genome sequences of gull circovirus (GuCV), pigeon circovirus (PiCV) and 
canary circovirus (Phenix et al., 2001; Todd et al., 2008; Todd et al., 2007). The N-terminal region of 
the CP contains nuclear localisation signals (NLSs) together with an overlapping DNA binding region 
which is enriched for basic amino acid residues (Heath et al., 2006). The CP is the sole protein 
constituent of the virion and is also responsible for shuttling the genome and Rep into the nucleus of 
the host cell for RCR (Heath et al., 2006; Nawagitgul et al., 2000; Stewart et al., 2007; Trible et al., 
2011). 
The function of the third ORF has yet to be determined for BFDV; however, in both PCV and chicken 
anaemia virus (CAV) it is associated with apoptosis (Bassami et al., 2001; Heath et al., 2004; 
Karuppannan and Kwang, 2011). Between the rep and cp is the intergenic region which contains a 
stem-loop structure important for the initiation of RCR (Bassami et al., 2001). Downstream of the 
stem-loop is a repeated octanucleotide motif (5ʹ-GGGCACCG-3ʹ) which has been identified as a 
putative Rep binding site (Johne et al., 2006; Todd et al., 2007). The stem-loop itself contains the 
conserved nonanucleotide motif (5ʹ-TAGTATTAC-3ʹ) which is identical to that of PCV-1. The motif 
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which differs slightly in PCV-2 (5ʹ-TAAGTATTAC-3ʹ) has been demonstrated to be critical for 
replication (Cheung, 2004) (Figure 1.3B). The Rep has been shown in the species Banana bunchy top 
virus to bind to the nonanucleotide motif situated on the stem-loop and facilitate DNA nicking and 
ligation (Mankertz et al., 1998). 
 
Figure 1.3: Genome organisation of BFDV. (A) The ambisense circular ssDNA genome consists of the rep (red), 
cp (blue), and a stem-loop structure (*) located in the intergenic region. (B) The stem-loop structure contains 
the nonanucleotide motif (yellow; 5ʹ-TAGTATTAC-3ʹ) from which RCR is initiated by Rep (yellow). 
1.2.3. Viral replication 
Upon entry into the host cell the CP shuttles both the viral genome and the Rep across the nuclear 
membrane; once in the nucleus the virus replicates through RCR (Bassami et al., 1998). Replication is 
dependent on the Rep for initiation and cellular enzymes for DNA polymerisation since the genome 
does not encode for a DNA polymerase (Heath et al., 2006). The current model for RCR in PCV-2 
begins with the conversion of the circular ssDNA genome to a superhelical double stranded DNA 
replicative intermediate. Binding of the Rep to the direct repeat sequences causes a destabilisation 
and unwinding of the DNA at the ori. The Rep then nicks the DNA within the nonanucleotide motif as 
shown (5ʹ-TAAGTATT/AC-3ʹ). The 3ʹ-OH is the site of plus strand DNA replication by cellular enzymes, 
while the Rep remains covalently attached to the 5ʹ end via a tyrosine residue situated in motif III. 
Once the first round of DNA synthesis is completed a second cleavage at the nonanucleotide motif 
between the nascent and original strand occurs. This is followed by ligation at the nonanucleotide 
motif of the displaced genome by Rep to reconstitute the circular ssDNA genome, thereby releasing 
Rep (Cheung, 2006). 
Virus assembly in circoviruses has been well studied for PCV. In PCV-2, transcripts and antigen can be 
detected 18 hours post infection, and their presence is correlated with DNA replication (Cheung and 
Bolin, 2002; Steiner et al., 2008). The CP can be detected 24 hours post infection while cell-free 
1
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progeny can be detected as early as 30 hours post infection (Cheung and Bolin, 2002; Liu et al., 
2001). Detection of recombinant BFDV CP expressed in Sf9 insect cells using a polyhedrin promoter 
has also been reported to be at 24 hours with expression peaking at 72 hours. In situ this early 
expression is thought to be necessary during infection to facilitate the transport of Rep into the 
nucleus (Stewart et al., 2007). Individual virions are thought to assemble within the nucleus, with the 
formation of paracrystalline arrays, as inclusion bodies, confined to the cytoplasm (Sanada et al., 
1999; Stewart et al., 2007). This confinement to the cytoplasm is inconclusive as intranuclear 
inclusion bodies in epithelial cells have also been widely reported in the literature; however, 
psittacines presenting this histopathology often made a spontaneous recovery, and it has been 
reported that these inclusions are not of viral origin (Gerlach, 1994; Pass and Perry, 1985; Ritchie et 
al., 1990). These nuclear and cytoplasmic paracrystalline arrays can often persist within the target 
cell population (Latimer et al., 1990; Todd et al., 2002). 
Similarly to virus assembly, virus uptake has also been well documented for PCV-2. Binding to the 
epithelial cell surface proceeds rapidly in a time dependent manner. The binding occurs in a random 
distribution indicating that all cells have receptors for virus uptake. The actual process of 
internalisation is slow, however, and infectious entry into the cell is through an actin polymerisation 
mediated cholesterol and dynamin independent small GPase regulated caveolin and clathrin 
independent pathway (Misinzo et al., 2009). 
1.2.4. Cell tropism 
The primary sites for BFDV infection are rapidly dividing tissues (Todd, 2000). Apoptosis is seen to 
facilitate cell to cell spread within these tissues, and the dissemination of the virus leads to the 
development of viraemia (Latimer et al., 1991; Raidal et al., 1993c; Trinkaus et al., 1998). The 
presence of virus in the blood and feather has been shown, in unvaccinated-control birds challenged 
with virus, to increase in a sigmoidal fashion (Bonne et al., 2009). In PCV the threshold for viraemia 
has been broadly set at 107 genome copies/mL (Beach et al., 2010). Three main systems are affected 
by BFDV: these are the epidermis, immune system and the alimentary system (Latimer et al., 1993). 
The virus targets replicating cells of the feather follicle and basal epithelium layers, with the resulting 
cell death being the cause of the characteristic feather abnormalities (Latimer et al., 1991; Latimer et 
al., 1993; Sanada et al., 1999; Trinkaus et al., 1998). The virus can persist in the epithelial cells and 
feathers after clinical symptoms have been resolved (Hess et al., 2004). 
Within the alimentary system the virus is predominantly found in the intestine and liver, and it has 
been found to be most concentrated in the basal epithelium layer (Rahaus et al., 2008; Ramis et al., 
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1994). Lesions found to contain inclusions have been identified in the palate, oesophagus, crop, 
intestine and liver (Latimer et al., 1990). 
In PCV-2 the immune system is seen as the primary target, with the virus infecting dividing 
macrophages and replicating in the lymph nodes (Fenaux et al., 2002; Trible et al., 2011). Evidence 
for the presence of BFDV has been found in both the bursa of Fabricius and the thymus. Both organs 
have been seen to be depleted, and studies on the bursa of Fabricius have found tissue destruction 
and lesions containing inclusion bodies (Kock et al., 1993; Latimer et al., 1990; Todd, 2004). 
Furthermore, inclusion bodies have also been detected in macrophages infiltrating endothelial and 
epithelial tissue (Kiatipattanasakul-Banlunara et al., 2002; Latimer et al., 1993; Sanada et al., 1999). 
Macrophages are thought to be the primary target of infection, and phagocytosis of viral particles is 
suggested to contribute to infection (Latimer et al., 1991). The virus has also been reported to infect 
embryonated eggs, an observation which has also been identified with PiCV (Duchatel et al., 2006; 
Rahaus et al., 2008). 
1.2.5. Psittacine beak and feather disease 
The disease caused by infection with BFDV is psittacine beak and feather disease (PBFD), previously 
called French Moult (Pass and Perry, 1985). Wylie and Pass (1987) identified BFDV as the disease 
agent through experimental transmission studies. Both male and female psittacines are vulnerable 
to the disease, with there being no difference between the rate of infections, and symptoms are 
often more pronounced in younger birds which are, also, at a higher risk of infection (Hess et al., 
2004; Jergens et al., 1988; Pass and Perry, 1985; Rahaus and Wolff, 2003; Raue et al., 2004). There is 
no defined time period between infection and onset of disease; however, once symptoms emerge 
the disease progression is unabating, and the prognosis of symptomatic birds is poor (Doneley, 2003; 
Greenacre et al., 1992). 
Transmission of BFDV between birds can occur either through horizontal or vertical transmission. 
Horizontal transmission can occur via ingestion or inhalation of the virus, and ingestion is seen as the 
primary route of transmission (Todd, 2004). The virus can be ingested either directly through 
preening or feeding of hatchlings, or indirectly through environmental contamination with virus-
laden faecal and feather material (Hsu et al., 2006; Latimer et al., 1991; Rahaus et al., 2008). 
Horizontal transmission is exacerbated by psittacines congregating into flocks and through 
contamination of nesting sites, which enables transmission between ecologically disconnected 
species (Peters et al., 2014; Raidal et al., 1993a; Sa et al., 2014). 
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Overall, transmission is dependent on the locus of persistence and the viral load during acute 
viraemia (Rahaus et al., 2008). It could be postulated that the high viral loads seen during viraemia 
may potentially facilitate horizontal spread through blood-feeding transmission vectors, adding an 
additional route whereby the virus can spread. However, no transmission vectors thus far have been 
identified for circoviruses, and environmental contamination is still regarded as the main route of 
transmission. Within breeding facilities, transmission is intensified by close quarters, the 
concentration of different psittacine species and the movement of breeding stock between facilities 
(Dolz et al., 2013; Ritchie et al., 2003). 
The disease can present in three forms: these are acute, chronic and subclinical. The acute form of 
the disease is mainly seen in young and neonatal birds; however, it has also been reported in adult 
African grey parrots (Psittacus erithacus) (Schoemaker et al., 2000; Shearer et al., 2009b). The 
progression of this form is rapid, and an antibody response is detectable within 3-4 weeks (Shearer 
et al., 2009b). Symptoms of the disease include rapid weight loss, diarrhoea, haemorrhaging in the 
shaft of developed tail and primary feathers and depression. Beak and feather abnormalities 
characteristic of the chronic form are absent (Pass and Perry, 1985). The acute form has a high 
mortality rate (Ha et al., 2007). 
 
Figure 1.4: Clinical signs of PBFD. (A) A Cape parrot with abnormal feathering characteristic of chronic BFDV. 
(B) A healthy Cape parrot for comparison purposes. Reprinted with permission from Dr. RS Boyes. 
By far the most reported form of the disease is the chronic form, which primarily affects adult birds 
(Schoemaker et al., 2000). Symptoms of chronic disease are the characteristic beak and feather 
abnormalities associated with PBFD (Ritchie et al., 1990) (Figure 1.4). Generally infection is followed 
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by a gradual replacement of feathers with abnormal ones after each successive moult (Gerlach, 
1994; Latimer et al., 1993; Pass and Perry, 1985). Feather abnormalities are accompanied by 
symmetric feather loss, this in turn causes the skin to discolour if exposed to sunlight (McOrist et al., 
1984; Ritchie et al., 1990). Beak abnormalities include fractures and progressive elongation (Ha et 
al., 2007). Larger psittacines may also experience claw abnormalities, though beak and claw 
abnormalities may be associated with specific species (Harkins et al., 2014; Riddoch et al., 1996). The 
progression to severe disease has been reported to be 6 months in Sulphur-crested cockatoos 
(Jacobson et al., 1986). Psittacines showing symptoms generally survive for a period of 6-12 months; 
however, there have been cases of psittacines surviving for 10 years in a featherless state (Gerlach, 
1994). There is a correlation between clinical signs of disease and viral load, with the detection of 
virus in the blood indicative of a recent infection or immunosuppression (Hess et al., 2004; Khalesi et 
al., 2005; Raidal et al., 1993c). Birds that are infected with BFDV become immunocompromised, 
which is the primary cause of chronic infection and persistent excretion of the virus in diseased birds 
(Bonne et al., 2009; Raidal et al., 1993b). 
Immunosuppression is an important aspect of BFDV infection, as death of psittacines with PBFD is 
largely due to secondary infections (Ritchie et al., 1990). Tissue necrosis seen in psittacines infected 
with BFDV is as a result of secondary bacterial infections (Trinkaus et al., 1998). The development of 
immunosuppression can be attributed to a depletion of lymphocytes and damage caused by lesions 
to the thymus and bursa of Fabricius (Latimer et al., 1990; Stanford, 2004). A decreased lymphocyte 
count would compromise the humoral part of the immune system, and this has been observed in 
infected psittacines that show an overall decrease in the concentration of serum protein (Jergens et 
al., 1988). Antibody titres have also been shown to be low in psittacines with active infections, while 
psittacines with detectable antibody titres test negative for BFDV during PCR and excrete less virus 
(Khalesi et al., 2005). 
The third form of the disease is subclinical infection: this presents the greatest risk for disease 
spread, as infected psittacines continue to shed virus at low concentrations (Bert et al., 2005; Raidal 
and Cross, 1994a). Reports vary on the prevalence of subclinical infections in psittacines from 
approximately 15% to as high as 95% (Bendheim et al., 2006; Ha et al., 2007). Depending on the 
detection method and whether or not a longitudinal study was undertaken one could argue that in 
fact these infections are possibly chronic infections still in the asymptomatic stage of development. 
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1.3. BFDV diagnosis 
1.3.1. Diagnostic assays 
Previously, diagnoses of PBFD were made using clinical symptoms and histology (Latimer et al., 
1992). Clinical symptoms were based on feather loss and abnormalities; however, these could also 
be the result of infections with other viruses or physiological conditions (Ortiz-Catedral et al., 2009). 
Histology focused on the identification of inclusions bodies which were either present in the 
cytoplasm or the nucleus of the feather follicle epithelium (Ritchie et al., 1990). This technique, 
however, has a low sensitivity and specificity, and in the case of PiCV has been found to result in a 
significant under-diagnosis of infection (Riddoch et al., 1996; Todd et al., 2002). 
1.3.2. Serological assays 
The haemagglutination assay (HA) was routinely used to detect BFDV, as BFDV virions agglutinate 
erythrocytes. This was considered the gold standard assay for feather eluates (Shearer et al., 2009b). 
The haemagglutination of red blood cells is dependent on the intact virion and hence the assembled 
CP (Stewart et al., 2007). This assay together with haemagglutination inhibition (HI) test can be used 
to quantify viral load and detect virus excretion, and the HI test can also to detect capsid-specific 
antibodies (Riddoch et al., 1996; Shearer et al., 2009a; Shearer et al., 2009b). A disadvantage of 
these assays is their inherent variability, which is a result of differences in erythrocytes, viral 
preparations and serum, and that they often fail to detect subclinical and incubating infections 
(Raidal and Cross, 1994b; Shearer et al., 2009a). 
Enzyme-linked immunosorbent assays (ELISA) have recently been developed for the detection of 
BFDV. This assay has a greater sensitivity when compared to the HI test, and variation can be 
reduced if monoclonal antibodies are used. Another advantage of ELISA over the HI test is that it can 
provide a continuous reading of percentage inhibition found between HI test endpoints (Shearer et 
al., 2009a). 
1.3.3. PCR-based assays 
The first DNA-based technology to be used in the detection of circoviruses was in situ hybridisation, 
which was regarded as having a greater sensitivity than histology (Todd et al., 2002). This was 
followed by PCR amplification of viral DNA, which is now preferred over DNA hybridisation and is 
used in most studies relating to BFDV (Bert et al., 2005; Latimer et al., 1992). One of the first PCR 
assays used for circoviruses was in fact a nested primer PCR capable of detecting single genome 
copies of CAV (Soine et al., 1992). 
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Standard PCR is considered to be the gold standard when testing psittacine blood samples, and most 
assays use the conserved rep as a template for amplification (Khalesi et al., 2005; Shearer et al., 
2009b). PCR is favoured when detecting virus because it has a high sensitivity and specificity. These 
criteria should be determined for each PCR assay to ensure valid data at low DNA concentrations 
and to reduce the number of false positives (Bert et al., 2005; Rahaus and Wolff, 2003). The assay 
sensitivity can be increased for samples with low DNA concentrations by using nested-primer PCR 
(Kiatipattanasakul-Banlunara et al., 2002). The detection limit for standard PCR used to detect PiCV 
has been shown to be as little 31 fg in one study and 103 genome equivalents in another (Freick et 
al., 2008; Todd et al., 2002). The sensitivity of the assay affects its value as a diagnostic in terms of 
differentiating between disease or infection (Todd et al., 2002). As with any PCR, it is important to 
include controls to eliminate false negatives: for this purpose a PCR with host genomic DNA as 
template is used for the detection of total DNA (Bert et al., 2005). Standard PCR has a higher 
sensitivity than HA; however, a drawback is that non-specific amplification of PCR products of sizes 
similar to the expected product cannot be differentiated by agarose gel electrophoresis (Katoh et al., 
2008; Khalesi et al., 2005). Virus diversity may also affect the reliability of PCR-based assays, as a 
recent report described the failure of universal primers to detect virus isolated from Budgerigars 
(Ogawa et al., 2010). 
Quantitative real-time PCR (qPCR) is currently being investigated as a suitable assay for BFDV 
detection. It allows for the measurement of viral load as a copy number ratio of virus and host genes 
(Lee et al., 2006). The problem of non-specific amplification experienced using standard PCR can be 
overcome through melting point determination using SYBR Green I, which forms part of the qPCR 
analysis (Katoh et al., 2008). The advantage of using qPCR is a high sensitivity, which is better than or 
equal to that of standard PCR for clinical samples, with the limit of detection being between 50-100 
copies (Katoh et al., 2008; Ramis et al., 1994; Shearer et al., 2009b). 
Another important aspect of PCR-based assays is the sample. Tissue samples can contain PCR 
inhibitors that can be present after DNA extraction and can affect the reaction resulting in false 
negatives (Freick et al., 2008; Khalesi et al., 2005; Tomasek et al., 2008). The three routine samples 
taken from psittacines suspected of being infected with BFDV are blood, feather and faecal samples. 
Both blood and feather samples can lead to false positives with the detection of non-replicating DNA 
(Ha et al., 2007; Shearer et al., 2009b). There isn’t a consensus as to the use of which sample - blood 
or feathers - is the more sensitive; however, no significant difference in detection has been found 
when using either feather or faecal samples (Bert et al., 2005; Hsu et al., 2006; Khalesi et al., 2005). 
The determination of viral load in the blood using qPCR could be seen as a more reliable diagnostic 
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for detecting infection and delimiting disease, and further research is needed to create a robust 
diagnostic assay. 
1.4. Phylogenetic analysis of virus relatedness 
Single-stranded DNA viruses have a recombination and nucleotide substitution rate similar to that of 
RNA viruses (Ortiz-Catedral et al., 2010). In BFDV, recombination is seen as an important driver of 
diversity (Massaro et al., 2012). The rate of nucleotide substitution in ssDNA viruses is in part due to 
the high rate of spontaneous deamination that occurs in the absence of the protective double helix 
(Ritchie et al., 2003). The subsequent rate of evolution, however, differs between the cp, rep and 
intergenic regions. The cp has been thought to possibly evolve faster than the rep and has been 
described to be subject to neutral or episodic positive selection (Kundu et al., 2012; Varsani et al., 
2011). The rep, however, is thought to be under purifying selection and no evidence of adaptive 
selection has been seen (Ritchie et al., 2003; Varsani et al., 2011). Purifying selection is in part due to 
functional constraints on Rep (Hughes and Piontkivska, 2008). Differences in the rate of evolution on 
different regions of the genome and the presence of recombination make it essential to analyse the 
full-length genome when comparing different isolates (Heath et al., 2004; Sarker et al., 2014b; 
Varsani et al., 2011). 
Breeding facilities bring together multiple strains of virus, which increases the risk of recombination 
which probably leads to the development of new strains (Julian et al., 2013). This is supported by 
evidence in wild psittacine populations, where isolates are usually genetically uniform (Harkins et al., 
2014). Recombination together with point mutations represents a major source of genetic diversity 
in BFDV, and individual psittacines have been shown to be infected with multiple genetic variants 
(Heath et al., 2004; Rosario et al., 2009; Sarker et al., 2014b). Recombination hot spots in the 
genome include the intergenic region and the periphery of the cp and rep (Varsani et al., 2011). It 
has been suggested that DNA secondary structure is an important mechanism of site-specific genetic 
recombination (Sarker et al., 2014b). Therefore, potential similarities in DNA secondary structure 
could be used to explain the recombination hot spots previously identified by Varsani et al. (2011). 
Recombination complicates the inference of phylogenetic relatedness, especially when break points 
create sequences of equal lengths (Heath et al., 2004). 
The demarcation criteria for BFDV strains as set by the ICTV are isolates sharing greater than 75% 
genome identity and greater than 70% cp identity (Todd et al., 2008). A more stringent demarcation 
threshold has been suggested by Varsani et al. (2011), which is set at 94% genome wide sequence 
identity. This was later revised to 95% by Julian et al. (2013). Isolates are then grouped into subtypes 
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if they share greater than 98% genome wide sequence identity. Isolates that share less than 89% 
whole-genome identity fall out of the species BFDV (Varsani et al., 2011). 
Based on these demarcations, Varsani et al. (2011) proposed 14 distinct strains of BFDV. A previous 
study identified 8 groups based on a divergence criteria of greater 8% (Hsu et al., 2006). Differences 
in the number of strains identified may be as a result of the increased stringency and larger dataset 
used by Varsani et al. (2011). The basis of how these strains come to exist is poorly understood. 
Hughes and Piontkivska (2008) found strong support for separating Circovirus species; however, 
when analysis was performed on clustering patterns within species the support was found to be low. 
It has been postulated that genetic drift and past selection pressure from the host immune system 
are reasons for strain evolution (Ritchie et al., 2003). Further reasons are discussed below. 
1.4.1. Geographic distribution 
Recent work on the origin of the virus has placed the most recent common ancestor in Australia, an 
observation which is consistent with historical records (Harkins et al., 2014). A few reports have 
speculated that strains arose from distinct geographical locations. Heath et al. (2004) identified 8 
lineages, with Southern African isolates representing 3 unique genotypes, and BFDV in Australia 
being the most genetically diverse with 4 clusters. They suggested that the introduction from 
Australia to Southern Africa was ancient since there was already significant genetic divergence 
between isolates from Southern Africa. In the context of South Africa there is evidence to indicate 
more than one introduction of BFDV (Kondiah et al., 2006). It has been thought that the disease is 
absent in Central and South American psittacines since birds imported to Europe all have tested 
negative; however, they are still susceptible to infection (Bert et al., 2005). The majority of 
publications, however, suggest that there is very little evidence to support strains arising from 
distinct geographical locations (Bassami et al., 2001; Heath et al., 2004; Hsu et al., 2006; Ogawa et 
al., 2005). 
Varsani et al. (2011) instead propose that the international trade in psittacines has resulted in 
haphazard strain dissemination, and Heath et al. (2004) has suggested that host specificity may 
predate this dissemination. The importation of psittacines from Australia into New Zealand as pets 
and for breeding has been blamed for the spread of the disease (Ritchie et al., 2003). The illegal 
trade in psittacines also exacerbates the spread of BFDV (Bendheim et al., 2006). Phylogenetic 
analyses of the virus isolates can be used as a tool to counter the growing illegal trade in psittacines, 
by tracing the source of BFDV infections (Massaro et al., 2012).  
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1.4.2. Species specificity 
There is less consensus in the literature on whether strains coevolved alongside host species than 
has been shown for psittacid herpesvirus (Styles et al., 2005). A high rate of evolution in ssDNA 
viruses may, however, possibly favour host specific evolution (Johne et al., 2006). This is evident in 
the high variation seen in the cp gene, which may be as a result of virus host interactions or selective 
pressure from the immune system (Raue et al., 2004). Differences in host factors may also play a 
role, with Khalesi et al. (2005) reporting a higher prevalence of BFDV in lovebirds than Budgerigars. 
Some analyses of isolates based on the cp sequence have suggested that clades of virus are 
associated with psittacine subfamilies (Ogawa et al., 2005). This is supported by a study that 
suggested that there were 3 clades which corresponded with the major psittacine families (Bert et 
al., 2005). Various studies have potentially identified strains that only affect specific hosts. A strain 
adapted to lorikeets has been reported in New Zealand; however, this was later shown to also infect 
other psittacine species (Heath et al., 2004; Khalesi et al., 2005). Viruses isolated from Budgerigars 
comprised two genotypes which were distinct from other BFDV sequences, and later described as 
strains of Budgerigar circovirus, a novel Circovirus species (Ogawa et al., 2010; Varsani et al., 2011). 
A distinct serotype affecting Cockatiels (Nymphicus hollandicus) has been reported (Shearer et al., 
2008a; Shearer et al., 2008b). These apparent species specificity could, however, be an artefact of 
breeding facilities (Varsani et al., 2011). This has been reported in psittacine species housed in 
separate enclosures, where the virus is then transmitted along pedigree lines or a single breeding 
stock species (Ritchie et al., 2003). 
In contrast to there being evidence for strain specificity, literature exists to suggest there is no host 
species specificity. Raue et al. (2004) was the first to suggest based on cp sequence data that isolates 
do not cluster according to species. Lineages described by Heath et al. (2004) were also unrelated to 
host species. In support of these findings, isolates in Mauritius have been shown to be transmitted 
between two distinct psittacine host populations (Kundu et al., 2012). Similarly, no species specificity 
could be detected between Rosella species (Massaro et al., 2012). Cross-reactivity of blood and 
feather samples from different species when assayed using HI tests has suggested that no distinct 
serotypes exist amongst different isolates (Khalesi et al., 2005). Virus purification and challenge 
experiments have shown that viruses share antigenic homology and that virus isolated from one 
species can be used to infect other species (Ritchie et al., 1990; Ritchie et al., 1992b; Wylie and Pass, 
1987). The link between virus isolate and host species appears, therefore, to be largely an artefact of 
genetic drift in geographically separated psittacines - and whether this would result in the 
emergence of a species-specific virus remains to be seen. 
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1.4.3. Strain pathogenicity 
It has been suggested that BFDV strains could cluster on the basis of disease severity. Isolates from 
lorikeets diagnosed with acute PBFD, for example, have been shown to cluster separately based on 
cp sequence data. Similar findings have been reported for isolates in African grey parrots, which 
cluster as separate groups birds affected by immunosuppression, and those with feather disorders 
(Raue et al., 2004). Gene mutations have been thought to influence strain pathogenicity, although 
there have been few studies on strain severity to create a consensus (Shearer et al., 2008a). Recent 
outbreaks of disease in wild birds have been attributed to functional mutations within the BFDV 
genes. Changes to the rep were thought to have been responsible for an outbreak of BFDV in 
endangered Mauritian Parakeets, while an outbreak of disease in Orange-bellied parrots (Neophema 
chrysogaster) in Australia were thought to be attributed to functional mutations in both the rep and 
cp (Kundu et al., 2012; Sarker et al., 2014b). 
Other studies suggest that pathogenicity is related to differences in the host immune system and 
host factors, and are not attributable to the genotype of the isolate (Bassami et al., 2001; Katoh et 
al., 2010b; Rahaus and Wolff, 2003). Cockatiels have been observed to have an innate resistance to 
infection, while a study of Budgerigars found no correlation between clinical forms and genotypes 
(Ogawa et al., 2010; Shearer et al., 2008a). Similarly, younger psittacines are more likely to be 
infected and to have a higher severity of disease than older birds (Bert et al., 2005; Wylie and Pass, 
1987). Further work is obviously required to differentiate between strain pathogenicity and species-
specific host factors. 
1.5. BFDV isolation and purification 
In order to determine the efficacy of a potential vaccine, its ability to protect must ordinarily be 
tested in a challenge trial. Following vaccination, birds are exposed to virus, either in the form of 
virus-containing serum or as purified virus. A potential drawback with using serum is that there may 
be unknown disease agent(s) present which can affect the outcome; therefore, isolation and 
purification of live virus is preferable as a source of inoculum (Fenaux et al., 2003). 
1.5.1. Virus purification from infected tissue 
BFDV purified from tissues of infected birds has been used to infect healthy birds and to characterise 
the virus (Ritchie et al., 1989b). CsCl density gradient centrifugation is useful as a purifying step, as 
the virus particles have a reported density of 1.35-1.378 g/cm3 (Raidal and Cross, 1994b; Todd et al., 
1991). Final yields from tissue are between 109-1010 virions/mL in the fraction containing peak HA 
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activity (Raidal and Cross, 1994b). Accurate quantitation can also be achieved using qPCR (Shearer et 
al., 2008a). Yields from diseased tissue are low and preparations are often contaminated with host 
proteins: this could potentially be addressed through the use of affinity purification using 
monoclonal antibodies specific for BFDV (Latimer et al., 1993; Ritchie et al., 1992a; Shearer et al., 
2009a). That said, virus particles purified from diseased tissue as well as crude homogenates have 
been used successfully to cause PBFD in neonates (Raidal et al., 1993a; Ritchie et al., 1990). Routes 
of inoculation have included nasal, oral, intracloacal and intramuscular, all of which have resulted in 
PBFD. The severity of disease caused by intramuscular inoculation was found to be dose dependent 
(Raidal et al., 1993a). There are, however, quite serious ethical considerations around sourcing 
infected birds in order to purify live virus from diseased tissue; thus, a suitable alternative is required 
(Shearer et al., 2009a). 
1.5.2. Growth in tissue culture 
Purification of virus from infected bird tissue could be circumvented by growing the virus in vitro; 
however, attempts to propagate BFDV in tissue culture have been unsuccessful thus far (Shearer et 
al., 2008a). Attempts to propagate other non-psittacine circoviruses (eg PiCV, goose circovirus 
[GoCV] and duck circovirus [DuCV]) have also been unsuccessful (Duchatel et al., 2006; Hattermann 
et al., 2003; Scott et al., 2006). This is in contrast to the genus Circovirus type species, PCV, which 
was first discovered as a PK-15 cell line contaminant (Fenaux et al., 2002). An obstacle to 
propagation has been the generation of suitable psittacine cell lines, as possibly the virus requires 
highly specific tissue with stringent growth requirements (Ritchie et al., 1989a). Another 
consideration has been the use of embryonated chicken eggs, as this has been successfully applied 
to avian herpesvirus. However, psittacine eggs would almost certainly be required, as previous 
attempts to infect embryonated chicken eggs with a circovirus isolated from canaries have failed 
(Panigrahy and Grumbles, 1984; Woods and Latimer, 2000). 
1.5.3. Infectious DNA clones 
Alternatives to purifying infectious virus have recently been investigated for circoviruses. One 
approach has been to develop infectious molecular DNA clones, by techniques similar to what has 
been successfully applied for native geminivirus genomes as well as for constructs used for gene 
amplification and recombinant protein expression in plants (Regnard et al., 2010). Using full-length 
genomic DNA clones to elicit an infection overcomes the difficulties and lack of reproducibility 
associated with virus purification, and was first demonstrated with Hepatitis B virus in chimpanzees 
(Will et al., 1982). The method also circumvents the need for infectious virus titration assays in cell 
culture, as DNA can be quantified using a spectrophotometer (Fenaux et al., 2002). For an infectious 
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molecular DNA clone carried on a theta-replicating vector plasmid to be infectious, two origins of 
replication (ori) are required, as the circular genome is linearised in the vector backbone. For this 
purpose, a partial genome repeat is used that incorporates the full genome between two oris. 
Infectious molecular DNA clones have been successfully developed for PCV, and have been shown to 
be infectious in tissue cultures, from which pure virus stocks have been produced (Fenaux et al., 
2002; Liu et al., 2001). Both DNA clones and pure virus stocks derived from them were infectious in 
pigs, and the DNA clone has been suggested as a suitable replacement for infectious virus (Fenaux et 
al., 2002). Uptake of plasmid DNA into muscle cells after direct intramuscular injection is reportedly 
between 1-2% (Fan et al., 2008). Chimaeras between PCV-1 and PCV-2 genomes have been created 
and tested, producing immunity against PCV-2 which is of economic importance while being 
attenuated in terms of symptoms produced in pigs (Fenaux et al., 2004; Gillespie et al., 2008). The 
chimaera remained stable in in vitro serial passage in PK-15 cells; however, it was found to be 
unstable after one passage in pigs, with the reversion of an inserted marker mutation (Gillespie et 
al., 2008). Infectious molecular DNA clones can similarly be developed for BFDV; however, testing 
would have to be performed on psittacines as no appropriate cell line or embryonated egg system 
has yet been found. 
1.6. BFDV vaccine development 
A commercial vaccine for BFDV is currently unavailable, and treatment is principally palliative and 
supportive (Jergens et al., 1988; Patterson et al., 2013b; Rahaus et al., 2008). Preventing disease 
spread has focused on identifying and removing infected psittacines for euthanasia (Bendheim et al., 
2006; Massaro et al., 2012; Stanford, 2004). Environmental disinfection and improved hygiene when 
handling psittacines has been suggested; however, Raidal and Cross (1994a) have shown there is an 
infection incidence of between 2-5% post biocontrol (Duchatel et al., 2006; Stanford, 2004). 
Treatments against circoviruses are in development, and antiviral compounds against PCV-2 have 
been tested. An antiviral trial involving a pan-caspase inhibitor zVAD, known to block the p53 
mediated apoptosis, was shown to reduce cell apoptosis during infection in mice, without negatively 
affecting the immune system and overall health of the mice (Karuppannan and Kwang, 2011). 
Research into therapeutic treatments against BFDV has focused on cytokines. Gamma interferon 
isolated from chicken cell culture was shown to be successful in clearing the virus and increasing the 
total lymphocyte count (Stanford, 2004). Similarly, treatment with β-(1,3/1,6)-D-glucan has been 
shown to augment interferon production and to have an immunomodulatory effect in Horned 
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parakeets (Eunymphicus cornutus), resulting in the virus being undetectable 7-9 months after 
commencement of treatment (Tomasek and Tukac, 2007).  
These efforts notwithstanding, it has been suggested that eradication of the disease is unlikely due 
to the prevalence of infection and the stability of the virus (Todd, 2004). A vaccine against BFDV 
would therefore be desirable, especially due to the presence of subclinical infections which may 
complicate biocontrol efforts and since the disease progression varies. The likelihood that a single-
strain vaccine would be successful is high, due to the absence of obvious serotypes which indicates 
conservation of major epitopes between isolates: there is therefore a high probability of cross-
isolate protection (Ritchie et al., 1992b; Shearer et al., 2009a). 
Preliminary reports of the development of a BFDV vaccine have shown that the host immune system 
does respond to BFDV vaccination, and chickens that have been inoculated with pure virus have 
been shown to develop high titres without infection (Raidal et al., 1993c; Ritchie et al., 1992b). 
Vaccination of clinically healthy psittacines with either inactivated virus or recombinant CP has been 
shown to confer immunity (Bonne et al., 2009; Raidal and Cross, 1994a). This has been used 
successfully together with other measures to control the prevalence of the BFDV in the USA (Bert et 
al., 2005). A number of commercial vaccines have been developed for PCV from inactivated and 
attenuated virus, to subunit, vector and DNA vaccines and development of these for BFDV is 
described below (Fachinger et al., 2008). 
1.6.1. Inactivated virus 
The first vaccines tested against BFDV were inactivated whole-virus vaccines. Inactivation was 
achieved using β-propiolactone which has a minimal effect on the structure of the CP. 
Paraformaldehyde has also been used in conjunction with β-propiolactone to inactivate virus (Raidal 
et al., 1993a; Wylie and Pass, 1987). Two adjuvants have been tested: these are a primary oil 
emulsion using Freund’s adjuvant, and a double oil emulsion. Both were effective; however, the 
Freund’s adjuvant was shown to cause undesirable tissue reactions (Raidal et al., 1993a). 
Vaccination with inactivated virus was shown to result in seroconversion and a low antibody titre in 
chicks, which conveyed protection from disease (Raidal et al., 1993a). Maternal immunity from 
vaccinated hens was passively transferred to neonates that were then challenged and were afforded 
temporary protection. The vaccine was shown not to prevent virus shedding, however, and is 
therefore unable to prevent viral replication and new infections (Raidal et al., 1993a). 
There are risks associated with inactivated vaccines. Vaccination with inactivated virus may 
aggravate subclinical infections, resulting in PBFD; partial inactivation may also cause inadvertent 
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infection (Raidal et al., 1993a). As BFDV cannot be cultured in vitro there is no means of assessing 
complete inactivation (Bonne et al., 2009). A recent study on an emergence of a chimaeric PCV1/2a 
strain speculated that the source of the outbreak could be traced back to the inclusion of full-length 
genomic DNA during preparation of a killed chimaeric vaccine. The contaminating genomic DNA, 
similar to the infectious DNA clones, could produce a viable infection after the vaccine has been 
delivered (Gagnon et al., 2010). Together with the risks, there are also ethical considerations that 
must be taken into account when sourcing diseased tissue for virus isolation, as mentioned 
previously (Bonne et al., 2009). 
1.6.2. Subunit vaccine 
Recombinant protein expression technologies can potentially be used to circumvent the need for 
sourcing diseased tissue in order to isolate live virus. Virus-like particles (VLPs) often form 
spontaneously from capsid proteins of simple viruses expressed in heterologous systems: these lack 
viral nucleic acid, making them non-infectious (Santi et al., 2006). A number of circovirus CPs, 
including BFDV CP, have been successfully produced in recombinant expression systems (Heath et 
al., 2006; Lai et al., 2014; Scott et al., 2006). Vaccination primarily results in a humoral immune 
response, as has been shown in pigs vaccinated with baculovirus-expressed PCV-2 CP (Fachinger et 
al., 2008). Furthermore, the expression the PCV-2 and BFDV CPs has been shown to result in 
spontaneous formation of VLPs (Nawagitgul et al., 2000; Stewart et al., 2007).  
Vaccination against BFDV has been shown to reduce the shedding of virus during challenge, and 
result in only transient viraemia after infection. The subunit vaccine was unable, however, to 
prevent vertical transmission and replication in chicks born from vaccinated psittacines. This 
indicated that neonates are still susceptible to infection in the presence of maternal antibodies, as 
has also been reported for the inactivated vaccine (Bonne et al., 2009; Shearer et al., 2009b). 
The use of the insect cell / baculovirus expression system to express the BFDV CP has been 
successful (Bonne et al., 2009; Heath et al., 2006). Vaccination with full-length CP produced in insect 
cells has been shown to result in seroconversion in chickens (Stewart et al., 2007). Similarly chickens 
immunised with insect cell derived truncated CP seroconverted and this was purported to be dose 
dependent (Heath, 2006). The advantages of using insect cell culture for recombinant virus subunit 
protein production are a generally high level of recombinant protein expression, the expressed 
proteins usually maintain immunogenicity and antigenicity, they may assemble into VLPs, and there 
is no need to handle infectious pathogen during vaccine production (Bucarey et al., 2009; Pérez-
Martín et al., 2010). 
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Fermentation technologies have also been used in the expression of circovirus capsid proteins. 
Bucarey et al. (2009) successfully expressed a codon-optimised PCV-2 CP in yeast, which was 
administered as an oral vaccine without purification. Bacterial fermentation has been used to 
express a truncated version of the BFDV CP, which was later purified using affinity and size exclusion 
chromatography with a reasonably high yield (Heath, 2006; Patterson et al., 2013b). Disadvantages 
of bacterial expression systems have been low protein solubility, and problems with protein folding 
and post-translational modifications. Interestingly, protein aggregations were shown to be as a 
direct result of amino acid sequence and could thus be at least partially avoided during expression 
by making alterations to the amino acid sequence (Patterson et al., 2013b). The low solubility of the 
CP could be attributed to the N-terminal region of the CP which is arginine rich and thought to be 
involved in binding BFDV genome DNA. The absence of viral DNA during recombinant expression 
may affect the overall stability of the protein resulting in the formation of insoluble aggregates. 
Extraction buffers designed to negate the charge of the arginine residues may make the proteins 
more soluble and would be convenient for ion-exchange chromatography. 
Plant-based production has gained traction as a complementary system to traditional cell culture 
and microbial fermentation technologies in the production of biopharmaceuticals. Plants are 
favourable for the production of region-specific and niche market products (Stoger et al., 2014). This 
system therefore aligns well with the requirements of a BFDV vaccine and may overcome difficulties 
associated with CP insolubility in microbial fermentation systems (Patterson et al., 2013b). Initial 
plant-based production of recombinant proteins focused on the generation of stable transgenic 
lines; however, transient expression using bacterial, viral or hybrid vectors are now favoured for the 
rapid optimization of recombinant protein expression (Sainsbury and Lomonossoff, 2014; Stoger et 
al., 2014).  
The use of Agrobacterium tumefaciens (A. tumefaciens) for transient expression of heterologous 
proteins in plants is an established technology and involves the transfer of DNA from the 
Agrobacterium into the plant cell nucleus (Sainsbury and Lomonossoff, 2014). Transient expression 
has been used successfully to produce a number of vaccine antigens against avian viruses such as: 
infectious bursal disease virus (Chen et al., 2012), avian influenza virus (Kanagarajan et al., 2012; 
Mortimer et al., 2013), and CAV which is very similar to BFDV in terms of genome and virus particle 
structure (Lacorte et al., 2007). The BFDV CP fused to an elastin-like polypeptide has been 
successfully expressed in Nicotiana benthamiana (N. benthamiana) under transient conditions. 
Although the authors were able to increase yield of the BFDV CP by fusing it with an elastin-like 
polypeptide, overall, the yield was low (Duvenage et al., 2013). 
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A major obstacle for the use of plant-based production has been the relatively low yields when 
compared with traditional cell culture and microbial fermentation technologies (Stoger et al., 2014). 
This has led to the development of a number of strategies to improve the overall expression and 
stability of recombinant proteins (Thomas and Walmsley, 2014). One of these approaches is to 
optimise codon usage to that of the plant expression system in order to remove rare plant codons 
present in the gene sequence. Codon optimisation has been successfully applied to PiCV to increase 
expression in Escherichia coli (E. coli)(Lai et al., 2014). Codon usage profiles exist for both N. 
benthamiana and Nicotiana tabacum (N. tabacum) and changing to these profiles has been 
associated with a significant increase in yield. The expression of human epidermal growth factor and 
Plasmodium antigen have both benefited from plant codon optimisation (Ma et al., 2012; Thomas 
and Walmsley, 2014). It has further been postulated that changes in the G+C content as a result of 
codon optimisation are responsible for increasing gene expression, rather than removing rare 
codons from the sequence (Hitzeroth et al., 2015). 
Recombinant proteins expression can be targeted with the addition of signal peptides to different 
organelles within the plant cell. This localisation can also contribute to an increase in protein stability 
and yield. Organelles targeted include: the chloroplast, endoplasmic reticulum (ER), vacuole and 
secretion into apoplastic spaces between cells. Localisation has been used successfully to increase 
plant expression of human papillomavirus (HPV) L1 capsid protein when targeted to the chloroplast 
and human epidermal growth factor when targeted to the vacuole (Maclean et al., 2007; Thomas 
and Walmsley, 2014). 
Yield can also be increased with the addition of enhancer elements up- and down-stream of the 
recombinant gene. This has been successfully applied with the inclusion of Cowpea mosaic virus 
(CPMV) untranslated regions (Sainsbury et al., 2009). However, transcription of recombinant genes 
with the use of strong promoters can trigger post-transcriptional gene silencing by the host which 
decreases the overall accumulation of recombinant protein. The inclusion and co-infiltration plant 
viral silence suppressor genes such as NSs from the tomato spotted wilt virus (TSWV) genome and 
p19 from tomato bushy stunt virus (TBSV) genome can effectively prevent gene silencing (Takeda et 
al., 2002; Voinnet et al., 2003). The above optimisations impact the accumulation of recombinant 
protein at the level of transcription and translation and can be combined to produce higher yields; 
however, the exact combination is dependent on the protein being expressed. 
An additional strategy for increasing protein yield has been to amplify the transient gene copy 
number. Gene amplification has been demonstrated using viral replication initiated from plasmid 
DNA after transfer from Agrobacterium (Regnard et al., 2010). Both RNA and DNA plant viruses have 
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been co-opted for this purpose (Gleba et al., 2005). The efficiency of gene amplification using viral 
replication has been demonstrated using a vector incorporating sequences derived from the bean 
yellow dwarf virus (BeYDV; family Geminiviridae, genus Mastrevirus) genome which increased gene 
DNA copy number by three orders of magnitude. However, this level of amplification does not 
necessarily translate into a three orders of magnitude increase in protein yield (Regnard et al., 
2010). Reasons for lower than expected protein yield may be the result of redirection of cell 
resources from mRNA transcription and protein translation to DNA replication. The inclusion of gene 
amplification together with other optimisations that increase protein accumulation could, however, 
further still improve yield. 
1.6.3. Live attenuated virus 
The development of infectious molecular DNA and cDNA clones has allowed attenuated viruses, 
including circoviruses, to be reasonably readily created and tested. With circoviruses there has been 
a particular focus on PCV, and the development of PCV1-2 chimaeras. These have been successfully 
tested, with a PCV1-2b live attenuated chimaeric vaccine against PCV2a and 2b which effectively 
lowered viral load, prevented viraemia, and decreased overall lymphoid lesions in pigs (Beach et al., 
2010). This holds significant promise for the development of a similar BFDV infectious molecular 
clone. 
1.7. Project aims 
This project aims at understanding the current status of BFDV diversity in South Africa with 
particular focus on the endangered wild Cape parrot population. The diversity of the virus will be 
investigated, and a diagnostic assay will be assessed. In terms of vaccine production, an 
experimental subunit vaccine produced in plants will be explored and a suitable infectious molecular 
DNA clone challenge model developed. 
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Chapter 2: Psittacine beak and feather disease outbreak in Cape 
parrots (Poicephalus robustus) in South Africa 
2.1. Introduction 
Research into PBFD in Africa remains limited and is focused on captive psittacines in South Africa. 
The first significant study of PBFD investigated the genetic diversity of BFDV in captive birds from 
southern Africa (Heath et al., 2004). This coincided with a report in South Africa on PBFD affecting 
Budgerigars and Ring-necked parakeets (Psittacula krameri), and was followed later by a study into 
the genetic diversity of rep sequences isolated in South Africa (Albertyn et al., 2004; Kondiah et al., 
2006). During this time HA routinely used in research in Australia was introduced and the reagents 
adapted for the psittacines species in South Africa (Kondiah et al., 2005). Additional BFDV isolates 
continued to be described, with Varsani et al. (2010) reporting unique genomes of BFDV isolates 
from Budgerigars sampled at a breeding farm in South Africa. The complete set of full-length BFDV 
genomes isolated from psittacines in South Africa was later included in analysis of all available full-
length genomes on databases, and used to characterise the global distribution of BFDV (Varsani et 
al., 2011). 
Apart from South Africa, there have been two reported cases of PBFD affecting psittacines in 
neighbouring countries. These were reported for captive flocks of Black-cheeked and Lillian's 
lovebirds (Agapornis lilianae) in Zimbabwe, and for a single wild Black-cheeked lovebird in Zambia 
(Kock, 1990; Warburton and Perrin, 2002). In addition, reports of captive psittacines imported from 
Africa and infected with BFDV have been reported in Italy (Bert et al., 2005). The only study on wild 
psittacines has been an extensive longitudinal study of BFDV introduced into Echo parakeets 
(Psittacula eques) indigenous to Mauritius (Kundu et al., 2012). However, no studies on wild 
psittacine populations on the African continent have been reported. 
Cape parrots (Poicephalus robustus) are endemic to South Africa and are endangered by the loss of 
forest habitat, persecution as a crop pest, and illegal capture for the wild-caught bird trade (Boyes, 
2011; Downs, 2005; Martin et al., 2014). Heath et al. (2004) suggested that Cape parrots could be 
threatened by PBFD after a unique viral strain was found in southern Africa. In 2008, a number of 
birds showing physical signs consistent with BFDV infection, including feather loss and 
discolouration, were observed in a wild Cape parrot population in the Amathole Region of the 
Eastern Cape Province. In 2010, similar signs of PBFD were also noted in the Transkei regions of the 
Eastern Cape Province, southern KwaZulu-Natal Province, and the Magoebaskloof area of Limpopo 
Province (Boyes, 2011). Understanding the BFDV outbreak in the endangered wild Cape parrot 
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population is important as it can be directly applied to the development of an effective conservation 
strategy. Furthermore, analysis of BFDV genetic diversity in wild species of African psittacines can 
contribute towards the development of a region-specific vaccine. 
Various techniques have been used to detect BFDV, and antibodies to it, in infected birds. Antibodies 
against the virus have been detected using HI assays and more recently by ELISA (Riddoch et al., 
1996; Shearer et al., 2009a). Detection of the virus has been routinely performed using both HA and 
viral DNA amplification by PCR; however, these methods can fail to detect latent or incubating 
infections (Raidal and Cross, 1994b; Ypelaar et al., 1999). The use of qPCR assays can be seen as a 
reliable and more sensitive alternative to HA and PCR, and to date there have been two qPCR assays 
developed for the quantification of BFDV (Katoh et al., 2008; Shearer et al., 2009b). The first was 
developed to detect multiple DNA viruses in psittacines, and was successfully applied to determine 
viral load in clinical samples (Katoh et al., 2008). The technique was also applied in a BFDV 
vaccination and challenge trial to track viraemia as reflected by viral copy number over the course of 
the experiment (Shearer et al., 2009b). Thus far, however, there have been no reports looking at the 
relationship between clinical signs and viral load in wild birds. 
In this study, 26 BFDV genomes were isolated and sequenced from blood samples of 22 wild and 
four captive Cape parrots caught between 2010 and 2011 in order to characterise the genomes and 
determine the possible origins of the virus through phylogenetic analysis. In addition, the viral load 
in 53 BFDV-infected Cape parrots was determined using qPCR DNA amplification from blood samples 
to test whether there was a useful correlation between viral load and clinical signs. This study 
represents the first detailed report of BFDV infecting wild psittacine populations in South Africa and 
the first to report on BFDV viral load in a wild psittacine population. 
2.2. Materials and methods 
2.2.1. General molecular techniques 
Agarose gel electrophoresis was performed in a 1x working solution of Tris-borate-EDTA (TBE) buffer 
(89 mM Tris, 89 mM boric acid and 2 mM EDTA at pH 8). DNA was resolved on TBE agarose gel 
containing 2.5 mg/mL ethidium bromide. Agarose gels were visualised under either short-
wavelength UV light (254 nm) or long-wavelength UV light (360 nm) illumination depending on 
requirements. 
Restriction enzyme digestions were performed according to manufacturer’s instructions, and all 
restriction enzymes were purchased from Roche (Switzerland), unless otherwise stated. 
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Gel fragments were excised under long-wavelength UV light and gel purified using the QIAquick® Gel 
Extraction kit (Qiagen, Netherlands) as per manufacturer’s instructions. 
Chemically competent E. coli DH5-α cells (E. cloni™, Lucigen, WI, United States of America) were 
transformed as described by Sambrook et al. (1989) and plated on Luria‐Bertani (LB) agar 
supplemented with ampicillin (100 μg/mL), and incubated for 16 hours at 37 °C. E. coli DH5-α 
capable of growth on ampicillin were then inoculated into 10 mL LB broth supplemented with 100 
μg/mL ampicillin and incubated with agitation for 16 hours at 37 °C. 
Plasmid isolations were performed on overnight cultures using the QIAprep® Spin Miniprep kit 
(Qiagen) as per manufacturer’s instructions. 
2.2.2. Sample collection1 
A total of 49 wild Cape parrots were caught using mist nets during the early morning. The captured 
parrots were immediately removed from the net, and each bird was handled by teams of two to 
minimise stress on the bird. Strict precautions were taken to minimise the risk of transmitting 
diseases between birds and the risk of cross-contamination of samples: each holding bag (cotton 
pillow cases) was only used once; new latex gloves were used for each parrot; samples were placed 
immediately into airtight bags and delivered as soon as possible to the lab for analysis. Sex and 
biometric measurements were recorded, and an overall physical condition score based on the 
rounded average of six scores (1-5) for clinical signs attributable to PBFD was assessed (Table 2.1). 
Blood samples were taken from the brachial vein and stored on FTA™ Classic Card (Whatman, 
United Kingdom) at 4 °C. Parrots were released at the location of capture within 10 minutes. This 
research was conducted under full approval from the University of Cape Town’s Animal Ethics 
Committee (Ethics clearance number: 2010/V12/RB) and under permits issued by the Department of 
Economic Development & Environmental Affairs (Eastern Cape) (Permit number: O8071A). 
Blood samples, from which BFDV full-length genomes were isolated, were collected from 26 Cape 
parrots from locations within South Africa. Three of these locations were in the Amathole region in 
the Eastern Cape Province and represented wild populations: 14 samples were collected from Alice, 
one from Stutterheim and seven from King William’s Town. Due to the close proximity of these 
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populations to each other (150 km between the furthest two) and the regular nomadic movements 
of feeding parrots in the area, these samples can be considered to come from a single meta-
population of a minimum of 287 parrots in 2011. Blood samples were collected from four captive 
Cape parrots situated in East London in 2011. Blood was also taken from four captive Cape parrots in 
Cape Town of unknown origin with no history of BFDV infection and used as a PCR control group. No 
assessment of physical condition was performed on the captive birds. 
Table 2.1: Summary of the condition scores. The scores were used to assess overall physical condition of Cape 
parrots based on possible symptoms of BFDV infection 
Clinical 
symptom 
Overall physical condition scores: 1 (Very poor) to 5 (Very good) 
Degraded 
beak 
Lesions, cracks and black blotches are: (5) Absent; (4) >15 mm apart or <10 % of beak 
area; (3) 10-15 mm apart or 10-25 %; (2) 5-10 mm apart or 25-50%; (1) <5 mm apart or 
>50 % 
Darkened 
cere 
Colour of the cere is: (5) White; (4) Light grey to white; (3) Light grey and dry; (2) Dark 
grey; (1) Dark grey to black with lesions 
Degraded 
feathers 
Area degraded/dead feathers estimated on R wing: (5) Absent; (4) < 25 %; (3) 25-50 %; 
(2) 50-75 %; (1) 100 % 
Black 
blotches 
Area black blotches estimated on breast: (5) Absent; (4) Single blotch; (3) 25-50 %; (4) 
50-75 %; (5) >75 % 
Degraded 
down 
feathers 
Area degraded or missing down feather estimated on breast: (5) Absent; (4) <25 %; (3) 
25-50 %; (2) 50-75 %; (1) 100 % 
Excessive 
feather 
dust 
Feather dust on breast is (5) Absent; (4) Visible on a few feathers; (3) Accumulates on 
latex glove during handling; (2) Dispersed into air when parrot moves; (1) Visible on all 
feathers 
DNA extraction and rolling circle amplification 
A circle (4 mm diameter) of FTA™ Classic Card (Whatman) containing dried blood was detached and 
resuspended in a final volume of 220 μL phosphate buffered saline (PBS; 137 mM NaCl, 10 mM 
Na2HPO4, 2.7 mM KCl, 2 mM KH2PO4 at pH 7.4). DNA was extracted from blood samples using a 
DNeasy® Blood & Tissue Kit (Qiagen) and prepared as per manufacturer’s instructions for the 
purification of total DNA from nucleated animal blood cells (spin-column protocol). The DNA sample 
was eluted in a final volume of 200 μL elution buffer. To isolate the BFDV circular ssDNA genome, 
rolling circle amplification (RCA) was performed on the DNA samples using an Illustra™ TempliPhi™ 
Amplification Kit (GE Healthcare, United Kingdom) as described by Shepherd et al. (2008). 
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2.2.3. DNA sequencing 
To clone the full-length BFDV genome, the DNA synthesised during the RCA step was cleaved using 
BamHI (Fermentas, MA, United States of America) and resolved on a 0.8 % (wt/vol) TBE agarose gel 
and gel purified. The 2-kb BFDV genome was then cloned into the pGEM®-3Zf(+)vector (Promega, 
WI, United States of America) as per manufacturer’s instructions. pGEM®-3Zf(+) constructs were 
transformed into competent E. coli DH5-α, and plasmid DNA was isolated from overnight cultures. 
The DNA sequence was determined using primer walking (Macrogen Inc., South Korea). The 
sequences were assembled using DNAMAN (version 5.2.9; Lynnon BioSoft) and Mega6 MEGA 
(Build#: 6140122) (Tamura et al., 2011). The GenBank accession numbers for the sequences are 
KM188440–KM188465. 
2.2.4. DNA sequence and phylogenetic analysis 
In silico analysis of the rep was performed using the Pfam database classification to identify motifs 
(Finn et al., 2014), and in silico amino acid sequence analysis of the CP was performed using 
prosite.expasy.org and the SeqNLS algorithm (Lin and Hu, 2013; Sigrist et al., 2002). 
The twenty-six BFDV genome sequences were aligned to 208 full-length genomes available in the 
GenBank database as at February 2014 using the instance of ClustalW available on Mega6, keeping 
to the default parameters (Varsani et al., 2011). Alignments were also performed separately for the 
rep and cp using the above sequences. Maximum likelihood phylogenies were inferred using Mega6 
with 1 000 nonparametric bootstrap replicates for the full-length genome (general time-reversible 
model using a discrete gamma distribution with five rate categories and by assuming that a certain 
fraction of sites are evolutionarily invariable), the rep (Tamura-Nei model using a discrete gamma 
distribution with five rate categories and by assuming that a certain fraction of sites are 
evolutionarily invariable) and the cp (Tamura-Nei model using a discrete gamma distribution with 5 
rate categories and by assuming that a certain fraction of sites are evolutionarily invariable). Nodes 
with a bootstrap value of less than 0.60 were collapsed using Mesquite (version 2.75 (build 564)). 
2.2.5. Quantitative real-time PCR 
qPCR analysis was performed following the minimum information for publication of quantitative 
real-time PCR experiments (MIQE) guidelines as described by Bustin et al. (2009). For further 
information regarding MIQE, details can found in  Minimum information for publication of 
quantitative real-time PCR experiments. 
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Each qPCR reaction was performed in triplicate using a LuminoCT® SYBR® Green qPCR ReadyMix™ 
(Sigma-Aldrich, MO, United States of America) as per manufacturer’s instructions and primers (5ʹ-
CAGTTAAGGGCGCTTTTGTGGAG-3ʹ and 5ʹ-TTCGGGTCACAGTCCTCCTTG-3ʹ) specific to a 97-bp region 
of the BFDV rep (GenBank accession number GQ165756) together with primers specific to a 97-bp 
region of the P. robustus reference gene, TGF beta 2 (GenBank accession number EU660286) (5ʹ-
TCCCATCTGGCACTGTCTCTG-3ʹ and 5ʹ-ACAGAGCTTTCACCCTCATTTATGG-3ʹ). The Cape parrot TGF 
beta 2 has been used previously to describe phylogeny in psittacines (Wright et al., 2008). This gene 
is present in both humans and mice as a single-copy gene, and it is therefore our assumption that 
this is also true for psittacines (Barton et al., 1987). A BLAT search of the recently sequenced 
Budgerigar genome using Cape parrot TGF beta 2 produced only one alignment, which supports our 
assumption (Ganapathy et al., 2014). Cloned plasmid DNA containing the amplicons in serial dilution 
served as the standard curve for the determination of gene copy number for both rep and TGF beta 
2. Thermocycling was performed using a Rotor-Gene RG-6000 (Qiagen), and the parameters 
consisted of a 10 minute hold at 95 °C followed by cycling (40 repeats) between a 15 s hold for 
denaturation at 95 °C, a 15 s hold at 55 °C for annealing, and a 15 s hold 60 °C for elongation. 
Template specificity was confirmed from the reaction melt curve analysis. The Cq values from the no 
template controls fell below the lower limit. The qPCR efficiencies and r2 values for each reaction 
were 0.990 (SD, 0.0418) and 0.997 (SD, 0.00250) for the BFDV rep and 1.01 (SD, 0.0577) and 0.996 
(SD, 0.00307) for the TGF beta 2 reference gene, respectively. 
2.3. Results 
2.3.1. Genome isolation 
Full-length BFDV genomes were isolated from 22 wild-caught Cape parrots sampled from three sites 
in the Amathole region of the Eastern Cape Province (South Africa) in 2010 (n = 6) and 2011 (n = 16) 
(Table 2.2). Blood samples were collected from wild Cape parrots at sites in King William’s Town (n = 
7), Stutterheim (n = 1) and Alice (n = 14) (Figure 2.1). Parrots captured at each site are thought to 
belong to a single meta-population of a minimum of 287 parrots in 2011. Many of the parrots 
captured for sampling appeared to be malnourished and displayed clinical signs of PBFD. 
BFDV genomes were isolated from an additional four captive Cape parrots in East London with a 
known history of PBFD (Table 2.2). These Cape parrots had been removed from the Amathole 
population in 1995 and subsequently kept together with two breeding pairs added from a captive 
source in KwaZulu-Natal. 
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Figure 2.1: The sampling sites of wild Cape parrots in the Eastern Cape, South Africa. 1, Alice; 2, Stutterheim; 
3, King William’s Town 
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Table 2.2: Data relating to each sequenced BFDV isolate. Listed are the GenBank accession number, isolate 
name and genome length; together with when the host Cape parrot was sampled, and whether the parrot was 
wild or captive. 
Accession # Isolate name Genome length (bp) Sampling year Wild/Captive 
KM188440 BFDV_ZA_FH01_2010 1990 2010 Wild 
KM188441 BFDV_ZA_FH05_2010 1993 2010 Wild 
KM188442 BFDV_ZA_FH07_2010 1992 2010 Wild 
KM188443 BFDV_ZA_FH14_2010 1992 2010 Wild 
KM188444 BFDV_ZA_FH15_2010 1992 2010 Wild 
KM188445 BFDV_ZA_FH16_2010 1991 2010 Wild 
KM188446 BFDV_ZA_FH21_2011 1992 2011 Wild 
KM188447 BFDV_ZA_FH22_2011 1992 2011 Wild 
KM188448 BFDV_ZA_FH23_2011 1992 2011 Wild 
KM188449 BFDV_ZA_FH24_2011 1989 2011 Wild 
KM188450 BFDV_ZA_FH27_2011 1992 2011 Wild 
KM188451 BFDV_ZA_FH37_2011 1991 2011 Wild 
KM188452 BFDV_ZA_FH38_2011 1989 2011 Wild 
KM188453 BFDV_ZA_FH42_2011 1991 2011 Wild 
KM188458 BFDV_ZA_KWT01_2011 1990 2011 Wild 
KM188459 BFDV_ZA_KWT02_2011 1991 2011 Wild 
KM188460 BFDV_ZA_KWT03_2011 1990 2011 Wild 
KM188461 BFDV_ZA_KWT04_2011 1991 2011 Wild 
KM188462 BFDV_ZA_KWT06_2011 1991 2011 Wild 
KM188463 BFDV_ZA_KWT07_2011 1988 2011 Wild 
KM188464 BFDV_ZA_KWT09_2011 1991 2011 Wild 
KM188465 BFDV_ZA_STUT01_2011 1992 2011 Wild 
KM188454 BFDV_ZA_GT02_2011 1995 2011 Captive 
KM188455 BFDV_ZA_GT07_2011 1994 2011 Captive 
KM188456 BFDV_ZA_GT10_2011 1994 2011 Captive 
KM188457 BFDV_ZA_GT11_2011 1995 2011 Captive 
 
2.3.2. Genome analysis 
All of the sequences derived from the 26 genomes successfully isolated and sequenced from Cape 
parrot blood samples were confirmed to be BFDV, with genome lengths varying between 1988-bp 
and 1995-bp (Table 2.2). All sequences were identified as having a characteristic circovirus 
nonanucleotide sequence (5ʹ-TAGTATT/AC-3ʹ) situated within a stem-loop structure followed, by a 
direct octanucleotide repeat as described by Bassami et al. (1998). 
A putative start codon (ATG) was identified for ORF1, encoding rep, together with an upstream TATA 
box and downstream AATAAA polyadenylation signal. A putative start codon (TCT) was identified, as 
described by Niagro et al. (1998), for ORF2 encoding cp, together with a downstream AATAAA 
polyadenylation signal, while no TATA box could be identified. 
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Within the amino acid sequence of the Rep, three motifs involved in RCR were identified in the N-
terminus: motif I (FTLNN, residues 14-18), motif II (GxxHLQGY, residues 48-55) which matches the 
motif found in the geminivirus, banana bunchy top virus, and motif III (YxxK, residues 89-92). A 
putative DNA-binding motif (GKS, residues 170-172) was also identified (Bassami et al., 1998). These 
motifs were also confirmed through analysis of the protein sequence for matches in the Pfam 
database, which identified a region belonging to the viral rep family and a DNA helicase domain (Finn 
et al., 2014). 
Within the amino acid sequence of the CP, a putative bipartite NLS (RRYRRRRRYFxxRRRRF, residues 
29-43) was identified in the N-terminal region (Figure 2.2). This region was also identified as having 
an arginine-rich profile and was found to lack acidic groups. An additional NLS (residues 16-56) was 
identified using the SeqNLS algorithm. Between amino acid residues 16 and 43, the following 
putative NLSs as described by Liu et al. (2001) for PCV were identified in BFDV: one pat7 (PxxRRR), 
four pat4 (RRRR/H) and three bipartite NLSs (Figure 2.2). 
 
Figure 2.2: Putative NLS identified within the N-terminal region of BFDV CP through in silico amino acid 
analysis. Four different NLSs were identified: bipartite NLSs (black), pat7 NLSs (blue), pat4 NLSs (red) and an 
undefined NLS (white). NLSs previously reported by Heath et al. (2006) are indicated by an asterisk (*). Dashed 
lines indicate iterative N-terminal gene deletions at residues 25, 40 and 56 previously performed by Heath et 
al. (2006). Residues 41-56 were required for nuclear localisation.  
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2.3.3. Phylogenetic analysis 
The 26 BFDV isolates were aligned with and compared to 208 full-length BFDV genomes available in 
the GenBank database (Figure 2.3). The 22 isolates from wild Cape parrots formed a separate cluster 
that did not include the four isolates from captive Cape parrots, indicating a different origin (Figure 
2.3, circles and branch lines in red). Within each cluster, the nucleotide pair-wise similarity between 
isolates was greater than 99 %, and for the isolates from wild Cape parrots, this was irrespective of 
location and year of sampling. The wild Cape parrot isolates were most closely related to sequences 
from captive psittacines sampled in Poland and Portugal, collected between 2003 and 2009, and in 
South Africa, collected in 2003 from the KwaZulu-Natal Province, which borders the Eastern Cape 
Province. Two of these sequences were isolated from captive Cape parrots from South Africa and 
Poland in 2003 (Figure 2.3, circles in blue). The four BFDV isolates from captive Cape parrots (‘‘GT’’) 
were most closely related to sequences derived from captive parrots sampled in Japan and Poland 
between 2006 and 2008, and South Africa from KwaZulu-Natal Province in 2003, and all except one 
were isolated from Budgerigars (Melopsittacus undulatus)(Figure 2.3, circles and branch lines in 
blue). Additional BFDV GenBank sequences of viruses isolated from Cape parrots not from this study 
clustered separately in the maximum likelihood phylogeny and were all sampled in the KwaZulu- 
Natal Province, South Africa, in 2003 and 2008 (Figure 2.3, blue circles). 
Inference of phylogenetic relatedness based on the rep separated the 22 wild Cape parrot isolates 
from the four captive Cape parrot isolates. The isolates from wild Cape parrots formed a distinct 
cluster from the rest of the sequences and shared a greater than 99 % nucleotide pair-wise 
similarity, irrespective of location and year of sampling (Figure 2.4, circles and branch lines in red). 
The rep from isolates from captive Cape parrots shared a greater than 99 % nucleotide pair-wise 
similarity and were most closely related to sequences from captive psittacines from Poland sampled 
in 2007 (Figure 2.4, circles and branch lines in blue). A similar pattern emerged when phylogenetic 
relatedness was inferred based on the cp (Figure 2.5). 
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Figure 2.3: Maximum likelihood phylogenetic relationships of the full-length genomes of Cape parrot BFDV 
isolates with all publicly available BFDV genomes. Wild-caught Cape parrot (●), captive Cape parrot (●) and 
Budgerigars (▲). For emphasis, sequences from this study are highlighted in bold, and the branch lines are in 
colour. Sequences isolated from Cape parrot and Budgerigars include the two letter country code and year of 
sampling. The tree was constructed in Mega6 MEGA (Build#: 6140122), and the numbers associated with the 
tree branches are indicative of the percentage of 1 000 full maximum likelihood bootstrap replicates that 
support the existence of the branches. 
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Figure 2.4: Maximum likelihood phylogenetic relationships of the rep of Cape parrot BFDV isolates with all 
publicly available BFDV rep sequences. Wild-caught Cape parrot (●), captive Cape parrot (●) and Budgerigars 
(▲). For emphasis sequences from this study are highlighted in bold and the branch lines are in colour. 
Sequences isolated from Cape parrot and Budgerigars include the two-letter country code and year of 
sampling. The tree was constructed in Mega6 MEGA (Build#: 6140122), and the numbers associated with the 
tree branches are indicative of the percentage of 1 000 full maximum likelihood bootstrap replicates that 
support the existence of the branches. 
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Figure 2.5: Maximum likelihood phylogenetic relationships of the cp of Cape parrot BFDV isolates with all 
publicly available BFDV cp sequences. Wild-caught Cape parrot (●), captive Cape parrot (●) and Budgerigars 
(▲). For emphasis sequences from this study are highlighted in bold and the branch lines are in colour. 
Sequences isolated from Cape parrot and Budgerigars include the two-letter country code and year of 
sampling. The tree was constructed in Mega6 MEGA (Build#: 6140122), and the numbers associated with the 
tree branches are indicative of the percentage of 1 000 full maximum likelihood bootstrap replicates that 
support the existence of the branches. 
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2.3.4. Correlation between signs of PBFD and viral load 
Viral load was determined as a ratio of BFDV rep copies to Cape parrot TGF beta 2 (Table 2.3). The 
condition of the Cape parrots sampled varied, and many appeared to be malnourished and to display 
clinical signs of PBFD (Figure 1.4). There was a significant difference in viral load between the 
different physical condition groups (Kruskal-Wallis; df = 4 (N = 49), H = 25.563, p < 0.0001) (Figure 
2.6A). Post hoc testing using multiple comparisons of mean ranks for all groups indicated that 
parrots with an overall condition score of 1 and 2 had viral loads that were significantly higher than 
birds in symptom score groups 4 and 5. Birds with an overall condition score of below three had a 
mean viral load ratio of greater than 103, while those with a condition score of three and greater had 
a mean viral load ratio of less than one. Males and females showed a similar correlation between 
viral load and overall condition. Two females with an overall physical condition score of 1 but with a 
viral load ratio of less than 1 were found to be infected with a Pseudomonas sp. (Figure 2.6B). 
2.4. Discussion 
To date, there have been nine studies of PBFD in wild parrot populations in New Zealand and 
Australia and in New Caledonia (Ha et al., 2007; Jackson et al., 2014a; Jackson et al., 2014b; Massaro 
et al., 2012; McOrist et al., 1984; Ortiz-Catedral et al., 2009; Peters et al., 2014; Raidal et al., 1993b; 
Sarker et al., 2014a), one in the United Kingdom (Sa et al., 2014), and two in Africa and associated 
islands in Black-cheeked lovebirds and Echo parakeets (Heath et al., 2004; Kundu et al., 2012). The 
first evidence of the emergence of PBFD in wild Cape parrot populations in South Africa was 
reported in 2008, via photographs and field observations. In 2009, 32 Cape parrots were sighted 
with aberrant yellow feathers and observed colour changes in the plumage have previously been 
reported in parrots affected with PBFD (Doneley, 2003; Gerlach, 1994). This prompted the initial 
capture of parrots in 2010 (Boyes, 2011). For the present study, I isolated and sequenced BFDV 
genomes from blood samples on filter paper from 22 wild and four captive Cape parrots collected in 
2010 and 2011 to analyse the genome and determine possible source(s) of the outbreak. 
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Table 2.3: Data relating to each sampled Cape parrot. Listed for each parrot are the sample code, qPCR data 
(presented in log10 scale), sex and overall physical condition score. 
Sample code 
Viral load ratio 
(log10) 
rep copy number 
(log10) 
TGFB2 copy number 
(log10) 
Sex Condition 
FH02 -2.8 1.0 3.8 M 5 
FH13 -2.6 0.9 3.5 M 4 
FH11 -2.4 0.5 2.9 M 4 
FH08 -2.3 1.3 3.6 F 4 
FH12 -1.8 1.3 3.1 M 3 
FH10 -1.7 1.0 2.7 F 5 
FH09 -1.6 0.8 2.4 M 5 
FH07 -1.2 2.7 3.9 F 3 
FH06 -1.2 1.9 3.1 M 3 
FH39 -0.8 2.9 3.7 M 4 
FH17 -0.6 2.9 3.5 M 4 
KWT02 -0.6 2.4 3.0 F 3 
FH30 -0.6 2.8 3.3 M 3 
KWT03 -0.6 2.6 3.2 M 4 
KWT05 -0.5 2.2 2.7 F 3 
KWT09 -0.3 2.7 3.0 F 1 
FH19 -0.3 2.9 3.2 M 5 
FH20 -0.2 2.4 2.6 F 3 
FH27 -0.2 2.4 2.7 F 3 
FH32 -0.2 2.8 2.9 F 4 
FH43 -0.2 2.7 2.8 F 4 
FH42 -0.1 3.2 3.3 M 4 
FH34 -0.1 2.5 2.6 M 4 
KWT10 -0.1 2.7 2.8 F 1 
FH41 0.0 3.1 3.1 M 3 
FH18 0.0 2.3 2.2 F 4 
FH40 0.4 3.6 3.3 M 4 
FH26 0.4 2.9 2.5 M 3 
KWT04 0.5 3.2 2.7 F 3 
FH03 0.9 3.5 2.5 F 2 
FH33 1.0 3.0 2.0 M 2 
FH29 1.0 3.5 2.5 M 3 
FH01 1.3 5.3 4.0 M 2 
FH23 1.9 4.7 2.8 F 3 
FH37 2.1 4.8 2.7 F 2 
FH31 2.5 5.3 2.8 F 2 
FH04 2.7 6.2 3.4 F 1 
KWT07 3.3 6.0 2.7 M 1 
KWT01 3.4 6.3 2.9 M 1 
FH28 3.5 6.8 3.3 M 2 
FH38 3.6 6.7 3.0 M 1 
FH05 3.6 6.9 3.3 F 2 
KWT06 3.7 6.8 3.1 M 1 
FH35 3.9 6.7 2.8 M 2 
STUT01 3.9 6.3 2.4 M 1 
FH21 4.1 7.0 2.9 F 3 
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FH16 4.4 6.7 2.3 M 3 
FH14 4.6 7.8 3.2 M 2 
FH24 4.7 7.6 2.9 F 2 
SE04 (captive) -3.0 0.2 3.2 - - 
SE03 (captive) -2.8 0.4 3.2 - - 
SE01 (captive) -2.7 0.6 3.3 - - 
SE02 (captive) -2.5 0.5 3.0 - - 
 
 
Figure 2.6: BFDV viral loads in Cape parrot. (A) A box plot of viral load in the blood as determined by qPCR 
using the BFDV rep and the Cape parrot TGF beta 2 gene in relation to overall physical condition score for Cape 
parrots. Overall condition was scored as one through five based on observable physical condition, with one 
being poor condition (p < 0.0001). There is no statistical difference within groups ‘a’ and ‘b’, while groups ‘a’ 
and ‘b’ are significantly different from each other. (B) A discontinuous plot of viral loads for males (●) and 
females (○) for each overall physical condition score. 
The isolated genomes were analysed to characterise the virus infecting wild Cape parrots. The 
sequenced BFDV genomes were found to be similar in length to those described in the literature 
(Bassami et al., 1998), and putative motifs identified in the rep sequence resemble those of PCV 
(Mankertz et al., 1998). The CP has been shown to transport the Rep into the nucleus to initiate RCR 
(Heath et al., 2006). Three bipartite NLSs have previously been identified in the N-terminal region of 
the CP; however, only one was found to be required to facilitate localisation. Deletion experiments 
showed that nuclear localisation was active without N-terminal amino acid residues 1-40 but was 
lost when amino acid residues 1-56 were removed, resulting in the loss of a bipartite NLS found 
between residues 39 and 56 (Heath et al., 2006) (Figure 2.2). Our in silico analysis of the CP sequence 
suggests that the NLSs are located between residues 16 and 56. Two bipartite NLSs 
(RRYRRRRRYFxxRRRRF) between residues 16 and 41 described here match those previously 
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identified by Heath et al. (2006). An additional NLS (residues 16-56), identified using the SeqNLS 
algorithm, encompasses all three NLSs identified by Heath et al. (2006). This NLS, together with one 
pat4 and two bipartite NLSs overlap the functional region required for nuclear localisation (residues 
39-56) described previously by Heath et al. (2006). However, none of the motifs that were identified 
fall exclusively within the functional region (Figure 2.2). This may suggest that an alternative motif 
may be present within region 39-56, which is required for nuclear localisation. This finding is not 
surprising, considering that only a limited number of NLSs have been described in the literature (Lin 
and Hu, 2013). 
The BFDV genomes isolated from 26 blood samples from infected birds were successfully cloned and 
sequenced in order to determine the source of the first reported outbreak of the disease in wild 
Cape parrots. These sequences fell into two distinct clades, separating viruses of wild parrots from 
those of captive parrots (Figure 2.3). This suggests that the captive parrots were infected after being 
removed from the wild population in 1995. The captive parrot sequences cluster with sequences 
isolated from Budgerigar samples originating from KwaZulu-Natal Province, South Africa, in 2003. 
This group of isolates was previously described as being unique to Budgerigars (Varsani et al., 2010). 
The captive Cape parrots were kept together with two Cape parrot breeding pairs added from a 
captive source in KwaZulu-Natal Province. It could be suggested that the source of this infection 
originated from these Cape parrot breeding pairs and is related to the isolates previously described 
in Budgerigars from the KwaZulu-Natal Province. Should these captive Cape parrots be reintroduced 
into the wild this poses a threat of potentially introducing a new strain of BFDV into the wild 
population. A similar introduction of BFDV has been suggested to have occurred in Mauritian Echo 
parakeets, in which aviaries used during the initial recovery of the wild population may have served 
as the source of the BFDV infection seen in the wild population (Kundu et al., 2012). As was seen in 
Mauritius, the potential for introducing a new BFDV strain through reintroduction of rehabilitated 
Cape parrots poses a significant threat to the wild population. 
The 22 BFDV isolates sequenced from the wild Cape parrot population shared a high degree of 
similarity irrespective of year or location, as seen from the maximum likelihood phylogenetic 
relationships (Figure 2.3). This similarity suggests that the disease outbreak occurred recently from a 
single introduction, as it has been previously estimated that BFDV has a high evolutionary rate, 
consistent with similar evidence for other small single-stranded DNA viruses (Kundu et al., 2012; 
Sarker et al., 2014b). The presence of BFDV in wild New Caledonian rainbow lorikeets from New 
Caledonia has also been suggested by Jackson et al. (2014b) to be the result of a single introduction 
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with the virus potentially having adapted to the host. A follow-up study of the wild Cape parrot 
population would be useful to assess the evolution of the virus within this population 
A recent outbreak in a wild population of Rose-fronted parakeet (Pyrrhura roseifrons) in New 
Zealand has also been described, stressing that wild endangered populations are susceptible to 
infection from external sources, especially from introduced species such as Eastern rosellas 
(Platycercus eximius) (Jackson et al., 2014a; Massaro et al., 2012). Considering the Cape parrot is 
South Africa’s only endemic psittacine, there is the potential for the emergence feral populations of 
imported parrots to pose a threat to the endemic populations and contribute to the viral diversity. 
The BFDV strain in the wild Cape parrot population probably has a single common ancestor 
throughout their distributional range, while BFDV in the captive population has a different common 
ancestor from a separate disease introduction event. The captive Cape parrots were, however, not 
the source of the outbreak seen in the wild Cape parrots. The origin of the BFDV in the wild Cape 
parrot population is unclear, but due to the lack of divergence among sequences across the 
distributional range, it is assumed to be recent. The clustering of the two clades of BFDVs within 
other, distinct clusters of viruses with diverse origins could indicate that both the captive and wild 
Cape parrots were infected from contacts with other captive parrots. The source of the outbreak 
may have originated from KwaZulu-Natal. To date, this is the most extensive study of PBFD in a wild 
parrot population on the African continent, and the first systematic investigation of virus diversity in 
Cape parrots. The only previous reports of PBFD in wild parrots on the African continent are from a 
single sample from a single Black-cheeked lovebird chick in Zambia and samples taken from Cape 
parrots that had been caught but housed in an aviary prior to being tested, and therefore, a wild 
origin of the virus could not be confirmed. 
Studying BFDV in wild Cape parrots provided a unique opportunity to investigate the relationship 
between viral load and overall physical condition, as wild populations are homogenous and larger 
than those normally found in captivity, and birds in the flock are at varying stages of disease 
progression. Most reports of viruses in captive birds have included small sample sizes and multiple 
species, which complicates assessing overall physical condition (Bert et al., 2005; Katoh et al., 2008). 
In this study, overall physical condition of wild Cape parrots was compared to BFDV viral load in the 
blood, measured by qPCR; previous studies of wild psittacine populations have relied on standard 
and non-quantitative PCR assays to detect the presence of BFDV (Ha et al., 2007; Kundu et al., 2012; 
Ortiz-Catedral et al., 2009).  
The results presented in the current study resemble that reported in a controlled challenge 
experiment in long-billed corellas, in which a peak viraemia of around 106 copies/μL was detected 
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from week two after challenge and continued past week six (Bonne et al., 2009; Shearer et al., 
2009b). This is similar to the maximum rep copy number found in this study (Table 2.3). This high 
viral load suggests that a proportion of Cape parrots in the present study had an active viral 
infection, corresponding to a greater severity of clinical signs. A similar finding for a similar virus has 
been reported in pigs infected with PCV-2 (Brunborg et al., 2004). Cape parrots with a viral load of 
less than one rep copy per reference gene, corresponding to 102 rep copies/μL, had a high overall 
condition score: this result was similar to the vaccinated long-billed corellas study, where a value of 
around 102 copies/μL was seen. This could indicate that these Cape parrots are mounting a 
successful immune response against the virus. This is supported by a previous study, where birds 
with a high HI score had a negative blood sample PCR result (Khalesi et al., 2005). Katoh et al. (2008) 
showed an overall viral load range of between 10-2 and 105 copies per cell in clinical samples 
obtained from a range of captive psittacine species; however, no comparison with overall physical 
condition was made. The viral loads determined in the present Cape parrot study also closely mirror 
these findings. It is worth mentioning that in this study, the isolation of full-length BFDV genomes 
amplified using RCA was only successful in samples with a rep copy number of greater than 102 rep 
copies/μL, and suggests a possible cut-off value for the current extraction protocol. Interestingly, 
there have been no literature reports of a viral load ratio less than 10-3. In the present study, the 
four captive birds with no history of PBFD had rep copy numbers in this range. Similarly, healthy wild 
Cape parrots also had low rep copy numbers, and this indicates that 10-3 is possibly a useful cut-off 
value for assessing birds as being disease-free. Two female Cape parrots with a low overall physical 
condition score were found to be co-infected with a Pseudomonas sp. This secondary infection may 
have contributed to the low overall physical condition score considering that the viral load in these 
birds was low. This is the first reported assessment of BFDV viral load in a wild psittacine population.  
In summary in silico analysis of BFDV CP sequences from this study could not confirm a previously 
identified bipartite NLS situated within residues 39-56, which is required for nuclear localisation. This 
may suggest that an alternate NLS is involved in shuttling the BFDV CP into the nucleus. Phylogenetic 
analysis of the BFDV isolates from wild and captive Cape parrots indicated that there were two 
separate infection events in different populations, and this highlights the potential risk of 
introducing new strains of the virus back into the wild population. Knowledge of isolates infecting 
both captive and wild psittacines in South Africa will assist in the development of a locally produced 
vaccine. It was demonstrated that the presence and degree of observed clinical signs of PBFD in 
Cape parrots correlate strongly with BFDV infection, and more specifically, with viral load. Therefore, 
clinical signs assessed as described may confidently be used to diagnose the presence and relative 
severity of BFDV infections in wild Cape parrots in the field. This will be very useful in ongoing Cape 
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parrot population surveys, and will make it only periodically necessary to capture birds to track the 
incidence of BFDV in the wild population – which will significantly decrease their stress and capture- 
and handling related injuries. 
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Chapter 3: Expression and optimisation of BFDV CP in N. benthamiana 
3.1. Introduction 
At present there are no commercially available treatments for or vaccines against BFDV-related 
disease (Patterson et al., 2013b). However, there is a commercial inactivated chimaeric vaccine 
currently available for the distantly-related PCV which infects pigs and is a major threat to the global 
pork industry (Pérez-Martín et al., 2010; Urniza et al., 2008). Research is ongoing into finding a 
treatment against circoviruses in general. A pan-caspase inhibitor, zVAD, has recently been tested 
against PCV in mice and has demonstrated a reduction in cell apoptosis without impacting on the 
functioning of the immune system (Karuppannan and Kwang, 2011). Considering apoptosis is seen as 
a possible mode of dissemination of BFDV in the gastrointestinal tract and epidermis, this antiviral 
compound may have potential as a treatment against PBFD (Latimer et al., 1991; Trinkaus et al., 
1998). 
Stanford (2004) described the use of interferon produced in chicken cell culture in the treatment of 
PBFD in African grey parrots. Results suggested that total lymphocyte count was increased and the 
virus was successfully cleared from the system. However, no further work has been published on the 
use of interferon, possibly suggesting that the cost of producing a commercial product for the 
treatment of PBFD is prohibitively expensive. Another antiviral that has been tested against BFDV is 
β-(1,3/1,6)-D-glucan. Results showed that viral DNA was absent in the blood after 7-9 months of 
treatment with β-(1,3/1,6)-D-glucan (Tomasek and Tukac, 2007). A treatment regime of this duration 
would not be a viable solution, as it would not prevent the disease from spreading and may not 
prevent repeat infection once treatment has been concluded. Thus, it is likely that the best 
treatment for PBFD is the development of a prophylactic vaccine to prevent the infection of parrots 
with BFDV. 
The virion of BFDV is extremely stable in the environment, therefore treatment of existing infections 
may not prevent re-exposure and infection once the treatment has ended (Latimer et al., 1991). A 
vaccine, however, would hopefully prevent infection from occurring, and would also contain the 
spread of the disease through undiagnosed subclinical infections (Ritchie et al., 1992b). A number of 
vaccine candidates have been developed against BFDV. The first were inactivated virus particles 
purified from whole animal tissue and feathers. The purified virions were inactivated using β-
propiolactone and paraformaldehyde and administered together with a double oil emulsion 
adjuvant (Raidal et al., 1993a). Vaccination resulted in seroconversion; however, the risk of 
incomplete inactivation and ethical considerations associated with isolating virus have made the use 
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of inactivated vaccines undesirable (Bonne et al., 2009; Woods and Latimer, 2000). An alternative to 
inactivated vaccines has been the use of recombinant expression systems for the production of 
subunit vaccines. 
Vaccination of parrots with an insect cell derived BFDV subunit vaccine has been shown to elicit an 
immune response, and reduce to viraemia and shedding after challenge (Bonne et al., 2009). This 
confirms that subunit vaccines are as effective as inactivated vaccines against BFDV. The vaccine 
was, however, unable to prevent viral replication or the vertical transmission of the virus to chicks, 
and would make unvaccinated birds susceptible to disease from vaccinated birds which continue to 
shed virus into the environment (Bonne et al., 2009; Shearer et al., 2009b). Furthermore, these 
recombinant expression systems are costly, and with bacterial fermentations, solubility and post-
translational modifications can adversely affect both protein yield and structural epitopes (Bucarey 
et al., 2009; Patterson et al., 2013b). An additional hindrance in the production of CP in recombinant 
expression systems has been the low yields, especially for the full-length CP. 
Yields of the BFDV CP can be increase if the 5ʹ-end of the gene sequence is removed. This domain of 
the CP has been shown to be arginine rich and contains a number of NLSs, and has been 
demonstrated to be involved in interacting with the viral genome (Heath et al., 2006). Deletion of 
this region could potentially increase expression through relieving the translation bottleneck created 
by repeating arginine residues or by preventing the accumulation of the BFDV CP in the nucleus 
where it could potentially interfere with the cell cycle. The deletion of the N-terminal region of the 
CP may, however, affect the ability of the protein to elicit virus neutralising antibodies. This could be 
through the loss of epitopes specific to the N-terminal region; however, considering the N-terminal 
region is situated within the virion and interacts with the genomic DNA, this would appear unlikely 
(Heath et al., 2006; Rosenberg et al., 1993). An alternative could be that the deletion results in a 
configurational change in the tertiary structure of the BFDV CP, thereby destroying epitopes present 
on the virion surface. A previous investigation by Heath (2006) into the expression of a truncated CP 
using insect cell culture and bacterial fermentation, demonstrated that the recombinant antigen 
reacted poorly to serum derived from infected psittacines. This despite antibodies produced against 
the insect cell and bacterial-produced truncated CP reacting positively when tested against antigen 
derived from the other recombinant expression system. Recent use of plant expression systems for 
the production of full-length BFDV CP show considerable promise for the production of low-cost 
BFDV vaccines (Duvenage et al., 2013). 
In addition to improving BFDV protein expression and accumulation through regulating gene copy 
number, transcription and translation in plants, extracting the protein in a soluble form is important 
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as this increases the final yield after purification. Before extraction, the day on which CP 
accumulation peaks in leaf tissue must be determined. This can be determined empirically through 
evaluating protein accumulation at different time points after initial Agrobacterium infiltration 
(Regnard et al., 2010). Increasing protein solubility during extraction is dependent on the 
components present in the extraction buffer. A number of buffers have been tested for the 
extraction of BFDV CP from insect cell culture and bacterial fermentations. Solubility was found to 
increase when the buffer pH was higher than 7 and a high salt concentration (greater than 100 mM) 
was used (Heath et al., 2006; Patterson et al., 2013b). The inclusion of a detergent has also been 
seen to increase solubility of the protein (Johne et al., 2004; Patterson et al., 2013b). An 
optimisation of extraction buffer would be required for plant-expressed BFDV CP to increase the 
final yield of soluble protein.  
In conclusion, the expression of the BFDV CP as a potential subunit vaccine has been investigated 
using a number of expression platforms. The BFDV CP has been successfully expressed in N. 
benthamiana by Duvenage et al. (2013); however, the yield was considered too low. Increasing 
recombinant protein accumulation in plants remains a challenge and must be determined 
empirically. A number of optimisations have been devised to increase accumulation of recombinant 
proteins and include: protein truncation, codon optimisation, directed protein localisation, 
transcription enhancer elements, suppressing silencing and gene amplification. Optimisation of the 
extraction time and buffer components can also be used to increase the final soluble protein yield. 
The aim of this study was to improve the expression and accumulation of the BFDV CP in N. 
benthamiana and to improve the yield after extraction. For the purposes of the study it was decided 
to design a vaccine candidate based genome sequence isolated from Budgerigars (M. undulatus). 
Cape parrots are considered endangered and are only found in South Africa, and as such Budgerigars 
are preferable for vaccine trials. Expression and accumulation of the BFDV CP in N. benthamiana was 
investigated through comparing and combining different expression optimisations, and through 
optimisation of the extraction buffer. 
3.2. Materials and methods 
3.2.1. General molecular techniques 
High-fidelity amplification of PCR fragments was performed using Pfu DNA Polymerase (Promega) or 
ACCUZYME™ DNA Polymerase (Bioline, United Kingdom) where stated as per manufacturer’s 
instruction. Pfu DNA Polymerase-generated PCR products are blunt-ended; therefore in order to 
prepare PCR products for TA cloning A-tailing was performed. Amplified PCR products were first 
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resolved on a 0.8 % (wt/vol) TBE agarose gel and gel purified. The A-tailing reaction comprised of 10 
ng of the PCR product, 2.5 mM MgCl2, 1x Taq DNA polymerase reaction buffer, 0.2 mM dATP 
(Bioline), 5 units of GoTaq® DNA polymerase (Promega) and deionised water to a final reaction 
volume of 10 μL. The reaction was incubated at 72 °C for 15 minutes; thereafter the PCR product 
was ready for TA cloning. 
Vector DNA was dephosphorylated using 1 U rAPid Alkaline Phosphatase (Roche) as per the 
manufacturer’s instructions. 
Ligation of DNA fragments was performed using T4 DNA ligase (Roche) according to the 
manufacturer’s instructions. 
3.2.2. Molecular cloning 
3.2.2.1. BFDV isolates 
Capsid genes from two BFDV isolates were used for transient protein expression in plants. The first 
isolate was AFG3-ZA (GenBank accession number AY450443) that had previously been isolated from 
an African grey parrot (P. erithacus) by Heath et al. (2004). To determine whether codon usage 
affected expression, the cp from isolate AFG3-ZA was codon optimised for N. tabacum (tco) and 
synthesised in silico by Geneart (Germany). Protein expression based on this isolate was used to 
compare the levels of expression between full-length and truncated capsid genes, and codon-
optimised and wild-type genes. 
A second cp used for transient protein expression in plants was from isolate BKS1ZA_84 (GenBank 
accession number GQ165756) previously described by Varsani et al. (2010) from a Budgerigar. The 
full-length BKS1ZA_84 genome was synthesised in silico by Geneart. Protein expression based on this 
isolate was used to compare the levels of expression based on different localisation signals, and 
between replicating and non-replicating plant expression vectors. 
3.2.2.2. Agrobacterium plant expression vectors 
The plant expression vectors used in this study were based on the pTRA binary Agrobacterium plant 
expression vector suite which was provided by Prof. Rainer Fischer of the Fraunhofer Institute for 
Molecular Biology and Applied Ecology in Germany (Maclean et al., 2007). The vector suite consists 
of three plant expression vectors: pTRAc, pTRAkc-ERH and pTRAkc-rbcs1-cTP (Figure 3.1A-C). All 
vectors contain an expression cassette consisting of a cauliflower mosaic virus (CaMV) 35S promoter 
with a duplicated transcriptional enhancer, chalcone synthase 5ʹ-untranslated region and a CaMV 
35S polyadenylation signal. The expression cassette is flanked by two scaffold attachment region of 
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the tobacco Rb7 gene which is in turn flanked by the left and right borders required for T-DNA 
integration. Each vector contains origins of replication for E. coli and A. tumefaciens, and a bla gene 
conferring ampicillin/carbenicillin resistance. In addition the pTRAkc-ERH and pTRAkc-rbcs1-cTP 
vectors also contain an nptII gene that confers kanamycin resistance required during production of 
transgenic plants. Expression of the nptII gene is controlled by the promoter and polyadenylation 
signal of the nopaline synthase gene, and the entire sequence is situated between the left border 
and scaffold attachment region. 
Each vector is responsible for targeting protein expression to different locations within the cell. 
Protein expression from pTRAc, in the absence of any intrinsic signal sequences encoded by the 
recombinant gene, accumulates in the cytoplasm. The pTRAkc-rbcs1-cTP vector contains an N-
terminal Solanum tuberosum chloroplast-transit peptide sequence of the rubisco small-subunit gene 
rbcS1 that is responsible for accumulating recombinant protein within the stromal compartment of 
the chloroplast. The pTRAkc-ERH vector contains an N-terminal plant codon-optimised signal peptide 
sequence from the murine mAB24 heavy chain gene and a C-terminal SEKDEL signal peptide 
sequence that is responsible for accumulating recombinant protein within the ER. Removal of the 
SEKDEL-encoding sequence for pTRAkc-ERH produces pTRAkc-AH, and allows for the secretion of the 
recombinant protein to the apoplast. 
A fourth plant expression vector that was used for the expression of the BFDV CP is pRIC 3.0 (Figure 
3.1D). This vector incorporates sequences of the BeYDV genome that allow for vector replication in 
planta (Regnard et al., 2010). The BeYDV short intergenic region with promoter activity and gene 
encoding the Rep are included adjacent to the expression cassette. This sequence is flanked by two 
BeYDV long intergenic regions (LIRs). The Rep and the two LIRs are responsible for initiating 
recircularisation and amplification of a replicon containing the expression cassette. 
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Figure 3.1: Agrobacterium pTRA plant expression vectors: pTRAc (A), pTRAkc-ERH (B), pTRAkc-rbcs1-cTP (C) 
and pRIC 3.0 (D). LB and RB, left and right borders for T-DNA integration; SAR, scaffold attachment region of 
the tobacco Rb7 gene; P35SS, CaMV 35S promoter with duplicated transcriptional enhancer; CHS, chalcone 
synthase 5ʹ untranslated region; pA35S, CaMV 35S polyadenylation signal; RK2 ori, origin of replication for A. 
tumefaciens; bla, ampicillin/carbenicillin-resistance bla gene; ColE1 ori, origin of replication for E. coli; LPH, 
signal peptide sequence from the murine mAb24 heavy chain; 6xHis, 6 His tag sequence; SEKDEL, ER-retention 
signal sequence; rbcs1-cTP, chloroplast-transit peptide sequence of a Rubisco small-subunit gene (rbcS1) from 
S. tuberosum; npt II, kanamycin-resistance npt II gene; Pnos and pAnos, promoter and polyadenylation signal 
of the nopaline synthase gene; LIR, BeYDV long intergenic region; rep/repA, BeYDV rep/repA gene; SIR, BeYDV 
short intergenic region. 
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3.2.2.3. pTRAc 6xHis TEV vector 
Initial expression of the BFDV CP was based on previous work performed by Heath (2006) in insect 
cell culture. The Bac-to-Bac® Baculovirus Expression System (Life Technologies, CA, United States of 
America), which included an N-terminal 6xHis tag together with a tobacco etch virus (TEV) protease 
cleavage site, was used to express the CP. It was initially decided to incorporate this tag and cleavage 
site into the design of recombinant plant expression vectors containing the BFDV CP. 
The 6xHis tag together with a TEV protease cleavage site and in-frame NcoI restriction enzyme site 
was amplified by PCR from pFastBac-HTc and modified to include a 5ʹ AflIII site and a 3ʹ XhoI site for 
cloning. The PCR, as described Appendix B.1, was performed using Pfu DNA polymerase (Promega) 
and primers that amplified a 97-bp 6xHis TEV PCR product (Table 3.1). 
The 6xHis TEV PCR product was ligated into pGEM®-T-Easy Vector (Promega) as per manufacturer’s 
instructions. The ligated plasmid constructs were transformed into competent E. coli DH5α. Plasmid 
DNA was isolated from overnight cultures, and the integrity of the clones was confirmed through 
sequencing (Macrogen Inc.) using M13 forward and reverse primers. 
The 6xHis TEV sequence was excised from the pGEM®-T-Easy backbone by digesting the plasmid 
DNA with restriction enzymes AflIII and XhoI, after which the DNA was gel purified. The digestion 
from pGEM®-T-Easy yielded an 82-bp 6xHis TEV fragment with a 5ʹ AflIII and 3ʹ XhoI cleavage sites. 
The pTRAc vector was linearised by restriction digestion with AflIII and XhoI (Figure 3.1A) and 
dephosphorylated. The 6xHis TEV fragment was directionally sub-cloned into pTRAc to produce 
pTRAc 6xHis TEV, and the ligated plasmid constructs were transformed into competent E. coli DH5α. 
Plasmid DNA was isolated from overnight cultures, and the integrity of the clones was confirmed 
through sequencing (Macrogen Inc.) using primers specific to the CHS (5ʹ-
CATTTCATTTGGAGAGGACACG-3ʹ) and pA35SS (5ʹ-GAACTACTCACACATTATTCTGG-3ʹ) regions of the 
expression cassette. 
  
6
6 
Table 3.1 Primers for PCR amplification used during molecular cloning. Underlined sequence indicates the position of the restriction enzyme sites used during cloning. 
Product Sense primer Antisense primer 
Description Size 
(bp) 
Sequence (5ʹ - 3ʹ) Cloning 
site 
Sequence (5ʹ - 3ʹ) Cloning 
site 
6xHis TEV 97 GATGATCACATGTCGTACTACCATCACCAT AflIII CTCTCGAGACCATGGCGCCCTGAAAATAC XhoI 
BFDV AFG3-ZA cp 781 GGAACGCGTTAGGTACATGTGGGGCACCTCTAACTGC AflIII CCTAGATCTCGAGTTAAGTACTTGGATTGTTGGGGGCAAAC BglII, XhoI 
BFDV AFG3-ZA ΔN40 cp 658 GGAACGCGTTAGGTACATGTTCTCAACCAATAGAATTTACAC AflIII CCTAGATCTCGAGTTAAGTACTTGGATTGTTGGGGGCAAAC BglII, XhoI 
BFDV tco AFG3-ZA ΔN40 cp 673 GGAACGCGTTAGGTACATGTTCTCTACTAACAGGATCTAC AflIII CATGAGCTCGAATTCTCTAGAAG  
  GTAACGCGTTAGGTACATGTGGGGCACCTCTAAC AflIII/MluI GTGATGGTGATGCCCTTCAGTTCTGGGATTATTGG  
BFDV BKS1ZA_84 cp 6xHis 796 GTAACGCGTTAGGTACATGTGGGGCACCTCTAAC AflIII/MluI CATCTCGAGCTAGTGATGGTGATGGTGATGCCCTTC XhoI 
rbcs1-cTP BFDV BKS1ZA_84 cp 6xHis 959 GGACCATGGCTTCCTCTGTTATTTCCTC NcoI CATCTCGAGCTAGTGATGGTGATGGTGATGCCCTTC XhoI 
  GTAACGCGTTAGGTACATGTGGGGCACCTCTAAC AflIII/MluI CTCATCTTTCTCAGAGTGATGGTGATGGTGATGCC  
BFDV BKS1ZA_84 cp 6xHis SEKDEL 814 GTAACGCGTTAGGTACATGTGGGGCACCTCTAAC AflIII/MluI CCTCTCGAGCTAGAGCTCATCTTTCTCAGAGTGAT XhoI 
LPH BFDV BKS1ZA_84 cp 6xHis SEKDEL 860 GGACCATGGAGTGGAGCTGGATCTTC NcoI CCTCTCGAGCTAGAGCTCATCTTTCTCAGAGTGAT XhoI 
LPH BFDV BKS1ZA_84 cp 6xHis 840 GGACCATGGAGTGGAGCTGGATCTTC NcoI CATCTCGAGCTAGTGATGGTGATGGTGATGCCCTTC XhoI 
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3.2.2.4. Subcloning 
The cp for isolate AFG3-ZA had previously been cloned into the pGEM®-T Easy Vector (Promega) by 
Heath et al. (2004) and served as template DNA for PCR amplification of a full-length and truncated 
cp with modifications for cloning into the pTRAc 6xHis TEV vector. The tobacco-codon-optimised 
AFG3-ZA cp synthesised by Geneart included restriction enzyme sites for direct cloning of the full-
length gene into the pTRAc 6xHis TEV vector and served as template for PCR amplification of a 
truncated version with modifications for cloning into the pTRAc 6xHis TEV vector. 
The AFG3-ZA cp was amplified by PCR and modified to include a 5ʹ AflIII site and a 3ʹ XhoI and BglII 
site after the stop codon. The truncated cp that would express a 40 residue N-terminal deletion 
product was produced by PCR amplification and modified to include a 5ʹ AflIII site and a 3ʹ XhoI and 
BglII site after the stop codon. The tobacco-codon-optimised AFG3-ZA truncated cp was produced by 
PCR amplification and modified to include a 5ʹ AflIII site. 
PCR reactions, as described Appendix B.2, were performed using Pfu DNA polymerase (Promega) 
and primers that amplified PCR products: 781-bp BFDV AFG3-ZA cp, a 658-bp BFDV AFG3-ZA ΔN40 
cp and a 673-bp BFDV tco AFG3-ZA ΔN40 cp (Table 3.1).  
The PCR products were individually ligated into the pGEM®-T-Easy Vector (Promega) as per 
manufacturer’s instructions. The ligated plasmid constructs were transformed into competent E. coli 
DH5α, and the plasmid DNA was isolated from overnight cultures. The integrity of the clones was 
confirmed through sequencing (Macrogen Inc.) using M13 forward and reverse primers. 
The modified BFDV AFG3-ZA cp variants were excised from the pGEM®-T-Easy backbone and 
Geneart carrier plasmid by digesting the plasmid DNA with AflIII and XhoI, after which the DNA was 
gel purified. The digestions yielded fragments: 746-bp BFDV AFG3-ZA cp, 623-bp BFDV AFG3-ZA 
ΔN40 cp, 749-bp BFDV tco AFG3-ZA cp and 626-bp BFDV tco AFG3-ZA ΔN40 cp all with 5ʹ AflIII and 3ʹ 
XhoI cleavage sites. The pTRAc 6xHis TEV vector was linearised by restriction digestion with NcoI and 
XhoI, and dephosphorylated. 
The modified BFDV AFG3-ZA cp variants were directionally sub-cloned into pTRAc 6xHis TEV (Figure 
3.2). The ligated plasmid constructs were transformed into competent E. coli DH5α. Plasmid DNA 
was isolated from overnight cultures, and the integrity of the clones was confirmed through 
sequencing (Macrogen Inc.) using primers specific to the CHS and pA35SS regions of the expression 
cassette. 
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The full-length genome for isolate BKS1ZA_84 synthesised by Geneart served as the template for 
PCR amplification of cp with modifications for cloning into the pTRAc, pTRAkc-rbcs1-cTP and pRIC 
3.0. The BKS1ZA_84 cp was amplified by PCR reaction and modified by a second PCR reaction to 
include a 5ʹ MluI site, chloroplast targeting linker sequence and AflIII site and a 3ʹ 6xHis tag, stop 
codon and XhoI site. The PCR reaction, as described in Appendix B.3, was performed using 
ACCUZYME™ DNA polymerase (Bioline) and primers that amplified a final 796-bp BFDV BKS1ZA_84 
cp 6xHis PCR product (Table 3.1). The amplified PCR product was resolved on 1 % (wt/vol) TBE 
agarose gel and gel purified. This served as template for the second primer pair under identical 
thermocycling parameters (Table 3.1). 
The amplified 796-bp BFDV BKS1ZA_84 cp 6xHis PCR product was purified and then digested with 
either AflIII and XhoI or MluI and XhoI, after which the DNA was gel purified. The digestions yielded 
BFDV BKS1ZA_84 cp 6xHis fragments of 773-bp (5ʹ AflIII and 3ʹ XhoI) and 784-bp (5ʹ MluI and 3ʹ XhoI). 
The pTRAc and pRIC 3.0 vectors were linearised by restriction digestion with AflIII and XhoI, while 
pTRAkc-rbcs1-cTP was linearised by restriction digestion with MluI and XhoI (Figure 3.1). The BFDV 
BKS1ZA_84 cp 6xHis fragments were directionally sub-cloned into the dephosphorylated vectors 
(Figure 3.2). The ligated plasmid constructs were transformed into competent E. coli DH5α. Plasmid 
DNA was isolated from overnight cultures, and sequence integrity was performed as described 
above. 
The pTRAkc-rbcs1-cTP BFDV BKS1ZA_84 cp 6xHis construct served as the template for PCR 
amplification of cp with modifications for cloning into the pRIC 3.0. The BFDV BKS1ZA_84 cp 6xHis 
gene including the 5ʹ chloroplast-transit peptide sequence was amplified by PCR reaction and 
modified to include a 5ʹ NcoI site. The PCR reaction, as described in Appendix B.5 was performed 
using ACCUZYME™ DNA polymerase (Bioline) and primers that amplified a 959-bp rcbs1-cTP BFDV 
BKS1ZA_84 cp 6xHis PCR product (Table 3.1). The amplified PCR product was resolved on a 1 % 
(wt/vol) TBE agarose gel and gel purified. 
  
6
9 
 
Figure 3.2: Plant expression cassettes used in this study together with the Agrobacterium plant expression vectors they were cloned into and the BFDV CP localisation. 
BFDV isolate AFG3-ZA cp (blue); ΔN40, gene truncated to express a 40 residue N-terminal deletion product; tobacco-codon-optimised BFDV isolate AFG3-ZA cp (green); 
BFDV isolate BKS1ZA_84 cp (purple); P35SS, CaMV 35S promoter with duplicated transcriptional enhancer; CHS, chalcone synthase 5ʹ untranslated region; 6xHis TEV, 6 His 
tag sequence and TEV protease recognition site; pA35S, CaMV 35S polyadenylation signal; 6xHis, 6 His tag sequence; LPH, signal peptide sequence from the murine mAb24 
heavy chain; SEKDEL, ER-retention signal sequence; rbcs1-cTP, chloroplast-transit peptide sequence of a Rubisco small-subunit gene (rbcS1) from S. tuberosum. 
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The purified PCR product was then digested with NcoI and XhoI, after which the DNA was gel 
purified. The digestion yielded a 951-bp rcbs1-cTP BFDV BKS1ZA_84 cp 6xHis fragment with 5ʹ NcoI 
and 3ʹ XhoI cleavage sites. The fragment was then directionally sub-cloned into 5ʹ AflIII and 3ʹ XhoI 
linear and dephosphorylated pRIC 3.0 (Figure 3.2). The ligated plasmid construct was transformed 
into competent E. coli DH5α. Plasmid DNA was isolated from overnight cultures, and sequence 
integrity were performed as described above. 
The pTRAc BFDV BKS1ZA_84 cp 6xHis construct served as the template for PCR amplification of cp 
with modifications for cloning into the pTRAkc-ERH vector. The BFDV BKS1ZA_84 cp 6xHis gene was 
amplified by PCR reaction and modified by a second PCR reaction to include a 3ʹ SEKDEL, stop codon 
and XhoI site. The PCR reaction, as described in Appendix B.7 was performed using ACCUZYME™ 
DNA polymerase (Bioline) and primers that amplified a final 814-bp BFDV BKS1ZA_84 cp 6xHis 
SEKDEL PCR product (Table 3.1). The amplified PCR product was gel purified, and served as template 
for the second primer pair under identical thermocycling parameters (Table 3.1). 
The PCR product was purified digested, along with pTRAc BFDV BKS1ZA_84 cp 6xHis, with AflIII and 
XhoI, after which the DNA was gel purified. The digestion yielded a 791-bp BFDV BKS1ZA_84 cp 6xHis 
SEKDEL fragment and 773-bp BFDV BKS1ZA_84 cp 6xHis fragment both with 5ʹ AflIII and 3ʹ XhoI 
cleavage sites. The pTRAkc-ERH vector was linearised by restriction digestion with NcoI and XhoI, 
and dephosphorylated (Figure 3.1B). The BFDV BKS1ZA_84 cp 6xHis SEKDEL and BFDV BKS1ZA_84 cp 
6xHis fragments were directionally sub-cloned into the pTRAkc-ERH vector (Figure 3.2). The ligated 
plasmid constructs were transformed into competent E. coli DH5α. Plasmid DNA was isolated from 
overnight cultures, and sequence integrity was performed as described above. 
The pTRAkc-ERH BFDV BKS1ZA_84 cp 6xHis SEKDEL construct served as the template for PCR 
amplification of cp with modifications for cloning into the pRIC 3.0. The BFDV BKS1ZA_84 cp 6xHis 
SEKDEL gene including the 5ʹ signal peptide sequence from the murine mAB24 heavy chain gene was 
amplified by two PCR reactions and modified to include a 5ʹ NcoI site and with the second PCR 
reaction to replace the 3ʹ SEKDEL sequence with an XhoI site. The PCR reactions, as described in 
Appendix B.7, were performed using ACCUZYME™ DNA polymerase (Bioline) and primers that 
amplified an 860-bp LPH BFDV BKS1ZA_84 cp 6xHis SEKDEL PCR product and an 840-bp LPH BFDV 
BKS1ZA_84 cp 6xHis PCR product (Table 3.1). The PCR products were purified using a QIAquick® PCR 
Purification kit (Qiagen). 
The purified PCR products were then digested with NcoI and XhoI, after which the DNA was gel 
purified. The digestion yielded an 848-bp LPH BFDV BKS1ZA_84 cp 6xHis SEKDEL and 830-bp LPH 
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BFDV BKS1ZA_84 cp 6xHis fragment both with 5ʹ NcoI and 3ʹ XhoI cleavage sites. The fragments were 
then directionally sub-cloned into 5ʹ AflIII and 3ʹ XhoI, linear and dephosphorylated pRIC 3.0 (Figure 
3.2). The ligated plasmid constructs were transformed into competent E. coli DH5α. Plasmid DNA 
was isolated from overnight cultures, and sequence integrity was performed as described above. 
3.2.3. Transformation of A. tumefaciens 
The A. tumefaciens GV3101::pMP90RK cells were made electrocompetent using the method 
described by Shen and Forde (1989). Cells were electroporated using 40–400 ng of recombinant 
plasmid as described by Maclean et al. (2007). Recombinant clones were selected using agar plates 
containing kanamycin (30 μg/mL), rifampicin (50 μg/mL) and carbenicillin (50 μg/mL) and incubated 
at 27 °C. 
Recombinant Agrobacterium clones were confirmed by preparing plasmid isolations from overnight 
cultures and back-transformation of the DNA into competent E. coli DH5-α. Plasmid isolations and 
sequence integrity were performed as described above. 
3.2.4. A. tumefaciens-mediated transient expression 
For infiltration, recombinant A. tumefaciens GV3101::pMP90RK were grown up overnight at 27 °C 
with agitation in induction medium (LB medium, 20 mM acetosyringone and 10 mM 2-morpholin-4-
ylethanesulfonic acid [MES] at pH 5.6) supplemented with kanamycin (30 μg/mL), rifampicin (50 
μg/mL) and carbenicillin (50 μg/mL). The strain LBA4404 containing pBIN-NSs, provided by Marcel 
Prins from the Laboratory of Virology, Wageningen in the Netherlands, was supplemented with 
kanamycin (30 μg/mL), rifampicin (50 μg/mL) and 2 mM MgSO4. The addition of MgSO4 was to 
prevent cell clumping during incubation (Maclean et al., 2007). The NSs protein has been shown to 
suppress post-transcriptional gene silencing in plants, leading to an increase in transient protein 
expression (Takeda et al., 2002). Cells were harvested by centrifugation at 4 000 g for 10 minutes, 
and resuspended in infiltration medium (3% sucrose, 10 mM MgCl2, 200 mM acetosyringone and 10 
mM MES at pH 5.6). The suspensions were diluted to the required absorbance (OD600) using an 
Ultrospec™ 10 Cell density meter (Amersham Biosciences, United Kingdom) and incubated at 22 °C 
for 2 hours. The incubation step was required for the expression of the Agrobacterium vir genes for 
T-DNA transfer into the plant cell. The OD600 at infiltration was optimised in order to determine the 
best density for the expression of the BFDV CP. The A. tumefaciens GV3101::pMP90RK suspensions 
of each expression construct were infiltrated with and without strain LBA4404 containing pBIN-NSs 
into 6-week-old N. benthamiana plants by injecting the suspension into the abaxial spaces using a 
needleless 1 mL syringe. The plants were maintained in a greenhouse under a 16 hour light and 8 
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hour dark photoperiod at light intensity of 60–80 μE/m2/s and 22 °C. Negative controls included 
plant leaf tissue that was non-infiltrated, infiltrated with infiltration medium only and infiltrated with 
a suspension containing only strain LBA4404 with pBIN-NSs. Time trials were conducted to evaluate 
and compare expression of the BFDV CP with the different vectors. 
3.2.5. Protein extraction and western blot analysis 
Leaf discs were harvested using the cap of a microcentrifuge tube at 1, 3, 5 and 7 days post 
infiltration (dpi). The plant material was prepared into a fine powder using a micro-pestle and liquid 
nitrogen. A 100 μL of extraction buffer per leaf disc was then added and the leaf material was 
vortexed. The extraction buffer used to prepare crude leaf extract included PBS and general lysis 
buffer (50 mM Tris, 100 mM NaCl, 10% glycerol and 1 mM dithiothreitol at pH 7.5). The general lysis 
buffer has been described as an initial starting buffer from which to further optimise (European 
Molecular Biology Laboratory, 2015). Individual components of the general lysis buffer were 
optimised: these included pH (buffer solutions included citric acid – sodium citrate; and glycine – 
NaOH), salt concentration, reducing agent and the addition of detergent (Triton X-100; BDH 
Laboratory Supplies, United Kingdom). The suspension of leaf tissue was clarified by centrifugation 
at 1500 g for 3 minutes and the supernatant representing the crude leaf extract was collected for 
further analysis. The crude leaf extracts were incubated at 90 °C for 10 minutes in sample application 
buffer prepared for analysis by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) (Sambrook et al., 1989). 
The proteins were resolved on 10% SDS polyacrylamide gels and an equal volume of crude plant 
extract or equal amount of total soluble protein (TSP) were loaded into each lane. Gels were stained 
with Coomassie Brilliant Blue stain for 2 hours at 37 °C and destained overnight. To determine the 
sizes of the resolved proteins in Coomassie stained gels and on nitrocellulose membranes a 
PageRuler™ Prestained Protein Ladder (Thermo Scientific, MA, United States of America) was used 
as a molecular weight marker. After gel electrophoresis the proteins were transferred onto 
nitrocellulose membranes at 15 V for 1 hour using a Trans-blot®SD semi-dry transfer cell (Bio-Rad, 
CA, United States of America). After electrophoretic transfer the membranes were blocked in 
blocking buffer (5% non-fat dairy milk and 1x PBST [137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 2 
mM KH2PO4 at pH 7.4 and 0.1% Tween-20]). The membranes were probed overnight at 4 °C with 
1:2000 anti-His tag mouse IgG antibody (AbD Serotec, NC, United States of America) or 1:2000 anti-
BFDV ΔN40 CP polyclonal IgG antibody produced in rabbit (Duvenage et al., 2013) diluted in blocking 
buffer. The membranes were washed four times with blocking buffer for 15 minutes each and 
afterward incubated in a 1:10 000 dilution of anti-mouse IgG (whole molecule) alkaline phosphatase 
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antibody produced in goat affinity isolated antibody (Sigma-Aldrich) or anti-rabbit IgG (whole 
molecule) alkaline phosphatase antibody produced in goat affinity isolated antibody (Sigma-Aldrich) 
in blocking buffer for 1 hour at 37 °C. Membranes incubated in secondary antibody were washed 
four times with 1x PBST, with 15 minutes for each wash. Detection was performed with 5-bromo, 4-
chloro, 3-indolylphosphate (BCIP) and nitroblue tetrazolium (NBT) phosphatase substrate (KPL, MD, 
United States of America). Protein expression, extraction and western blot analysis was repeated at 
least three times to confirm the expression of the BFDV CP. 
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3.3. Results 
3.3.1. Expression of the BFDV CP in N. benthamiana 
Recombinant Agrobacterium containing the BFDV cp fused to a histidine tag sequence was 
infiltrated into N. benthamiana to determine whether the gene was expressed. A silencing 
suppressor, NSs, was co-expressed to improve expression of the cp. Leaf tissue was harvested and 
analysed by western blot using an antibody specific for the histidine tag. Results show that the 30.1 
kDa CP was expressed in N. benthamiana (Figure 3.3). This was not present in the control lanes and 
was not as a result of the expression of the silencing suppressor; however, a band of approximately 
17 kDa was present in all samples. The antibody also detected a protein of approximately 60 kDa and 
a fainter band at approximately 120 kDa. The co-infiltration with the silencing suppressor improved 
expression of the CP as an increase in protein band intensity is apparent for the CP co-expressed 
with the silencing suppressor. 
 
 
Figure 3.3: Western blot analysis of BFDV CP expression in N. benthamiana. BFDV CP (GenBank accession 
number GQ165756) fused with a C-terminal histidine tag (30.1 kDa) was expressed in the leaves of N. 
benthamiana after infiltration with Agrobacterium containing the BFDV cp in the presence (+) and absence (-) 
of the silencing suppressor NSs. Negative controls were non-infiltrated plant leaves, leaves infiltrated with 
medium only, and medium containing NSs only. Arrow indicates BFDV CP with C-terminal histidine tag. TSP 
was extracted from leaf tissue harvested on day 6 post-infiltration. An equal volume of each sample was 
loaded into the lanes, the CP was detected using anti-histidine antibody and the BCIP/NBT substrate reaction 
was performed for 1 hour. M – prestained protein marker. 
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To confirm that the protein that was expressed was indeed the BFDV CP, antiserum raised in rabbits 
against BFDV CP produced in bacteria was used as a primary antibody to detect expression of the CP 
in the leaves of N. benthamiana (Figure 3.4). The CP fused to a histidine tag both in the presence and 
absence of the silencing suppressor was unable to be detected using this antibody. However, the 
native protein (30 kDa) was readily detected and the intensity of the band was increased in the 
presence of the silencing suppressor. 
 
Figure 3.4: Western blot analysis of BFDV CP using anti-BFDV CP serum raised in rabbits. The BFDV CP fused 
to (+) and without (-) a C-terminal histidine tag was expressed in the leaves of N. benthamiana infiltrated with 
Agrobacterium containing the BFDV cp in the presence (+) and absence (-) of the silencing suppressor NSs. TSP 
was extracted from leaf tissue harvested on day 3 post-infiltration. An equal volume of each sample was 
loaded into the lanes, the CP was detected using anti-BFDV CP and the BCIP/NBT substrate reaction was 
performed for 1 hour. M – prestained protein marker. 
3.3.2. Optimisation of BFDV CP expression in N. benthamiana 
To determine whether the expression of BFDV CP in N. benthamiana is affected by deletion of the N-
terminal region the first 120 nucleotides of the cp encoding the first 40 amino acid residues was 
removed and expression compared to that of the full-length gene (Figure 3.5). The expression of the 
N-terminal deletion CP (26.5 kDa) was higher than the full-length CP and peaked on day 5 post-
infiltration. The plant-produced N-terminal deletion CP corresponded in molecular weight to the 
positive control which was N-terminal deletion CP (26.5 kDa) previously produced in insect cell 
culture (Heath, 2006). The expression of the full-length protein was seen to peak on day 3 post-
infiltration. The expression of both proteins decreased sharply after the peak was reached. 
 
 
Figure 3.5: Western blot analysis of plant-produced full-length and truncated BFDV CP. Transient expression 
of BFDV CP via Agrobacterium infiltration into N. benthamiana leaves was assessed over seven days. An equal 
volume of sample was loaded into the lanes. The full-length (32.1 kDa) and N-terminal deletion (26.5 kDa) 
BFDV CP, fused to a N-terminal histidine tag and TEV protease cleavage site, was detected using anti-histidine 
antibody and the BCIP/NBT substrate reaction was performed for 1 hour. M – prestained protein marker; P – 
positive control (truncated BFDV CP produced in insect cell culture). 
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The codon usage of the full-length (western blot data not shown) and N-terminal deletion BFDV cp 
were optimised to that of N. tabacum to determine whether this would result in an increase in 
protein expression (Figure 3.6). The expression of the N-terminal deletion of both the codon-
optimised and wild-type gene appeared similar and increased over the 5 day period. Further 
optimisation studies were based on the full-length gene in an attempt to improve expression while 
retaining the DNA binding domain of the BFDV CP. 
 
Figure 3.6: Western blot analysis of BFDV CP encoded by codon-optimised and wild-type cp. Expression over 
five days of N-terminal deletion BFDV cp variants, fused to an N-terminal histidine tag and TEV protease 
cleavage site. An equal volume of sample was loaded into the lanes. The CP was detected using anti-histidine 
antibody and the BCIP/NBT substrate reaction was performed for 1 hour. M – prestained protein marker; P – 
positive control (plant-produced N-terminal deletion BFDV CP). 
Another factor to consider when optimising expression is the day on which the leaf tissue is 
harvested. The consensus for when accumulation of the full-length BFDV CP expressed in leaf tissue 
reached its maximum was found to be day 3 (Figure 3.7A). The expression peaked on day 3 after 
which there was a marked decline towards day 7. This expression pattern was mostly observed for 
the expression of all iterations of full-length CP tested. In comparison to the 30 kDa protein marker, 
the full-length BFDV CP with the C-terminal His tag was found to be smaller in size and therefore 
smaller than the size determined through in silico analysis (30.1 kDa). To further enhance expression 
of the full-length BFDV CP, the OD600 at which the Agrobacterium was infiltrated into N. 
benthamiana leaves was optimised. Optimisation of OD600 was performed for Agrobacterium 
containing the cp and the NSs silencing suppressor (Figure 3.7B-C). Expression of the full-length 
BFDV CP in the absence of the NSs silencing suppressor was improved when N. benthamiana leaves 
were infiltrated at an OD600 of between 0.50 and 1.00 (Figure 3.7B). When the NSs was co-infiltrated 
at an OD600 of 0.25 expression was improved when compared to expression without the presence of 
NSs. Co-infiltration of NSs with an OD600 of 0.50 and 1.00 did not improve expression of the CP. The 
NSs silencing suppressor infiltrated at an OD600 of 0.25 improved the expression of the CP at all 
absorbance values (Figure 3.7C). The greatest difference in expression in the presence and absence 
of NSs was seen when the cp was infiltrated at an OD600 of 0.50. 
 77 
 
Figure 3.7: Western blot analysis of BFDV CP expression over a seven day period and on day 3 using different 
Agrobacterium infiltration densities. (A) A representative western blot of the accumulation over seven days of 
full-length BFDV CP with C-terminal histidine tag in the presence of the NSs silencing suppressor. (B) 
Optimisation of absorbance (OD600) of Agrobacterium suspension infiltrated into N. benthamiana leaves and 
harvested on day 3. Absorbance was assessed for Agrobacterium containing the cp or NSs silencing suppressor 
gene. (C) The variation of the infiltration OD600 for Agrobacterium containing the cp in the presence or absence 
of NSs silencing suppressor gene infiltrated into N. benthamiana leaves. An equal amount of TSP was loaded 
into each lane, the CP was detected using anti-histidine antibody and the BCIP/NBT substrate reaction was 
performed for 30 minutes. M – prestained protein marker and histidine tagged protein marker, P – positive 
control (plant-produced full-length BFDV CP). 
The effect of targeting the full-length BFDV CP to different organelles was assessed together with 
gene amplification. The organelles targeted were the chloroplast and the ER, and secretion to the 
apoplast was also investigated. The CP was successfully expressed for each plant expression vector 
(Figure 3.8). Additional proteins with higher molecular weights than the CP were detected in the 
SDS-PAG electropherograms, and are similar to bands detected in Figure 3.3. Protein expression in 
the cytoplasm resulted in histidine-tagged proteins of approximately 55 kDa, 70-100 kDa and 100-
130 kDa. Additional histidine-tagged proteins, with approximate molecular weights of 35 kDa, 55-70 
kDa and 100 kDa, were also detected when the CP was targeted to the chloroplast. To a lesser 
extent, the CP targeted to the ER and apoplast resulted in additional histidine-tagged proteins of 
approximately 55 kDa and 100-130 kDa which were similar to those found in the cytoplasm. The 
cytoplasm remained the most favourable location for expression, followed by targeting to the 
chloroplast and the ER. Accumulation of protein when targeted to the apoplast was lower than that 
in the other locations. Gene amplification had a mixed effect on expression. Expression in the 
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cytoplasm together with targeting of the CP to the chloroplast appeared to be improved when gene 
amplification occurred. However, gene amplification appeared to decrease expression when the CP 
was secreted to the apoplast and had no effect on expression when targeted to the ER. Overall, 
expression in the cytoplasm with gene amplification was most favourable. 
 
Figure 3.8: Western blot analysis of the effect of targeted BFDV CP localisation and BFDV cp gene 
amplification on expression. Protein was extracted on day 3 from N. benthamiana leaves. Expression of the CP 
as indicated by black arrows in the cytoplasm (30.1 kDa), the chloroplast (36.0 kDa), ER (33.0 kDa) and 
secretion into the apoplast (32.3 kDa). Expression in the presence (+) or absence (-) DNA amplification of the 
cp was assessed in all cases. An equal amount of TSP was loaded into each lane, the CP was detected using 
anti-histidine antibody and the BCIP/NBT substrate reaction was performed for 30 minutes. M – prestained 
protein marker, P – positive control (plant-produced full-length BFDV CP). 
3.3.3. Optimisation of BFDV CP extraction from N. benthamiana leaf tissue 
Initially TSP from harvested leaf tissue was extracted using PBS buffer (pH 7.6). To determine 
whether optimisation of extraction buffer could increase the yield of full-length BFDV CP a general 
lysis buffer (pH 7.5) was tested. This buffer was further optimised for salt and reducing agent 
concentration, detergent (% v/v) and pH (Figure 3.9). The use of the general lysis buffer increased 
the yield of CP when compared to the PBS buffer. No improvement in extraction was observed when 
the salt concentration in the general lysis buffer was increased or removed all together. Neither the 
addition of detergent nor the removal of the reducing agent had a positive effect on the extraction 
(Figure 3.9A). When the pH of the general lysis buffer was lowered to pH 6.0 more CP was extracted. 
At pH 4.5 less CP was extracted from the leaf tissue while at pH 9.0 and pH 10.5 a similar yield was 
achieved (Figure 3.9B). Combining both pH 6.0 and a high salt concentration did not improve CP 
extraction over and above the original general lysis buffer (Figure 3.9C). 
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Figure 3.9: Western blot analysis of buffer optimisation for extracting BFDV CP. (A) TSP was extracted leaf 
tissue harvested on day 3 post-infiltration using PBS buffer (pH 7.6) or general lysis buffer (50 mM Tris, 100 
mM NaCl, 10% glycerol and 1 mM dithiothreitol at pH 7.5). Optimisation of the general lysis buffer with 
respect to salt, detergent and reducing agent. (B) Optimisation of the general lysis buffer with respect to pH. 
(C) Comparison between PBS buffer, general lysis buffer and a buffer (pH 6.0, 500 mM salt, and 1 mM reducing 
agent) optimised for salt concentration and pH. An equal volume of each sample was loaded into the lanes, 
the CP was detected using anti-histidine antibody and the BCIP/NBT substrate reaction was performed for 
between 30 minutes and 1 hour. M – prestained protein marker and histidine tagged protein marker. 
3.4. Discussion 
A number of recombinant expression systems have been successful used to produce the BFDV CP. 
These include insect cell culture, and bacterial and yeast fermentation expression platforms (Heath 
et al., 2006; Johne et al., 2004; Patterson et al., 2013b; Sariya and Prompiram, 2014; Stewart et al., 
2007). The disadvantage with these recombinant expression systems is that they are generally costly 
in the case of eukaryotic cells, and with bacterial fermentations solubility and post-translational 
modifications can affect protein yield and structural epitopes (Bucarey et al., 2009; Patterson et al., 
2013b). An increasingly useful alternative technology has been the use of plant expression systems, 
which can been seen as a complementary system to traditional cell culture and microbial 
fermentation technologies for the production of region-specific and niche market products (Stoger 
et al., 2014). 
The use of plant expression systems, specifically whole-plant N. benthamiana, has already been used 
successfully in the expression of the BFDV CP fused to a elastin-like polypeptide (Duvenage et al., 
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2013). In the present study the cp from BFDV isolates AFG3-ZA and BKS1ZA_84 were cloned into 
plant expression vectors and transiently expressed in plants. Isolate AFG3-ZA was chosen as it had 
previously been used in the successful expression of BFDV CP through recombinant baculoviruses in 
insect cell culture (Heath et al., 2006). The choice of isolate BKS1ZA_84, identified in Budgerigar, 
follows from the investigation into BFDV affecting endemic Cape parrot. BFDV isolates from captive 
Cape parrot were found to be closely related to South African Budgerigar isolates, including 
BKS1ZA_84, previously identified by Varsani et al. (2010). The choice was also based on the parallel 
development of a suitable Budgerigar challenge model in which a partial repeat of the BKS1ZA_84 
full-length genome was developed. 
3.4.1. Expression of the BFDV CP in N. benthamiana 
In the present study the BFDV CPs for isolates AFG3-ZA and BKS1ZA_84 were successfully expressed. 
Analysis in silico of the CP predicted a 30.1 kDa protein when fused with a C-terminal 6xHis tag and a 
32.1 kDa protein when fused to an N-terminal 6xHis tag together with TEV protease cleavage site. 
These predicted sizes corresponded with those seen in the western blot analysis (Figure 3.3 and 
Figure 3.5). However, when the CP fused with a C-terminal 6xHis tag was compared to 30 kDa 6xHis 
tag protein marker the protein weight was found to be slightly smaller than 30 kDa (Figure 3.7A). A 
possible explanation for this discrepancy could be due to incomplete denaturation by SDS of the CP 
(Rath et al., 2009). In comparison, the largest protein associated with purified virus was reportedly 
26.3 kDa and alternative recombinant expression systems have produced CP that was approximately 
32 kDa when expressed in insect cell culture and 38 kDa when expressed in yeast (Heath et al., 2006; 
Ritchie et al., 1990; Sariya and Prompiram, 2014). The larger sizes observed for recombinant protein 
is a result of the inclusion of signal tags which would increase the overall protein size. 
In addition to the 30.1 kDa protein, proteins of approximately 60 kDa, 70-100 kDa and 120 kDa were 
also detected when the CP was expressed without localisation (Figure 3.3 and Figure 3.8). 
Interestingly, a similar band of 58 kDa considered to be a minor viral protein was reported for 
purified virus (Ritchie et al., 1990). The molecular weights of the additional proteins detected are 
approximately multiples of the 30.1 kDa CP. It could be suggested that the protein described in the 
previous study and the larger proteins detected in this study are potentially CP dimers, trimers and 
tetramers, and that these could potentially be precursors to the pentameric subunits described by 
Crowther et al. (2003). In addition, this would suggest that the C-terminal 6xHis does not impact 
protein-protein interactions, and that denaturation by SDS was incomplete; this contributes to 
previous reports that the virion, and by extension the CP, is extremely stable (Davidson et al., 2008; 
Raidal and Cross, 1994a). 
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To counter the potential effect of RNA silencing on BFDV CP yield, the plasmid constructs were co-
infiltrated into N. benthamiana with the RNA silencing suppressor NSs. The silencing suppressor 
activity of the NSs protein from TSWV has previously described by Takeda et al. (2002). Co-
infiltration with the silencing suppressor resulted in an increase in CP yield suggesting that as with 
most recombinant proteins expressed in plants, the transcription of RNA from the BFDV cp is 
susceptible to RNA silencing (Figure 3.3). 
Interestingly, when anti-BFDV ΔN40 CP polyclonal IgG antibody was used to detect the BFDV CP 
fused to a C-terminal histidine tag, the protein was undetectable; however, BFDV CP lacking a C-
terminal histidine tag was readily detected by the polyclonal antibody (Figure 3.4). This suggests that 
the C-terminal histidine tag interferes with the epitope recognition of the antibody. Whether this 
epitope is located at the C-terminal or disrupted as a result of changes in the protein tertiary 
structure remains to be seen. It must be noted that the C-terminal histidine tag used in this study 
was used to detect protein expression and purification while a suitable antibody specific for the 
BFDV CP was in development.  
3.4.2. Optimisation of BFDV CP expression in N. benthamiana 
To determine the optimum conditions required for BFDV CP expression in N. benthamiana a number 
of parameters were investigated. Expression of circovirus capsid proteins in insect cell culture and E. 
coli have suggested that an N-terminal deletion can greatly improve yield (Daum et al., 2009; Heath, 
2006; Johne et al., 2004; Shang et al., 2008). In this study, plant expressed full-length CP was 
compared to a truncated version in which the first 40 residues were removed (Figure 3.5). The 
expression of the CP in N. benthamiana was greatly improved when the first 40 residues were 
removed, as has been shown in other recombinant expression systems. 
The N-terminal region of the CP has been shown to be responsible for nuclear localisation and 
contains a DNA binding domain that interacts with the BFDV genome (Heath et al., 2006). It could 
therefore be suggested that in the absence of genomic DNA the full-length CP may localise to the 
nucleus where it could interact with the host genome disrupting cellular functions. Removal of the 
N-terminal region probably consigns the CP to the cytoplasm where it accumulates without 
interfering with the host genome. 
To further investigate improving expression of the BFDV CP the gene was codon optimised for N. 
tabacum (Figure 3.6). Codon optimisation had no effect on protein expression for either the full-
length or truncated CP. This result is supported by a previous finding in which plant-codon 
optimisation of the HPV L1 gene did not result in an increase in expression (Maclean et al., 2007). It 
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is interesting to note that plant-codon optimisation maintained the overall G+C content of the cp. 
The G+C content of the wild-type gene was 47.63 % whereas the plant-codon-optimised gene was 
45.19 %. It has been suggested that increasing the overall G+C content of the sequence can lead to 
an improve expression alongside codon optimisation, and could possibly explain the absence of any 
improvement in expression of the BFDV CP (Hitzeroth et al., 2015). A recent result in which the 
overall G+C content after plant-codon optimisation remained the same has been reported by 
Thomas and Walmsley (2014); however, expression was improved based on codon optimisation 
alone, whether the effects are cumulative must still be determined. 
Although the N-terminal truncation greatly increased expression further work focused on improving 
expression of the full-length CP. The full-length was chosen because tentative evidence suggested 
that plant-produced CP was assembling into pentameric subunits and the DNA binding domain on 
the N-terminal region would be required in the production of pseudovirions. 
The optimisation of protein expression is not only determined by improving the efficiency of protein 
translation through gene deletions and codon optimisation but can include steps both preceding and 
following translation. Post-translational accumulation can be affected by post-transcriptional gene 
silencing and protein degradation pathways. A time trial was performed to determine the day at 
which BFDV CP accumulation was greatest. After mitigating for post-transcriptional gene silencing by 
including the NSs silencing suppressor the optimal day post-infiltration for protein accumulation was 
determined to be day 3 (Figure 3.7A). It could be suggested that after day 3 the CP enters into a 
protein degradation pathway. Plant leaves expressing the BFDV CP start undergoing leaf tissue 
damage from day 5 (data not shown). This could also account for the decrease in the total CP 
present in the leaf tissue as the CP is degraded and plant cell integrity is compromised leading to the 
release of proteases into the cytoplasm. A similar finding has been reported for the expression of 
haemagglutinin antigen in N. benthamiana in which the highest gene expression was observed on 
day 6 after which the was a decrease accompanied by plant wilting (Kanagarajan et al., 2012).  
The expression of the BFDV CP is also affected by the efficiency at which the T-DNA from 
Agrobacterium is transferred into the plant cells found in the leaf tissue. Increasing the 
concentration of Agrobacterium in the suspension that is infiltrated into air spaces between the leaf 
tissue may lead to a greater number of T-DNA copies entering plant cells and therefore resulting in 
an increase in expression. An increase in the absorbance (OD600) at which Agrobacterium was 
infiltrated at led to an increase in protein accumulation; however, this increase was reversed with 
the increase in the OD600 at which co-infiltrated Agrobacterium containing the NSs silencing 
suppressor was infiltrated (Figure 3.8B). This suggests possible competition of transcriptional and 
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translational resources between the transferred T-DNA containing the BFDV cp and the NSs silencing 
suppressor. Co-infiltration with the NSs silencing suppressor at optimal OD600 of 0.25; however, 
resulted in an increase in expression for all absorbance values tested for the cp (Figure 3.8C). It is 
established that silencing suppressors can effectively inhibit post-transcriptional gene silencing of 
recombinant genes expressed in plants (Voinnet et al., 2003). The optimum infiltration absorbance 
for Agrobacterium containing the BFDV cp was 0.50 while for the NSs silencing suppressor it was 
determined to be 0.25. 
Protein localisation can also affect accumulation and various cellular compartments were tested for 
the expression of the BFDV CP (Figure 3.9). Expression to the cytoplasm led to the greatest 
accumulation of CP on day 3 when compared to the chloroplast, apoplast and ER. This is to be 
expected considering the expression of the CP during viral infection in the host occurs in the 
cytoplasm from where NLSs located on the protein transport the protein into the nucleus (Heath et 
al., 2006). The nuclear localisation may negatively affect targeting to other cellular compartments. 
Similarly processing of the chloroplast-targeted signal would appear to be disrupted by the presence 
of an additional protein band of higher molecular weight. This could be as a result of the CP being 
transported into the nucleus before the signal tag could be cleaved and CP deposited into the 
chloroplast. In order to confirm this, fluorescently labelled BFDV CP could be used together with an 
inverted epifluorescence microscope to trace the localisation of the protein in the plant cell as has 
been demonstrated by Heath et al. (2006). The NLSs are located in the N-terminal region and could 
compete effectively with the N-terminal signal tags. Interestingly inclusion of the ER retention 
SEKDEL sequence results in a reduction in CP accumulation. It could be suggested that the retention 
in the ER resulted in the CP being diverted to proteolytic vesicles. This would reduce the overall 
accumulation of CP in the plant cell. An additional cellular compartment that could be investigated is 
the vacuole. Thomas and Walmsley (2014) reported the accumulation of human epidermal growth 
factor was greatest when targeted to the vacuole when compared to the ER and apoplastic space. 
An increase in gene copy number had a variable effect on protein accumulation dependent on the 
protein localisation. Gene amplification increased the overall protein accumulation in the cytoplasm 
and chloroplast, while a decrease in accumulation was observed in the apoplastic space and ER. As 
has been previously reported, an increase in gene copy number by means of gene amplification 
based on BeYDV RCR resulted in up to three orders of magnitude increase in gene copy number that 
translated into a marginal increase in protein accumulation (Regnard et al., 2010). This could be as a 
result of diversion of cell resources away from transcription and protein translation to DNA 
replication. Analysis of mRNA transcription from a non-replicating plant expression vector has shown 
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transcript levels to peak at three orders of magnitude (Kanagarajan et al., 2012). Gene amplification 
would therefore likely compete with transcription for cell resources. A solution to this would be to 
control the level of gene amplification. 
Although optimisations increased the expression of BFDV CP, the protein was undetectable in SDS-
PAGE when stained with Coomassie. Coomassie dye reagents can detect as few 25 ng per band for 
most proteins. This would indicate that the concentration of BFDV CP was below 625 ng/mL. In 
comparison to TSP the BFDV CP would represent less than 0.00025 % of TSP, and in terms of overall 
yield of BFDV CP per gram of fresh weight this would be less than 5 mg/kg. In comparison this is 
similar to recombinant expression levels seen for plant-produced HIV p17 ⁄ p24 of 5 mg/kg (Meyers 
et al., 2008; Regnard et al., 2010). However, in order for plant-produced BFDV to be viable, yields 
approaching 50 mg/kg are required to commercial production, as has been reported for Influenza 
VLPs (D’Aoust et al., 2008). 
3.4.3. Optimisation of BFDV CP extraction from N. benthamiana leaf tissue 
The BFDV CP was extracted using PBS. To further increase the yield for small-scale protein extraction 
a general lysis buffer was tested with individual components optimised including pH, salt 
concentration, reducing agent and the addition of detergent (Figure 3.9A). An increase in salt 
concentration had no effect on CP yield, while addition of a detergent or removal of reducing agent 
resulted in a decreased yield. A pH of 6.0 resulted in the greatest yield of CP (Figure 3.9B). The pI for 
the BFDV CP based on in silico analysis (isoelectric.ovh.org) was determined to range between 10.8-
11.3. Decreasing the extraction buffer pH below the pI would result in a positively charged CP. 
Removing salt from the extraction buffer would decrease the ionic strength of the buffer and would 
reduce the solubility of the positively charged CP. Combining a pH of 6.0 and salt concentration of 
500 mM did, however, not have a cumulative effect on protein yield (Figure 3.9C). 
In summary, the BFDV CP can be expressed in whole-plant N. benthamiana, and the full-length CP 
would appear to have the potential to assemble into VLPs. However, the CP was poorly expressed in 
plants, and various optimisations were undertaken to increase yield. Recombinant expression was 
greater for the truncated CP than the full-length CP, and these findings are similar to reports for 
other circoviruses. Optimisation of the codon usage appeared to have little effect; however, this may 
be more related to the G+C content than removal of rare codons. Localisation of proteins after 
expression did not improve the expression of the CP; possibly due to NLSs in the CP interfering with 
the signal tags. Gene amplification was seen to slightly improve expression, and could be diverting 
cell resources away from protein translation. Changes to the composition of the extraction buffer 
increased extraction; however, it is unknown how these changes would affect CP stability. The main 
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differences in expression were seen during co-infiltration of the silencing suppressor NSs and 
optimisation of the Agrobacterium cell density in the infiltration media. Both increased expression, 
and expression and accumulation of CP was highest on day 3, when Agrobacterium containing cp 
was co-infiltrated at an absorbance of 0.5 together with NSs at an absorbance of 0.25. 
Further work on plant-produced BFDV CP should continue to optimise expression. Disabling the NLSs 
within the CP may improve expression, though at what cost to protein stability. Targeting the CP to 
additional organelles, such as the vacuole, may also counter the potential effect of the NLSs. The cp 
should be codon-optimised such that the G+C content is raised to see whether this would affect 
expression. Insect cell produced BFDV CP has been shown to readily form VLPs, investigation of VLP 
formation in plants should be investigated. 
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Chapter 4: Plant-produced BFDV CP and virus-like particles 
4.1. Introduction 
The virions of BFDV consist of icosahedral capsids of approximately 20.5 nm in diameter, containing 
a 2-kb circular ssDNA genome that apparently encodes two genes: these are the cp, which produces 
the CP, and the rep, which produces Rep (Bassami et al., 1998; Bassami et al., 2001; Crowther et al., 
2003). The virion is extremely stable in the environment and horizontal transmission through 
ingestion of contaminated material is seen as the primary route of infection (Davidson et al., 2008; 
Todd, 2004). The persistence of virus outside of the host and a dearth of available treatments have 
resulted in considerable research towards developing a vaccine against BFDV. 
Initial vaccine research centred on inactivated virus vaccines derived from whole tissue of infected 
birds, purified from feathers or internal organs (Raidal and Cross, 1994a). This was problematic, 
however, as production of purified virus was reliant on sourcing infected birds, which has ethical 
implications and can be limiting in terms of availability of harvestable tissue (Bonne et al., 2009). 
Furthermore, problems arising from incomplete inactivation of the purified virus have made a an 
inactivated BFDV vaccine an unattractive option (Raidal et al., 1993a). The virus has not as yet been 
propagated in tissue culture; therefore, the application of recombinant DNA technologies has been 
viewed as an alternative to infected whole tissue as a source of virus (Shearer et al., 2008a). Recent 
work towards expression of recombinant BFDV CP shows great promise. 
Recombinant BFDV CP has been successfully expressed using a number of expression platforms, 
including bacterial and yeast fermentation, insect cell culture and plants (Duvenage et al., 2013; 
Heath et al., 2006; Patterson et al., 2013b; Sariya and Prompiram, 2014). Tissue culture technology 
has also been applied in the expression of PCV and GoCV CPs (Fachinger et al., 2008; Scott et al., 
2006). Use of recombinant PCV CP as a vaccine has been shown to result in a humoral response that 
can produce sterile immunity (Pérez-Martín et al., 2010; Trible et al., 2011). Limited studies have 
been conducted on expressed recombinant BFDV CP, however. Bonne et al. (2009) reported that 
vaccination produced a humoral response that failed to produce sterile immunity and instead 
resulted in a decrease in viraemia, replication and virus shedding. Despite the inability of the vaccine 
to produce sterile immunity, this research indicates that recombinant BFDV CP could be used to 
affect a response in the immune system. Further optimisation would be required to improve the 
strength of the immune response. 
One area of focus has been in the production of VLPs. These lack viral nucleic acids and are therefore 
non-infectious, while retaining the same structural characteristics of the infectious virion (Santi et 
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al., 2006). VLPs are highly immunogenic and stimulate both the humoral and cellular response 
pathways, and have been successfully applied in poultry against influenza (Nerome et al., 2015; 
Scotti and Rybicki, 2013). The BFDV virion has a T = 1 symmetry and is assembled from 60 CP 
subunits that are arranged into 12 pentamer units (Crowther et al., 2003). The virion of circoviruses 
is comprised of a single protein, making it an attractive target for investigation of the production of 
VLPs – and these have in fact been demonstrated for PCV and insect cell produced BFDV CPs 
(Nawagitgul et al., 2000; Stewart et al., 2007; Wu et al., 2012). 
Recombinant BFDV CP expressed in insect cell culture has been found to spontaneously assemble 
into VLPs. These particles ranged in size from 16-22 nm in diameter, which falls within most reported 
sizes for infectious virions (10-22 nm in diameter; Figure 1.2)(Stewart et al., 2007). Attempts to 
produced BFDV VLPs using other recombinant systems have been limited. The expression of the full-
length BFDV CP using bacterial fermentation resulted in insoluble protein (Patterson et al., 2013b). 
Although the expression of a truncated version was successful, this may hinder the assembly of 
intact VLPs. Plant-based expression in N. benthamiana of BFDV CP by Duvenage et al. (2013) 
included a C-terminal-fused 140 or 255 residue elastin-like polypeptide to improve protein 
purification. The fusion of the BFDV CP to such purification tag would potentially affect the ability of 
the CP to assemble into VLPs. The assembly of plant-expressed BFDV CP into VLPs has not been 
assessed to date. 
Agrobacterium-mediated expression of BFDV CP in N. benthamiana through the use of replicating 
plant expression vectors may have the unintended consequence of packaging replicon DNA into the 
VLPs. Plant expression vectors such as those derived from geminiviruses employ gene amplification 
as a method for increasing protein yield (Regnard et al., 2010). Replication of the derived vector via 
RCR produces circular ssDNA replicons. These replicons and the BFDV genome are alike in that both 
are circular ssDNA, therefore the expressed recombinant BFDV CP may recognise the replicon. 
Depending on the size of the replicon the DNA could potentially be packaged by recombinant BFDV 
CPs to form pseudovirions. 
In summary, the development of a vaccine against BFDV has moved away from inactivated virus 
towards the recombinant expression and purification of BFDV CP. This has been shown to 
successfully produce a humoral response in vaccinated birds. Insect cell derived BFDV CP has been 
reported to assemble into VLPs, but has otherwise not been shown for bacterial fermentations or 
plant systems.  
 88 
The aim of this study was to investigate the formation and purification of BFDV VLPs in N. 
benthamiana through the expression of the BFDV CP using a BeYDV-based replicating vector. In 
addition the incorporation and packaging of replicon DNA by the BFDV CP was explored. The 
replicating plant expression vector was chosen over the non-replicating vector based on the results 
seen in Chapter 3 and the possibility of VLP assembly including vector replicons produced in planta. 
4.2. Materials and methods 
4.2.1. A. tumefaciens growth kinetics 
The expression of BFDV CP for purification was performed using the replicating BeYDV mastrevirus-
derived pRIC 3.0 vector without protein localisation signals. The cloning of the BFDV cp into pRIC 3.0 
was performed as described in Section 3.2.2.4. Infiltration using this construct would result in 
amplification of the BFDV gene followed by expression and accumulation of the CP in the cytoplasm. 
An initial starter culture of the recombinant A. tumefaciens GV3101::pMP90RK containing the 
plasmid pRIC 3.0 BFDV BKS1ZA_84 cp 6xHis and strain LBA4404 containing pBIN-NSs were grown up 
overnight at 27 °C with agitation in LB medium and supplemented as described in Section 3.2.4. 
Gram stains of the cultures were performed, as described by Smith and Hussey (2005) to visualise 
the Agrobacterium strains using an inverted microscope (DIAPHOT-TMD, Nikon, Japan). 
4.2.1.1. Growth curve analysis 
Starter cultures were used to inoculate 500 mL induction medium for final OD600 of less than 0.01 
and grown for 48 hours at 27 °C with agitation. Cultures of strain GV3101::pMP90RK strain LBA4404 
were supplemented as described in Section 3.2.4. The absorbance for both strains was assessed 
every 2 hours from 8 hours after inoculation. Agrobacterium culture was sampled and diluted in 
triplicate using sterile induction medium for a 1:10 dilution and the absorbance (OD600) was 
determined using an Ultrospec™ 10 Cell density meter (Amersham Biosciences). From the curve the 
Agrobacterium doubling time based on absorbance could be determined. 
4.2.2. A. tumefaciens-mediated transient expression 
The Agrobacterium cultures were grown in induction medium as described in Section 3.2.4 after 
which cells were harvested by centrifugation at 4 000 g for 10 minutes, and resuspended in 
infiltration medium. The absorbance (OD600) was adjusted using infiltration medium such that strain 
GV3101::pMP90RK containing the plasmid pRIC 3.0 BFDV BKS1ZA_84 cp 6xHis was diluted to an 
absorbance of 1.00 and strain LBA4404 containing pBIN-NSs was diluted to an absorbance of 0.25 
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using an Ultrospec™ 10 Cell density meter (Amersham Biosciences). The diluted Agrobacterium 
cultures were then incubated at 22 °C for 2 hours as described in Section 3.2.4 and used for both 
syringe and vacuum infiltration. 
A set of infiltration and recombinant expression controls were established and the relevant A. 
tumefaciens suspensions were infiltrated into 6-week-old N. benthamiana using a needleless 1 mL 
syringe as describe in Section 3.2.4. The following controls were tested: plant leaf tissue only, plant 
leaf tissue infiltrated with infiltration medium only, plant leaf tissue infiltrated with strain LBA4404 
only, plant leaf tissue infiltrated with strain GV3101::pMP90RK only and plant leaf tissue co-
infiltrated with both strains. On day 3 protein extraction with PBS and western blot analysis was 
performed as describe in Section 3.2.5. 
4.2.2.1. Vacuum infiltration of A. tumefaciens into whole plants 
Vacuum infiltration of A. tumefaciens into N. benthamiana was performed as described by Maclean 
et al. (2007) with the following modifications. The Agrobacterium strains were combined in 
infiltration medium for a final absorbance (OD600) of 1.00 for strain GV3101::pMP90RK and 0.25 for 
strain LBA4404 making a total OD600 of 1.25. The 6-week-old N. benthamiana plants were prepared 
for inversion into infiltration medium by sealing the base of the plant through the use of a 130 x 130 
mm Perspex sheet that contained a 10 mm channel to the centre to allow for the plant stem to be 
inserted (Figure 4.1). This prevented soil from falling into the infiltration medium while the plant was 
inverted and leaves and stem submerged. 
Plants were submerged into the bacterial suspension and subjected to a vacuum of -90 kPa for 5–10 
minutes, with occasional agitation to release trapped air bubbles. The vacuum was released rapidly 
(approximately 10 kPa/s). In addition, a recombinant expression control, using strain LBA4044 only, 
was vacuum infiltrated into plants. The plants were grown as described in Section 3.2.4.  
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Figure 4.1: Perspex seal used to enclose soil during vacuum infiltration of N. benthamiana. A Perspex sheet 
(130 x 130 mm) prevented soil from upturned plants from falling into the infiltration medium. 
4.2.3. Extraction and purification of BFDV CP from N. benthamiana 
On day 3 post-infiltration plant leaves were harvested and approximately 25 g of leaf tissue was used 
for the extraction of expressed recombinant BFDV CP. Leaves were rinsed in water to remove soil 
particulates and dried with paper towel to remove excess water, after which the plant material was 
ground into a fine powder in liquid nitrogen using a mortar and pestle. The plant material was then 
combined with extraction buffer using ratio of one part plant material (eg 1 g) to two parts 
extraction buffer (eg 2 mL). The extraction buffer used in the extraction of BFDV CP was PBS 
containing cOmplete™ Mini, EDTA-free protease inhibitor (Roche). PBS has previously been used as a 
buffer for the extraction of BFDV virions from whole tissue of diseased psittacines (Raidal and Cross, 
1994b). The mixture was then homogenised for 5 minutes at 10 000 rpm and 4 °C using a T 25 digital 
ULTRA-TURRAX® (IKA® Works Inc., NC, United States of America). 
4.2.3.1. Slow speed centrifugation 
The homogenate was centrifuged at either 4 000 g for 10 minutes or 15 000 g for 15 minutes at 4 °C 
using a JA-14 rotor (Beckman Coulter, CA, United States of America) to determine optimum relative 
centrifugal force required to separate particulate plant material from TSP. The supernatant was 
filtered through two layers of Miracloth (Merck, Germany) in preparation for sucrose cushion 
centrifugation. The pellet was resuspended in an equal volume of buffer for analysis. The 
resuspended pellet was analysed alongside the supernatant to determine the extent of protein 
solubility. 
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4.2.3.2. Sucrose cushion centrifugation 
Sucrose cushion centrifugation was based on purification PCV-2 capsid particles by Wu et al. (2012). 
A 40 % by weight sucrose solution (470.6 mg/mL of solution) was prepared and confirmed using a 
R5000 hand refractometer (Atago, Japan). A 2 mL 40% sucrose cushion was prepared in 5 mL Ultra-
Clear™ centrifugation tubes (Beckman Coulter) and layered with supernatant derived from the slow 
speed centrifugation step. The tubes were centrifuged in a SW 55 Ti rotor (Beckman Coulter) at 
40 500 rpm (RCFmax ≈ 200 000 g) for 6 hours at 4 °C. The sucrose cushion was fractionated using a 
Foxy® Jr. Fraction Collector (Teledyne Isco, NE, United States of America) and the pellet was 
resuspended in a volume equivalent to one fraction. The fractions were analysed using western blot 
as described in Section 3.2.5. The pellet was further analysed by transmission electron microscopy 
(TEM). 
4.2.3.3. Transmission electron microscopy 
Analysis of BFDV CP particle assembly was determined using TEM. Copper grids (mesh size 200) were 
made hydrophilic by glow discharging at 25 mA for 30 s using a Model 900 SmartSet Cold Stage 
Controller (Electron Microscopy Sciences, PA, United States of America). The grids were then placed 
on a 1:100 dilution of the samples for 5 minutes and then washed three times in sterile water. The 
grids were negatively stained on uranyl acetate for 10 s and again for a further 20 s and viewed using 
a Tecnai™ F20 Scanning Transmission Electron Microscope (FEI, OR, United States of America). 
4.2.4. CsCl density gradient centrifugation 
CsCl density gradient centrifugation was performed based on a protocol modified from Ritchie et al. 
(1989b). Leaves containing expressed recombinant BFDV CP were extracted as described above 
using a 50 mM Tris at pH 7.6 buffer at a ratio of 3:1 buffer to plant material. The sucrose cushion 
centrifugation was modified such that a 45 % by weight sucrose solution (541.1 mg/mL of solution) 
was prepared. The sample together with a 5 mL sucrose cushion was centrifuged in a SW 32 Ti rotor 
(Beckman Coulter) at 32 000 rpm (RCFmax ≈ 175 000 g) for 2 hours at 4 °C. The resulting pellet was 
used during CsCl density gradient centrifugation. 
The pellets were resuspended in Tris buffer containing CsCl at a density of 1.406 g/cm3. CsCl density 
was confirmed using a R5000 hand refractometer (Atago). The resuspended pellets were centrifuged 
using a SW 55 Ti rotor (Beckman Coulter) at 48 000 rpm (RCFmax ≈ 280 000 g) for 20 hours at 20 °C. 
The CsCl gradients were performed in duplicate or triplicate and were fractionated using a Foxy® Jr. 
Fraction Collector (Teledyne Isco). The refractive index for each fraction was determined using a 
R5000 hand refractometer (Atago) and 10 μL of each fraction was spotted onto nitrocellulose 
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membrane and western blot analysis was performed as described in Section 3.2.5. The BFDV CP 
present on the nitrocellulose membrane was then quantified using a Syngene Gene Genius imaging 
system and GeneTools software (Synoptics Inc., United Kingdom). In addition to quantifying the 
BFDV CP in each fraction, TSP and total DNA was determined using a ND-1000 Spectrophotometer 
(NanoDrop®, DE, United States of America). 
Fractions containing the greatest concentration of BFDV CP were pooled and dialysed using dialysis 
tubing cellulose membrane (Sigma-Aldrich) against 50 mM Tris at pH 7.6. Dialysed pooled fractions 
were analysed using western blotting and standard PCR. No TEM was performed on the dialysed 
pooled fractions. 
The PCR reaction, as described in Appendix B.7, was performed using GoTaq® DNA Polymerase 
(Promega) according to manufacturer’s instructions and primers (5ʹ-AGTGAAATCAGACTGGCAACC-3ʹ 
and 5ʹ- GTAAATTCCACGTCATTTTCC -3ʹ) that amplified a 1-kb BeYDV gene fragment. The amplified 
PCR products were resolved on 1 % (wt/vol) TBE agarose gels. 
4.3. Results 
4.3.1. Growth optimisation of Agrobacterium strains for vacuum infiltration 
To culture sufficient Agrobacterium for the volumes required for vacuum infiltration a starter culture 
is required and followed by inoculation into a larger volume. Two strains of Agrobacterium were 
used, the first being GV3101::pMP90RK that contains the plant expression plasmid with the BFDV cp. 
The second strain, LBA4404, contains the NSs silencing suppressor. The growth rates of these strains 
differ considerably requiring each strain to be cultured separately. In order to optimise this process 
the individual strains were analysed and their doubling times determined. Gram stain analysis of the 
two strains showed differences in cell morphology (Figure 4.2). Culture of strain LBA4404 consisted 
of uniform bacilli that were present as singles, pairs or aggregates (Figure 4.2A), whereas culture of 
strain GV3101::pMP90RK consisted of irregularly sized coccobacillus that didn’t appear as 
aggregated as strain LBA4404 (Figure 4.2B). Budding daughter cells were readily observed for strain 
GV3101::pMP90RK. 
 93 
 
Figure 4.2: Light microscopy of Gram-negative A. tumefaciens strains. (A) LBA4404 and (B) GV3101::pMP90RK 
at 100 x magnification. 
These strains grow at different rates and scale up of both cultures to the correct absorbance (OD600) 
requires that the cultures be inoculated at separate time intervals or absorbance values. To 
determine the generation time of both strains growth curve analysis was performed (Figure 4.3). As 
the spectrophotometer used to measure absorbance at 600 nm had a detection limit of 0.01 units 
the lag phase for both strains was not recorded, the strains were therefore already in exponential 
phase when a change in absorbance was first detected. The strain LBA4404 entered stationary phase 
at approximately 24 hours with an absorbance reading of 1.77 (SD, 0.06), while GV3101::pMP90RK 
entered stationary phase at approximately 40 hours with an absorbance reading of 1.67 (SD, 0.06). 
The generation time for strain LBA4404 was calculated to be approximately 115 minutes and was 
based on the exponential phase taken from 12 hours to 24 hours. The generation time for strain 
GV3101::pMP90RK was calculated to be approximately 180 minutes and was based on the 
exponential phase taken from 16 hours to 26 hours. The approximate μmax was determined to be 
0.29 h-1 for strain LBA4404 and 0.27 h-1 for strain GV3101::pMP90RK. 
 94 
 
Figure 4.3: Agrobacterium cell density as measured by absorbance at 600 nm over time. Comparison 
between strain LBA4404 containing the NSs silencing suppressor gene and GV3101::pMP90RK containing the 
full-length BFDV cp. The detection limit for the spectrophotometer used to measure absorbance was 0.01 
units. Error bars represent SD of technical repeats (n = 3). 
To produce enough CP for purification requires the infiltration of plants as opposed to individual 
leaves. Agrobacterium infiltration of leaves can be performed using a syringe; however, this method 
is inefficient should more than one plant be required for expression purposes. Multiple plants can be 
effectively infiltrated using vacuum infiltration. In this method plants are submerged in infiltration 
medium containing Agrobacterium and a vacuum is created during which time air moves out the 
intercellular spaces through the stomata. A sudden increase in pressure when the vacuum is 
released forces infiltration medium containing the Agrobacterium through the stomata and into the 
intercellular spaces. This allows for the entire plant to be infiltrated as opposed to syringe infiltrating 
individual leaves. Leaves can then be harvested after expression and processed accordingly. 
After optimising the Agrobacterium strains for vacuum infiltration a comparison was made between 
the two methods of infiltration (Figure 4.4). Results show that the 30.1 kDa CP is expressed in N. 
benthamiana using both infiltration methods. The CP was not present in the negative control lanes. 
The antibody also detected protein bands present at approximately 55 kDa, 70 kDa, between 100 
kDa and 130 kDa and above the 130 kDa prestained protein marker. The silencing suppressor 
improved expression of the CP as an increase in band intensity is apparent for the CP co-expressed 
with the silencing suppressor. 
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Figure 4.4: Western blot analysis of BFDV CP expression comparing syringe versus vacuum infiltration of 
Agrobacterium. Negative controls were non-infiltrated plant leaves, leaves infiltrated with medium and NSs 
only. The presence (+) or absence (-) of each component is specified. TSP was extracted from leaf tissue 
harvested on day 4 post-infiltration. An equal volume of each sample was loaded into the lanes, the CP was 
detected using anti-histidine antibody and the BCIP/NBT substrate reaction was performed for 1 hour. M – 
prestained protein marker. 
4.3.2. Purification of full-length BFDV CP 
A larger mass of leaf tissue is required for the purification of VLPs, therefore it was decided to 
homogenise leaf tissue using a mechanical blender maintaining the preparation at 4 °C. The 
homogenate was filtered to remove large particulates at the filtrate was centrifuged at either 4 000 
g or 15 000 g to determine if plant material can be removed without pelleting the proteins (Figure 
4.5). Western blot analysis of TSP extracted from leaf tissue indicated the presence of the BFDV CP 
and the presence of larger histidine-tagged proteins at regular intervals. The approximate sizes were 
60 kDa, 90 kDa, 120 kDa and 150 kDa. The CP was found mainly in the pellet as opposed to the 
supernatant and the concentration CP in the pellet was increased when the relative centrifugal force 
was increased. 
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Figure 4.5: Western blot analysis of the initial centrifugation step in the purification of BFDV CP. 
Centrifugation was performed at two different relative centrifugal forces. The Agrobacterium was vacuum 
infiltrated into plants and TSP was extracted from leaf tissue harvested on day 6 post-infiltration. Plants 
infiltrated with NSs only served as a negative control. An equal volume of each sample was loaded into the 
lanes, the CP was detected using anti-histidine antibody and the BCIP/NBT substrate reaction was performed 
for 1 hour. M – prestained protein marker. 
After an initial centrifugation the supernatant was layered onto a sucrose cushion and centrifuged. 
After the centrifugation was complete fractions of the sucrose cushion were collected and the pellet 
was resuspended for western blot analysis (Figure 4.6). The CP was found mainly in the pellet but 
was also present at the interface between the sample and sucrose cushion. A green layer was also 
present at the interface between the sample and sucrose cushion. 
 
Figure 4.6: Western blot analysis of fractions collected from sucrose cushion centrifugation during the 
purification of BFDV CP. Fractions collected and then analysed are indicated. Fractions were numbered in the 
order they were collected starting from the bottom of the tube. An equal volume of each sample was loaded 
into the lanes, the CP was detected using anti-histidine antibody and the BCIP/NBT substrate reaction was 
performed for 1 hour. M – prestained protein marker. 
The pellet from the sucrose cushion was resuspended and analysed using TEM (Figure 4.7). The TEM 
analysis of the pellet from leaf tissue expressing the BFDV CP together with the silencing suppressor 
NSs detected regular particles ranging between 13-23 nm in diameter (Figure 4.7A). The 
predominant size detected was approximately 17 nm in diameter. Analysis of the pellet from leaf 
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tissue expressing the silencing suppressor NSs only did not find anything consistent with VLPs (Figure 
4.7B). 
 
Figure 4.7: Transmission electron micrographs of the partially purified BFDV VLPs (indicated by white 
arrows) after sucrose cushion centrifugation. (A) Resuspended pellet from leaf tissue expressing the BFDV CP 
with C-terminal histidine tag together with the silencing suppressor NSs. (B) Resuspended pellet from leaf 
tissue expressing only the silencing suppressor NSs which served as a negative control. 
The sucrose cushion pellets for BFDV CP co-expressed with NSs and the NSs control were further 
analysed using CsCl density gradient centrifugation. The resuspended pellets were combined with 
CsCl for final CsCl density of 1.406 g/cm3 and centrifuged until isopycnic equilibrium was achieved. 
Fractions of the CsCl density gradients were collected for immunoblotting, and spectrophotometric 
analysis (Figure 4.8). Dot blot analysis using anti-histidine antibody on CsCl density gradient fractions 
detected a relative intensity peak at fraction 6 for sample containing the BFDV CP co-expressed with 
the NSs silencing suppressor and a shoulder peak was detected in fraction 8 (Figure 4.8A). These 
peaks were absent in the sample in which only the NSs silencing suppressor was expressed. The 
fractions represent a CsCl density gradient that ranged from 1.29 g/cm3 to 1.58 g/cm3. The peak in 
relative intensity seen in fraction 6 for the sample containing the BFDV CP co-expressed with the NSs 
silencing suppressor corresponded to a CsCl density of 1.38 g/cm3. The shoulder peak seen in 
fraction 8 had a CsCl density of 1.34 g/cm3. Fractions 5-7 of for each density gradient were pooled, 
dialysed and analysed by Coomassie staining and western blot (Figure 4.8B). The BFDV CP was 
undetectable when stained with Coomassie (data not shown). The 30.1 kDa CP and histidine-tagged 
protein of approximately 60 kDa were detected in the sample containing the BFDV CP co-expressed 
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with the NSs silencing suppressor. No histidine-tagged proteins were detected for the pooled 
fractions of the NSs silencing suppressor expressed on its own.  
 
Figure 4.8: CsCl density gradient centrifugation profile of BFDV CP. (A) The CsCl density () and relative 
intensity of histidine tagged protein as determined by dot-blot from leaf tissue co-expressing the BFDV CP and 
NSs silencing suppressor () or the NSs silencing suppressor alone (). (B) Western blot analysis of pooled 
fractions 5-7 after dialysis. M – Prestained protein marker, 1 – NSs control, 2 – BFDV CP and NSs. An equal 
volume of each sample was loaded into the lanes, the CP was detected using anti-histidine antibody and the 
BCIP/NBT substrate reaction was performed for 1 hour. 
PCR analysis on pooled, dialysed fractions was performed to determine whether DNA replicons 
produced by the expression vector were present in the observed relative intensity peak seen 
between fractions 5 and 7 (Figure 4.9 lane 1). Amplification of a 1-kb DNA product of the expression 
vector BeYDV rep was successful for the pooled fractions and corresponded to that seen in the 
positive control. 
 
Figure 4.9: The detection of BeYDV replicon DNA in dialysed BFDV CP fractions. Pooled and dialysed fractions 
that correspond to relative intensity peak of BFDV CP seen between fraction 5 and 6 were tested. M – DNA 
marker, (+) – positive control with vector DNA, (-) - negative control with no template DNA, 1 – pooled and 
dialysed fractions. 
To further analyse the CsCl density gradient fractions spectrophotometric readings for protein and 
DNA concentration were performed. Three densities gradients for the BFDV CP co-expressed with 
the NSs silencing suppressor were prepared and analysed (Figure 4.10). The relative intensity 
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determined by dot blot analysis using anti-histidine antibody was compared to CsCl density, TSP 
concentration, and total DNA concentration. A similar relative intensity peak was observed between 
fraction and 6 and corresponded to a CsCl density of between 1.41 g/cm3 and 1.44 g/cm3 (Figure 
4.10A). The shoulder peak seen in the previous results was absent. The CsCl density gradient ranged 
from 1.29 g/cm3 to 1.55 g/cm3. A peak in TSP of 0.92 mg/mL at fraction 5 was observed that 
corresponded to the relative intensity peak seen between fraction 5 and 6 (Figure 4.10B). A second 
smaller peak for TSP was observed at fraction 9 and corresponded to a CsCl density of 1.34 g/cm3, 
while a final peak was present at a density of 1.55 g/cm3. Similar peaks were detected for total DNA 
concentration (Figure 4.10C).  
 
Figure 4.10: CsCl density gradient centrifugation profiles of BFDV CP, protein and DNA concentration. 
Comparison of relative intensity of histidine tagged protein as determined by dot-blot from leaf tissue co-
expressing the BFDV CP and NSs silencing suppressor () with (A) CsCl density (), (B) TSP concentration () 
and (C) total DNA concentration (). 
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4.4. Discussion 
4.4.1. Growth optimisation of Agrobacterium strains for vacuum infiltration 
One method broadly employed for the recombinant expression of proteins in plants is through the 
use of Agrobacterium. The transfer of the recombinant gene from the Agrobacterium into the plant 
cell requires a direct interaction between cells. In order to facilitate this, Agrobacterium is infiltrated 
between the intercellular spaces of N. benthamiana leaves through either needleless-syringe or 
vacuum. In the case of needleless-syringe infiltration a relatively small volume of infiltration medium 
containing Agrobacterium is needed. However, the drawback to this method is that each leaf on the 
plant has to be infiltrated separately, reducing the throughput time of plants that can be infiltrated. 
This, however, can be overcome through the use of vacuum infiltration in which plants are directly 
submerged into infiltration medium. This greatly enhances the throughput of plants that can be 
processed. 
Vacuum infiltration requires considerably larger volumes of infiltration medium owing the large 
volume that is required to fully submerge an entire plant. Maclean et al. (2007) noted that between 
1-7 L of infiltration medium was required for vacuum infiltration of large numbers of plants in a 
laboratory scale setting, considerably more than if syringe infiltration were used. However, vacuum 
infiltration would be necessary for scale-up of operations for convenience and has been successfully 
used to produce Influenza VLPs for clinical trials on a large scale (D’Aoust et al., 2010). 
In the expression of BFDV CP in plants two strains of Agrobacterium were utilised. The strain 
GV3101::pMP90RK containing the plasmid pRIC 3.0 BFDV BKS1ZA_84 cp 6xHis was used together 
with strain LBA4404 containing pBIN-NSs. These strains grew at different rates requiring separate 
inoculation schedules. In order to streamline the process, the strains were analysed and the 
doubling time determined. These two strains are morphologically different (Figure 4.2) and had very 
different growth rates (Figure 4.3). In order to produce the volumes required for vacuum infiltration, 
these strains would need to be inoculated at different absorbance values in order for the correct 
final absorbance for both strains to be reached and to avoid cultures from entering stationary phase. 
The doubling time of strain GV3101::pMP90RK was approximately 50% longer than that of strain 
LBA4404, and this could be based on the strains themselves (Figure 4.3). Alternatively, the difference 
in doubling time may be explained by the selection pressures of the two strains: strain 
GV3101::pMP90RK was under the selective pressure of three different antibiotics, two antibiotics 
selected for the Agrobacterium and helper plasmid, while the third antibiotic, selected for the plant 
expression plasmid. In contrast, strain LBA4404 was under the selective pressure of two antibiotics. 
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The diversion of cellular energy into the production of enzymes that inactivate the antibiotics would 
affect the overall growth rate of the cell. Similarly it could explain the difference in morphologies 
considering under no selective pressure Agrobacterium are bacillus-like in shape (Schaad et al., 
1988). An alternate explanation of the difference in observed morphologies could be the difference 
in plant expression vectors. It has been demonstrated that a the mammalian PCV can replicate via 
RCR in E. coli (Cheung, 2006). The replicating BeYDV plant expression vector could similarly be 
replicating via RCR in Agrobacterium and this may place additional strain over and above antibiotic 
selection pressure causing changes in the overall morphologies of the cell. Both strains of 
Agrobacterium enter stationary phase at an absorbance reading of between 1.67 and 1.77 (Figure 
4.3). Whether this phase results in the dormancy or cell death would have to be determined through 
viable cell counts by determining the number of colony forming units. It could also be postulated 
that these upper absorbency readings are the result of depletion of nutrients. Whether infiltrating 
Agrobacterium, that have entered stationary phase, into plant leaves affects the transfer of T-DNA 
remains to be determined. 
In order to ensure reliable viability of the Agrobacterium strains during infiltration induction medium 
should be inoculated at an absorbance that would result in maximum growth of viable cells before 
entering stationary phase. To do this strain LBA4404 would require inoculation into induction 
medium for a final absorbance of 0.04 while strain GV3101::pMP90RK would require inoculation into 
induction medium for a final absorbance of 0.06. At these absorbance values the exponential phase 
would approach the stationary phase in 16 hours. 
Vacuum infiltration results in the same level of expression as when Agrobacterium suspensions are 
infiltrated using a needleless syringe, and as has previously been demonstrated the co-expression of 
the silencing suppressor protein NSs results in an increase in BFDV CP accumulation (Figure 4.4). 
4.4.2. Purification of full-length BFDV CP 
Initial low speed centrifugation prior to sucrose cushion centrifugation revealed that the majority of 
expressed BFDV CP was in the pellet (Figure 4.5). This could indicate the presence of particulate 
plant tissue that bypassed the filtration step, or it could indicate an insoluble fraction. This insoluble 
fraction has similarly been reported for expression of full-length CP using bacterial fermentation 
(Patterson et al., 2013b). Increasing the absolute centrifugal force resulted in further accumulation 
of the BFDV CP in the pellet fraction. 
The supernatant containing the soluble BFDV CP was used for sucrose cushion centrifugation (Figure 
4.6). The majority of soluble BFDV CP accumulated as part of the pellet; however, the protein was 
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also seen to concentrate at the interface between the sample and the sucrose cushion. Previous 
work on purification of PCV particles used sucrose cushion centrifugation to effectively pellet VLPs 
(Wu et al., 2012). 
TEM analysis of the sucrose cushion pellet revealed negatively stained particles were circular and 
featureless. This description fits that used to describe infectious BFDV particles by Crowther et al. 
(2003). The plant-produced BFDV particles ranged between 13-23 nm in diameter and were similar 
to BFDV VLPs produced in insect cell culture which range between 16-22 nm diameter (Stewart et 
al., 2007). The predominant diameter measured was approximately 17 nm which falls within the 10-
22 nm range reported for infectious virions (Figure 1.2). These findings are comparable to insect cell-
produced PCV VLPs that averaged 20 nm in diameter, closely resembling the infectious PCV virion 
that consists of a 1.7-kb genome encapsidated within a 20.5 nm non-enveloped capsid (Crowther et 
al., 2003).  
Fractionation of CsCl gradients of the pellet produced during sucrose cushion centrifugation 
produced two peaks of BFDV CP. The major peak was found to have an approximate density of 1.38 
g/cm3, while a shoulder peak at 1.34 g/cm3 was also detected (Figure 4.8). It could be that the major 
peak represents VLPs containing plant expression vector replicon DNA generated from RCR and the 
shoulder peak could represent empty VLPs. A similar density of 1.365 g/cm3 has been reported for 
PCV VLPs produced in Tn5 insect cells (Liu et al., 2008). Considering the BeYDV replicon is 
approximately 3.3-kb it is questionable whether it could be successfully packaged by the BFDV CP. A 
BeYDV replicon that was similar in size to the 2-kb BFDV genome would be more suitable for 
encapsidation. The higher observed density could also be the result of the presence of the C-
terminal 6xHis tag. The absence of viral DNA has been seen to affect the density of the VLPs. 
Infectious BFDV virions when purified using CsCl have a density that ranges between 1.35-1.378 
g/cm3, while intact VLPs range between 1.215-1.325 g/cm3 (Raidal and Cross, 1994b; Stewart et al., 
2007; Todd et al., 1991). A similar decrease in density has been reported for PCV VLPs (Nawagitgul et 
al., 2000). 
Although the BeYDV replicon used to express the BFDV CP is larger than the BFDV genome, standard 
PCR analysis of dialysed sample containing BFDV CP was found to be associated with the plant 
expression vector BeYDV rep (Figure 4.9). In order to confirm the presence of the replicon, RCA could 
be performed on the dialysed sample to retrieve the circular ssDNA replicon. Spectrophotometric 
analysis of protein and DNA concentrations in samples from CsCl gradient fractions revealed similar 
peaks corresponding to the BFDV CP and BeYDV DNA. This suggests that the BFDV CP could indeed 
be packaging the amplicon DNA. Plant viral CPs have been shown to effectively and spontaneously 
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package nucleic acids of mammalian viruses (Azizgolshani et al., 2013). These pseudovirions have 
then been shown to release their nucleic acids into the cytoplasm of mammalian cells. This 
technology has also been used successfully using a plant-produced bamboo mosaic virus particles 
containing infectious bursal disease virus antigens for the immunisation of chickens (Chen et al., 
2012). Plant-produced CP derived from circoviruses could be similarly be used to package nucleic 
acids that have been replicated in planta using the BeYDV replication system. These pseudovirions 
could then potentially be used to create a potent vaccine capable of eliciting a strong humoral and 
cellular response in the target host. 
In conclusion, different Agrobacterium strains or antibiotic selection pressures can have an effect on 
the growth rate of cultures required for infiltration into N. benthamiana. The Agrobacterium strain 
GV3101::pMP90RK doubling time was approximately 50% longer than that of strain LBA4404 and the 
morphology appeared different. This could be as a result of differences between the strains, in the 
level of antibiotic selection pressure or plant expression vectors. The strains enter stationary phase 
at an absorbance of between 1.67-1.77. A better understanding of Agrobacterium growth kinetics is 
required to determine whether the stationary phase has an impact on T-DNA transfer and optimise 
culture scale up for vacuum infiltration. The BFDV CP has been shown to be successfully expressed in 
N. benthamiana via vacuum infiltration. It has also been shown to self-assemble into VLPs that can 
be detected using electron microscopy and purified using CsCl centrifugation; however the yield was 
low, as the CP was undetectable when stained with Coomassie. The detection of VLPs in plants 
allows for refinement of the purification method, possibly by incorporating the sedimentation 
coefficient determined for PCV and CAV to improved isolation by centrifugation. These plant-
produced BFDV VLPs resemble those produced in insect cells and infectious virions. It is possible that 
the VLPs are spontaneously incorporating amplicon DNA produced from the replicating BeYDV plant 
vector. The resulting pseudovirions could be used to further the efficacy of vaccines against BFDV. 
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Chapter 5: The production of infectious BFDV agents 
5.1. Introduction 
In order for the efficacy of a viral vaccine to be established, the vaccine must be tested against an 
infectious virus during a challenge trial (Fenaux et al., 2003). For BFDV the preparation of infectious 
virus has until now relied on the extraction of virus from whole tissue of deceased parrots known to 
be infected with the virus. This technique is still in use as the virus has yet to be grown in vitro using 
tissue culture (Patterson et al., 2013a). The difficulties in culturing the virus have been put down to 
tissue specificity and in vivo growth requirements (Ritchie et al., 1989a). Similar problems have been 
reported for other avian circoviruses such as GoCV and PiCV (Duchatel et al., 2006; Scott et al., 
2006). Recently DuCV has been shown to replicate - albeit with a low efficiency - in continuous cell 
lines derived from Muscovy ducks (Cairina moschata)(Mészáros et al., 2014). Research advances 
have therefore been focused on the economically important and culturable PCV, while 
developments with avian circoviruses have lagged behind. 
PCV-1 was first described as a tissue culture contaminant in PK-15 cells and has been extensively 
studied (Karuppannan and Kwang, 2011). Considering the simple genome and replication strategy of 
circoviruses, an infectious molecular clone of PCV-2 could be readily synthesised and tested in tissue 
culture. A dsDNA replicative form of the PCV genome was shown to produce virus particles in a 
foetal porcine retina cell line (VIDO R1)(Liu et al., 2001). Similar results have been reported for PK-15 
cells that were transfected with circular dsDNA full-length PCV-2 genomes (Dezen et al., 2010). In 
addition infectious molecular PCV-2 DNA clones have been used to produce active infections in pigs 
through direct injection into the liver and lymph nodes (Fenaux et al., 2002). The ability to uncouple 
viral replication and virion production has enabled researchers to create PCV1-2 chimeras that 
produce immunity against PCV-2 but are attenuated in pigs (Fenaux et al., 2004; Gillespie et al., 
2008). This technology can potentially be directly applied to BFDV and would circumvent the 
difficulties associated to virus purification from birds (Fenaux et al., 2002). 
A BFDV infectious molecular DNA clone could be made as for PCV. RCR of BFDV is dependent on the 
expression of the Rep and presence of the ori whose sequence contains a nonanucleotide motif (5ʹ-
TAGTATTAC-3ʹ) displayed on a stem-loop (Cheung, 2006; Heath et al., 2006). A BFDV infectious 
molecular DNA clone would consist of a partial genome repeat, in which the ori sequence is 
repeated, cloned into a theta-replicating plasmid. The benefits of using an infectious molecular DNA 
clone for BFDV challenge experiments would be the ease of producing endotoxin-free DNA and 
spectrophotometric quantification. In comparison the quantification of purified virus requires 
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titrations of the virus in tissue culture or potentially in animals in order to calculate the viral titre 
(Fenaux et al., 2002). Pure BFDV virus isolates could also be produced from infectious molecular DNA 
clones, thus ensuring viral preparations are free of other pathogens. A suitable system for 
generating virus particles would need to be explored. 
Thus far infectious molecular DNA clones of PCV have been successfully used in pigs and porcine cell 
lines to produce infectious virus particles (Dezen et al., 2010; Fenaux et al., 2002; Liu et al., 2001). As 
no continuous psittacine cell lines exist an infectious BFDV molecular DNA clone would require 
testing in psittacine embryonated eggs or an alternate system. Cheung (2006) demonstrated that 
PCV was capable of replicating in E. coli, suggesting that BFDV could potentially replicate outside of 
avian host cells. The mechanism of RCR has been successfully harnessed from work with 
geminiviruses in our laboratory to create a replicating plant expression system based on BeYDV 
capable of amplifying heterologous genes in N. benthamiana (Regnard et al., 2010). Considering the 
replication strategies of both BeYDV and BFDV are similar, BeYDV could be capable of assisting the 
replication of BFDV in planta and the prospect is worth investigating.  
The aim of this study was to prepare potentially infectious BFDV agents which can be used as 
challenge material for vaccine testing. First, virus particles were purified from whole tissue taken 
from organs and visualised using TEM. Second, a putatively infectious BFDV molecular DNA clone 
was designed and tested in mammalian cell culture. Replication was investigated using RCA, qPCR 
and replication-deficient clones. Replication of the infectious BFDV molecular DNA clone was also 
assessed using qPCR in N. benthamiana in the presence of BeYDV replication components. 
5.2. Materials and methods 
5.2.1. Extraction of BFDV virions from whole tissue organs 
A deceased Palm cockatoo (Probosciger aterrimus) known to have succumbed from PBFD was 
received by the laboratory for necropsy. Blood and feather samples were collected and internal 
organs weighing approximately 20 g collected. The organs were immediately stored on ice after 
which they were added to 150 mL extraction buffer (PBS and 0.5 % [wt/vol] SDS). The tissue was 
homogenised for 10 minutes at 4 °C using a T 25 digital ULTRA-TURRAX® (IKA® Works Inc.), after 
which the homogenate was filtered through Miracloth (Merck). The filtrate was centrifuged at 5 000 
g for 10 minutes at 4 °C. The supernatant was then adjusted to include 1 M NaCl and 10% (wt/vol) 
polyethylene glycol (PEG) 6000 and incubated for 1 hour at 4 °C. The solution was then centrifuged 
at 11 000 g for 20 minutes after which the supernatant was discarded and pellet resuspended in PBS 
containing CsCl at a density of 1.30 g/cm3. CsCl density was confirmed using a R5000 hand 
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refractometer (Atago). The resuspended pellets were centrifuged in 5 mL Ultra-Clear™ 
centrifugation tubes (Beckman Coulter) using a SW 55 Ti rotor (Beckman Coulter) at ≈ 40 500 rpm 
(RCFmax 200 000 g) for 20 hours at 4 °C. After isopycnic equilibrium visible bands present in the CsCl 
gradient were collected by piercing the side of the tube using a needle and 1 mL syringe. Samples 
were then dialysed in PBS using a Slide-A-Lyser™ Dialysis Cassette, 10K MWCO (Thermo Scientific). 
The BFDV genomic DNA concentration of the dialysed sample was determined using rep specific 
qPCR as described in Section 2.2.5. 
5.2.2. DNA extraction, rolling circle amplification and PCR 
Total DNA from feather, blood and organ samples were extracted and analysed as described in 
Section 0. Total DNA from dialysed samples was extracted as described in Section 0. The DNA from 
the dialysed samples was analysed using qPCR and PCR. The reaction, as described in Appendix B.7 
was performed using GoTaq® DNA Polymerase (Promega) according to manufacturer’s instructions 
and primers (5ʹ-AGATCTAGTCCGTCCAAGGAGGGATCTG-3ʹ and 5ʹ-
AAGCTTCTAATAATTGATGGGGTGGGCGAG-3ʹ) that amplified a 900-bp BFDV rep fragment. The 
amplified PCR products were resolved on 0.8 % (wt/vol) TBE agarose gels. 
5.2.3. Transmission electron microscopy 
Analysis of dialysed BFDV virus particles was performed using TEM. Copper grids (mesh size 200) 
were made hydrophilic by glow discharging at 25 mA for 30 s using a Model 900 SmartSet Cold Stage 
Controller (Electron Microscopy Sciences). The grids were then placed on a solution with a 1:1 ratio 
of sample and 0.5 mg/mL tobacco mosaic virus (TMV) for 30 s and then washed twice in sterile 
water for 5 s. The grids were negatively stained on uranyl acetate for 30 s and again for a further 30 
s and viewed using a Tecnai™ F20 Scanning Transmission Electron Microscope (FEI). 
5.2.4. Design and synthesis of the BFDV infectious molecular DNA clone 
The infectious molecular DNA clone was based on isolate BKS1ZA_84 (GenBank accession number 
GQ165756) previously described by Varsani et al. (2010) from a Budgerigar (M. undulatus), given 
that the probable challenge model would involve this animal. The partial genome repeat of 
BKS1ZA_84 was synthesised in silico by Geneart (Figure 5.1). The sequence included a 5ʹ PstI and 3ʹ 
HindIII and XbaI restriction enzyme sites for cloning purposes. The stem-loop as described by 
Bassami et al. (1998) was identified and was confirmed through ssDNA secondary structure analysis 
using the mfold web server (Zuker, 2003)(Figure 5.2). 
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5.2.5. Cloning and mutation strategy 
The BFDV infectious molecular DNA clone was modified using PCR to disrupt either the rep or the 
nonanucleotide motif situated in the first stem-loop. To disrupt the nonanucleotide motif the 5ʹ-
TAGTATTAC-3ʹ was modified to include a BamHI restriction enzyme site (Figure 5.3). An initial PCR 
reaction, as described in Appendix B.8, was performed using ACCUZYME™ DNA polymerase (Bioline) 
and primers that amplified a 401-bp PCR product (Table 5.1). The amplified PCR product was 
resolved on 1 % (wt/vol) TBE agarose gels and gel purified. A final PCR amplified a 421-bp BFDV 
BKS1ZA_84 N9 PstI mutant PCR product under identical thermocycling parameters (Table 5.1). The 
amplified PCR product was resolved on 1 % (wt/vol). The gel-purified BFDV BKS1ZA_84 N9 PstI 
mutant fragment was then used to replace the existing sequence through restriction enzyme 
digestion with PstI and SacI. The ligated constructs were transformed into competent E. coli DH5α, 
and the plasmid DNA was isolated from overnight cultures. The integrity of the clones was confirmed 
through sequencing (Macrogen Inc.). 
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Figure 5.1: Sequence of infectious molecular BFDV DNA clone based on isolate BKS1ZA_84 (GenBank 
accession number GQ165756). BFDV cp (blue), stem-loop (black box) as described by Bassami et al. (1998), 
nonanucleotide motif (yellow), and rep (red). 
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Figure 5.2: Predicted BFDV stem-loop structures as determined through the use of the mfold web server. 
BFDV cp (blue), and nonanucleotide motif (yellow). 
To disrupt translation of the rep the ATG start codon was replace by a SpeI restriction enzyme site 
(Figure 5.3). Initial PCR reactions, as described in Appendix B.9 , introduced the modifications and 
amplified a 265-bp BFDV BKS1ZA_84 rep SacI mutant and 239-bp BFDV BKS1ZA_84 rep PstI mutant 
PCR product (Table 5.1). These PCR products were gel purified and amplified, as described in 
Appendix B.10, together to produce a 504-bp BFDV BKS1ZA_84 rep SpeI mutant PCR product (Table 
5.1). The gel purified BFDV BKS1ZA_84 rep SpeI mutant fragment was then used to replace the 
existing sequence through restriction enzyme digestion with PstI and SacI. The ligated constructs 
were transformed into competent E. coli DH5α, and the plasmid DNA was isolated from overnight 
cultures. The integrity of the clones was confirmed through sequencing (Macrogen Inc.). 
The BFDV genome constructs were then inserted into a modified pTRAc plant expression vector. The 
plant expression cassette of pTRAc was removed through restriction enzyme digestion with SapI and 
PmeI. The resulting linearised plasmid, without the plant expression cassette, contained the left and 
right borders for T-DNA transfer into plant cells. The linear DNA fragment was ligated together with 
a 30-bp DNA fragment containing a MCS with the restriction enzyme sites: SapI, PstI, HindIII, and 
PmeI (Table 5.1). The BFDV infectious molecular DNA clones were then cloned into the modified 
pTRAc using PstI and HindIII. The ligated constructs were transformed into competent E. coli DH5α, 
and the plasmid DNA was isolated from overnight cultures. The integrity of the clones was confirmed 
through sequencing (Macrogen Inc.). 
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Table 5.1: Primers for PCR amplification used during molecular cloning of BKS1ZA_84 mutants. Underlined sequence indicates the position of the restriction enzyme sites 
used during cloning. 
Product Sense primer Antisense primer 
Description Size (bp) Sequence (5ʹ - 3ʹ) Cloning site Sequence (5ʹ - 3ʹ) Cloning site 
BFDV BKS1ZA_84 N9 BamHI mutant 401 AGGCGGCGGTTAGGATCCGCCGCCGCCTGGGGCAC BamHI TCTGCATCACTCCCTTTAGCGC - 
BFDV BKS1ZA_84 N9 PstI mutant 421 GCCCTGCAGAGGTGCCCCACAGGCGGCGGTTAGGA PstI, BamHI TCTGCATCACTCCCTTTAGCGC - 
BFDV BKS1ZA_84 rep PstI mutant 239 TGAGCGCGACGTAATACGACTC - GACGGACTAGTTCCCGGGC SpeI 
BFDV BKS1ZA_84 rep SacI mutant 265 GCCCGGGAACTAGTCCGTC SpeI TCTGCATCACTCCCTTTAGCGC - 
BFDV BKS1ZA_84 rep SpeI mutant 504 TGAGCGCGACGTAATACGACTC - TCTGCATCACTCCCTTTAGCGC - 
pTRAc linker SapI PmeI 30 CATTGAAGAGCCTGCAGGTGAAGCTTGTTT 
SapI, PstI, 
HindIII, PmeI 
AAACAAGCTTCACCTGCAGGCTCTTCA 
SapI, PstI, 
HindIII, PmeI 
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Figure 5.3: BFDV BKS1ZA_84 infectious molecular DNA clones used in this study. N9 – nonanucleotide motif (5ʹ-TAGTATTAC-3ʹ), BFDV rep (red), BFDV cp (blue). Elements 
subject to disruption (dashed boxes) with sequence description below. Nucleotides changed in the sequence are indicated by lower-case lettering. 
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5.2.6. Transfection of 293TT cells 
Endotoxin-free plasmid DNA was prepared using a NucleoBond® Xtra Midi EF (Macherey-Nagel, 
Germany) as per manufacturer’s instructions from E. coli cultures containing the BFDV BKS1ZA_84 
infectious molecular DNA clones. 
The 293TT cell line, kindly provided by Dr. J Schiller, was originally generated from a human 
embryonic kidney (HEK) cell line, HEK 293T, that was stably transfected with an SV40 Large T Antigen 
cDNA expression cassette. The 293TT cell line was maintained at 37°C, in a 5 % atmospheric CO2 and 
95 % humidity incubator. The nutrient medium was exchanged every 2-3 days, with DMEM, high 
glucose, GlutaMAX™ Supplement, pyruvate (Life Technologies) supplemented with 10 % HyClone™ 
Fetal Bovine Serum (South America), Research Grade (GE Healthcare), 1 % Penicillin/Streptomycin 
(100x, Sigma-Aldrich), 1 % MEM Non-essential Amino Acid (NAA) Solution (100x, Sigma-Aldrich), 0.5 
% 50 mg/mL Hygromycin B (Roche). 
A day prior to transfection, cells in 3 mL of complete growth medium (DMEM and 10% Fetal Bovine 
Serum) were plated in a 6-well plate for a final density of 5 X 105 cells per well. A FuGENE®HD:DNA 
ratio of 3.0:1 was used for all transfections. A 931 μL solution was prepared in sterile deionised 
water for each BFDV infectious molecular DNA clone at a concentration of 0.020 μg/μL. To this, 59 
μL of FuGENE® HD reagent (Promega) was added, briefly vortexed and incubated for between 5-10 
minutes at room temperature. A 150 μL of the complex was added per well to the cells, and mixed 
thoroughly and incubated for 24 hours. After incubation the nutrient medium was exchanged and 
for day 0, cells were immediately harvested for total DNA extraction using DNeasy® Blood & Tissue 
Kit (Qiagen), while the remaining cells were incubated for 3 days before being harvested. 
5.2.7. Transfer and analysis of BFDV infectious molecular DNA in N. benthamiana 
BFDV infectious molecular DNA clones in the modified pTRAc plant vector were transformed in A. 
tumefaciens as described in Section 3.2.3 and then infiltrated into N. benthamiana as described in 
Section 3.2.4. Total DNA was extracted from plant leaf tissue using an Extract-N-Amp™ Plant PCR Kit 
(Sigma-Aldrich) and used in RCA, as described in Section 0, and qPCR analysis. 
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5.2.8. Quantitative real-time PCR 
Each qPCR reaction was performed in triplicate using a LuminoCT® SYBR® Green qPCR ReadyMix™ 
(Sigma-Aldrich) as per manufacturer’s instructions and primers (5ʹ-TATTGGTTGAGAAGCGGCGTCT-3ʹ 
and 5ʹ-GACGTAGATATGCCCGCCCAT-3ʹ) specific to a 96-bp region of the BFDV cp. Cloned plasmid 
DNA containing the amplicons in serial dilution served as the standard curve for the determination 
of gene copy number for cp. Thermocycling was performed using a Rotor-Gene RG-6000 (Qiagen), 
and the parameters consisted of a 10 minute hold at 95 °C followed by cycling (40 repeats) between 
a 15 s hold for denaturation at 95 °C, a 15 s hold at 53 °C for annealing, and a 15 s hold 60 °C for 
elongation. Template specificity was confirmed from the reaction melt curve analysis. In addition 
BFDV rep primers were also used as described in Section 2.2.5. SD and SE were calculated were 
applicable and probability was calculated using a Student’s t-Test with two-tailed distribution and 
two-sample unequal variance. 
5.3. Results 
5.3.1. Extraction and purification of virus particles from diseased whole tissue 
To determine the presence of BFDV in each Palm cockatoo sample, DNA was extracted and RCA 
performed after which the DNA was cleaved using BamHI. The RCA reaction was confirmed by the 
amplification and cleavage of the pUC19 plasmid DNA control to produce a linear 2.7-kb dsDNA 
fragment (Figure 5.4A lane 5). An additional control, a 2-kb circular BFDV genomic dsDNA, was also 
successfully amplified using RCA and cleaved to produce a linear fragment (lane 4). The extracted 
DNA from all three samples indicated the presence of a linear 2-kb dsDNA fragment that is 
consistent with the size of the BFDV genome used as a control (lane 1-3). A 2-kb fragment was 
subsequently cloned, sequenced and confirmed to be BFDV. 
Approximately 25.57 g of internal organs were collected and used for extraction of virus particles. 
The extract was fractionated using CsCl gradient centrifugation. After equilibrium sedimentation two 
white bands were visible in the CsCl density gradient (Figure 5.4B). These bands were isolated and 
dialysed to remove CsCl. PCR analysis of the dialysed samples indicated that the white band with a 
higher CsCl density tested positive for BFDV DNA (Figure 5.4C). The concentration of virus present in 
dialysed sample was determined using qPCR to be approximately 109 genomes/µl. TEM of the 
dialysed sample testing positive for BFDV indicated the presence of virus particles with a diameter of 
approximately 21 nm (Figure 5.5). 
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Figure 5.4: Purification of BFDV virus particles from whole tissue taken from a Palm cockatoo (P. aterrimus). 
(A) RCA product linearised with BamHI to detect the presence of BFDV genomic DNA in various tissue samples, 
M – DNA marker, 1 – feather, 2 – blood, 3 – organs, 4 – positive control (circular dsDNA BFDV genome), 5 – 
RCA control (pUC19 plasmid). (B) CsCl gradient centrifugation to purify BFDV virus particles from internal 
organs, band 1 and 2 collected for analysis. (C) Standard PCR analysis of dialysed CsCl bands collected 1 – band 
1, 2 – band 2, M – DNA marker, 3 – positive PCR control. 
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Figure 5.5: Transmission electron micrographs of purified BFDV virus particles after CsCl gradient 
centrifugation. (A and B) BFDV virus particles indicated by white arrows, TMV (18 nm width) included as a size 
control. Scale bar represent 200 nm. 
5.3.2. Replication of a BFDV dsDNA molecular clone in 293TT cells 
To determine whether a synthesised BFDV dsDNA molecular clone is functional at the level of DNA 
replication, endotoxin-free DNA was used to transfect 293TT cells. Total DNA from cells extracted on 
day 0 and day 3 after transfection were analysed using RCA and qPCR. Amplified DNA produced 
during RCA was linearised with BamHI and resolved using gel electrophoresis (Figure 5.6A lane 1). 
The RCA reaction was confirmed by the presence of a linear 2.7-kb dsDNA fragment for the reaction 
containing the pUC19 plasmid control DNA. The presence of a linear 2-kb BFDV full-length genome 
was absent on day 0 and present on day 3 for the BFDV dsDNA molecular clone (Figure 5.6A lane 4 
and 5). This circular genome was cloned, sequenced and confirmed to be identical in sequence to 
the input DNA. A linear 2-kb BFDV genome was absent on both day 0 and 3 for the negative control 
that did not contain sequence elements responsible for BFDV replication (Figure 5.6A lane 2 and 3). 
Analysis of the total DNA samples using qPCR confirmed that there was a significant increase in the 
copy number of the cp from day 0 to day 3 for the BFDV clone (Figure 5.6B). There was a significant 
decrease in the copy number of the cp from day 0 to day 3 for the negative control DNA. 
To confirm whether the 2-kb genome detected using RCA and the increase in gene copy number 
observed using qPCR were as a result of BFDV replication, the synthesised BFDV dsDNA molecular 
clone was altered at either the rep, to prevent translation, or at the nonanucleotide motif found 
within the stem-loop, to prevent DNA nicking by Rep. Endotoxin-free DNA was prepared for the 
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mutants and used to transfect 293TT cells. Total DNA from cells extracted on day 0 and day 3 after 
transfection were analysed using RCA. Amplified DNA was linearised with BamHI and resolved using 
gel electrophoresis (Figure 5.6C). The presence of a linear 2-kb BFDV full-length genome was absent 
on day 0 and present on day 3 for the BFDV dsDNA molecular clone (Figure 5.6C lane 3 and 4). A 
linear 2-kb BFDV genome was absent on both day 0 and 3 for the negative control (lane 1 and 2) 
together with the mutant containing the rep alteration (lane 5 and 6) and the nonanucleotide 
alteration (lane 7 and 8). 
5.3.3. BeYDV-assisted replication of a BFDV dsDNA molecular clone in N. benthamiana 
To determine whether the BFDV dsDNA molecular clone was capable of replicating in N. 
benthamiana, the clone was inserted into a plant expression vector and Agrobacterium-infiltrated 
into plant leaves in the presence or absence of the BeYDV replicating vector. Total DNA from leaf 
tissue was extracted on day 1-4 after infiltration and analysed using qPCR (Figure 5.7A). In the 
absence of the BeYDV vector the BFDV cp copy number remained constant over the 4 day period. In 
the presence of the BeYDV vector the BFDV cp increased by two orders of magnitude from day 1 to 
day 3, after which the copy number remained constant. 
The BFDV genome mutant containing the altered nonanucleotide sequence was tested to determine 
whether the observed replication was as a result of the BFDV dsDNA molecular clone (Figure 5.7B). 
No difference in cp copy number in the presence of the BeYDV vector was observed between the 
mutant and the BFDV dsDNA molecular clone. To confirm this was result was not an artefact of 
BeYDV replicating, further analysis was performed. 
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Figure 5.6: Replication of a BFDV dsDNA molecular clone in 293TT cells. (A) RCA product linearised with 
BamHI to detect the presence of BFDV genomic DNA on day 0 and day 3 post transfection, M – DNA marker, 1 
– RCA control (pUC19 plasmid), non-replicating control 2 – day 0, 3 – day 3, BFDV dsDNA molecular clone 4 – 
day 0, 5 – day 3. (B) qPCR analysis of cp copy number on day 0 and day 3 of non-replicating control (white) and 
BFDV dsDNA molecular clone (shaded), ** - p < 0.01. (C) RCA product linearised with BamHI to detect the 
presence of BFDV genomic DNA on day 0 and day 3 post transfection, M – DNA marker, non-replicating control 
1 – day 0, 2 – day 3, BFDV dsDNA molecular clone 3 – day 0, 4 – day 3, BFDV dsDNA molecular clone (rep 
mutant) 5 – day 0, 6 – day 3, BFDV dsDNA molecular clone (nonanucleotide sequence mutant) 7 – day 0, 8 – 
day 3, 9 – RCA control (pUC19 plasmid). 
The BFDV molecular clone and BeYDV vector were infiltrated into plants and total DNA was 
extracted on day 5 after infiltration and analysed using RCA. Amplified DNA produced during RCA 
was linearised with BamHI and resolved using gel electrophoresis (Figure 5.8A). No 2-kb linear 
fragment was detected for the BFDV dsDNA molecular clone only or when co-infiltrated with the 
BeYDV replicating vector (lane 1 and 2). A 2.5-kb BeYDV replicon was detected in plants infiltrated 
with the BeYDV vector (lane 2 and 3). 
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Figure 5.7: BeYDV-assisted replication of a BFDV dsDNA molecular clone in N. benthamiana. (A) qPCR 
analysis of cp copy number between day 1 and day 4 post infiltration, BFDV dsDNA molecular clone in the 
presence (■) and absence (▲) of the BeYDV replicating vector. (B) qPCR analysis of cp copy number on day 1 
and day 3 of BFDV dsDNA molecular clone (white) and BFDV dsDNA molecular clone (nonanucleotide sequence 
mutant, shaded) in the presence of the BeYDV plant replicating vector, ns – not significant, * - p < 0.05. 
To distinguish between the replication of the BFDV genome and the BeYDV replicon, the copy 
number for both was determined using cp and rep specific qPCR. A BeYDV replicating vector 
containing cp would allow for the copy number of the replicon to be determined. The BFDV dsDNA 
molecular clone was co-infiltrated into plant leaves in the presence of an empty BeYDV replicating 
vector or one containing a copy of the BFDV cp. Total DNA from leaf tissue was extracted on day 1 
and 4 after infiltration. The total DNA was analysed using qPCR to determine gene copy number of 
rep for the BFDV genome and cp for both the BFDV genome and the BeYDV replicon containing cp 
(Figure 5.8B and C). Analysis using primers specific for the cp indicated an increase in gene copy 
number from day 1 to day 4 for both infiltrations (Figure 5.8B). The cp copy number increased by 
over an order for magnitude when the BFDV dsDNA molecular clone was infiltrated alongside an 
empty BeYDV replicating vector. However, when infiltrated with the vector containing a cp the BFDV 
gene copy number increased by three orders of magnitude. 
Analysis of the rep copy number produced a similar increase in gene copy number for both 
infiltrations and served as a control (Figure 5.8C). An increase of one order of magnitude was 
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observed for the BFDV dsDNA molecular clone infiltrated alongside an empty BeYDV replicating 
vector. A similar increase in copy number of rep, by an order of magnitude, was observed when 
infiltrated alongside the BeYDV replicating vector containing a cp. When compared to the empty 
BeYDV replicating vector, the vector, containing cp, had a rep copy number on day 4 that was 
significantly lower. 
 
Figure 5.8: Distinguishing between BFDV dsDNA molecular clone and BeYDV replication in N. benthamiana. 
(A) RCA product linearised with BamHI to detect the presence of BFDV genomic DNA on day 5 post infiltration, 
M – DNA marker, 1 – BFDV dsDNA molecular clone only, 2 – BFDV dsDNA molecular clone and BeYDV 
replicating vector, 3 – BeYDV replicating vector only, 4 – RCA control (pUC19 plasmid). (B) qPCR analysis of cp 
copy number on day 1 and day 4 of BFDV dsDNA molecular clone in the presence of the BeYDV plant 
replicating vector only (white) or containing the BFDV cp (shaded), * - p < 0.05. (C) qPCR analysis of rep copy 
number on day 1 and day 4 of BFDV dsDNA molecular clone in the presence of the BeYDV plant replicating 
vector only (white) or containing the BFDV cp (shaded), ** - p < 0.01 
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5.4. Discussion 
5.4.1. Extraction and purification of virus particles from diseased whole tissue 
Whole tissue collected from psittacines infected with BFDV can be used to successfully isolate virion 
particles. In this study whole tissue from internal organs were used for virus purification as has been 
previously described (Wylie and Pass, 1987). Virus particles have also been successfully extracted 
from feathers of diseased animals (Raidal and Cross, 1994b; Ritchie et al., 1990; Shearer et al., 
2008a). Before the production of recombinant BFDV CP, purified virus was the sole source of BFDV 
antigen for use as a reagent in HI tests (Raidal and Cross, 1994a; Shearer et al., 2009a). As the virus 
cannot be cultured, virus preparations from whole tissue samples are still required for material used 
in challenge experiments. The virus isolated from this study was from a Palm cockatoo that had 
succumbed to PBFD. The virus was detected using RCA in the feathers, blood and organs and could 
be said to be systemic (Figure 5.4). Virus was purified using CsCl density gradient centrifugation from 
internal organs collected during necropsy. 
The yield for purified virus in this study was 109 genome copies/μL which is three orders of 
magnitude higher than previously reported values. BFDV particle yields for feathers after extraction 
and density gradient centrifugation have been reported to be between 106 particles/μL and 107 
particles/μL (Raidal and Cross, 1994a). These yields are reportedly low making the process 
unsuitable for the large scale preparation of reagent used in HI testing (Shearer et al., 2009a). 
Interestingly peak viraemia during BFDV infection has been reported as being in the region 106 
genome copies/μL (Bonne et al., 2009). Reasons for the difference in virus quantity could be in the 
choice of tissue used for the extraction or the assay used to quantify the virus preparation. 
Approximately 220 g of feather material from eight diseased psittacines was used in the extraction 
of virus as described in Raidal and Cross (1994b). It is unclear whether the author used whole 
feathers or a specific region of the feather. The BFDV virus is known to affect the replicating cells in 
the feather follicle and basal epithelial layer resulting in feather dystrophy (Latimer et al., 1993). The 
use of whole feathers would therefore not result in high yields as only a small portion of the feather 
contains viral particles and any healthy feathers would suggest that any infection in the follicle is 
relatively new. Previous studies have relied on HA to quantify virus concentration whereas in this 
study qPCR was used (Raidal et al., 1993c). The variability in results produced from these assays is 
high as a result of batch differences in the erythrocytes, viral preparations and polyclonal antibodies 
used (Raidal and Cross, 1994a). Quantification using qPCR is seen as a more reliable method of 
determination (Shearer et al., 2009b). 
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Analysis of virus particles using TEM indicated that that the diameter of particles was approximately 
21 nm (Figure 5.5). This diameter is larger than most of the particle sizes described in the literature 
(Figure 1.2) and falls within the range described in two publications and one chapter (Crowther et 
al., 2003; Gerlach, 1994; Jacobson et al., 1986). The size of 20.5 nm as put forward by Crowther et al. 
(2003) was calculated based on the three dimensional structure for BFDV virions, as determined by 
cryoelectron microscopy. These values are higher than expected and may have been as a result of 
the preparation. For comparison purposes TMV was combined with the sample and the widths of 
the particles were also found to be approximately 21 nm. This value is larger than the literature 
values which describe the TMV virion as having a width of 18 nm and length of 300 nm (Tidona and 
Darai, 2011). This further supports the suggestion that the preparation of the sample on the copper 
grids may have affected the staining of the particles. The purified virions (21 nm) were also larger in 
comparison to the plant-produced BFDV VLPs that were on average 17 nm in diameter (Section 
4.3.2). The size reported for the BFDV particles purified in this study, however, falls within range of 
reported values in the literature. To confirm infectivity the purified virus could be tested in 
embryonated eggs before being used as challenge material for vaccine testing. 
There are a number of disadvantages to using virus purified from whole tissue from infected 
psittacines. Firstly the purification process is expensive and time consuming and more often than not 
produces low yields (Latimer et al., 1993; Shearer et al., 2009a). The yields are low in part because of 
the availability of infected whole tissues used for extraction. This also hampers consistency as birds 
sourced from different locations may have different BFDV isolates. Secondly, the purified virus can 
be contaminated with host proteins affecting the perceived yield and use in serological assays or 
with other viruses, considering psittacines infected with BFDV more often than not have 
accompanying secondary infections (Stewart et al., 2007; van den Brand et al., 2007). Finally there is 
the ethical dilemma faced with producing purified virus from whole tissue of diseased psittacines. 
Continual harvesting of feather material from birds with chronic PBFD or the intentional infection of 
these birds for the purpose of producing infectious virus is ethically questionable, therefore 
researchers mainly rely on naturally infected birds that succumb to the PBFD as a source of virions 
(Shearer et al., 2009a). Although there is an absence of any obvious serotypes for BFDV and a high 
probability of cross-isolate protection, the testing of vaccine efficacy would be better served using 
virus and vaccine antigen originating from the same isolate (Ritchie et al., 1992b; Shearer et al., 
2009a). 
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5.4.2. Replication of a BFDV dsDNA molecular clone in 293TT cells 
To circumvent the disadvantages faced when using BFDV virus purified from whole tissue, a 
synthetic BFDV dsDNA molecular clone was synthesised and tested in tissue culture. 293TT cells 
were transfected and the presence of circular BFDV genomic DNA three days later was identified 
using RCA (Figure 5.6A). This is the first time BFDV has been demonstrated to replicate in 
mammalian tissue culture. Using qPCR analysis an approximately ten-fold increase in DNA copy 
number could be observed (Figure 5.6B). This increase is modest in comparison to active viraemia 
seen in psittacines infected with purified virus in which a viral load increases by six orders of 
magnitude; however this is over a two week period. The underperformance in replication efficiency 
could be attributed to the cell type used, considering that mammalian cells are not the natural host 
for BFDV. In addition, since the synthetic BFDV dsDNA molecular clone was transfected into the 
293TT cells it is also likely that replication is confined to the transfected cells. The absence of cell-to-
cell spread would also explain the modest increase in genome copy number. 
To confirm that the increase in genome copy number was driven by the synthetic BFDV DNA 
molecular clone, the clone was altered either to prevent translation of the BFDV rep or to prevent 
the initiation of replication by Rep at the nonanucleotide motif situated on the stem-loop. The 
modification of the nonanucleotide motif was based on results obtained through single-site 
mutations along the nonanucleotide motif of PCV-2 (Cheung, 2004). These were then transfected 
into 293TT cells to determine whether circular BFDV genomic DNA was generated (Figure 5.6C). Both 
altered clones failed to produce a 2 kb circular BFDV genome as has previously been shown for the 
synthetic BFDV DNA molecular clone. This is the first confirmation that Rep and the nonanucleotide 
are required in BFDV for initiation of replication. 
5.4.3. BeYDV-assisted replication of a BFDV dsDNA molecular clone in N. benthamiana 
To explore alternative systems for replicating BFDV and ultimately producing virus particles, the 
synthetic BFDV dsDNA molecular clone was tested in N. benthamiana. It has previously been 
reported that replication elements of BeYDV have been successfully used for amplification of 
heterologous genes in plants (Regnard et al., 2010): these authors reported that gene copy number 
increased by three orders of magnitude over a three day period as the vector replicated. For the 
present study it was decided to measure gene copy number over a four day period. 
The synthetic BFDV dsDNA molecular clone was unable to replicate on its own after Agrobacterium 
T-DNA transfer into the plant cell nucleus (Figure 5.7A). This would be expected, considering the 
promoters in the BFDV genome have evolved for an avian host and animal promoters generally do 
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not work well in plants. When the synthetic BFDV dsDNA molecular clone tested in the presence of 
the replicating BeYDV-derived plant vector; however, a measurable increase in gene copy number 
over the four-day period was seen. By day 3 the gene copy number had increased approximately two 
orders of magnitude, indicating that the BeYDV Rep was able to initiate replication of the BFDV 
genome from the nonanucleotide motif in the construct. The nonanucleotide motif for geminiviruses 
is 5ʹ-TAATATTAC-3ʹ, while for BFDV it is 5ʹ-TAGTATTAC-3ʹ; however, it has been shown for PCV-2 (5ʹ-
AAGTATTAC-3ʹ) that the nucleotide in position three (underlined) does not influence replication 
efficiency (Cheung, 2004; Laufs et al., 1995). This could hold true too for recognition of the BFDV 
nonanucleotide motif by the BeYDV Rep, as the BFDV genome was replicated reasonably efficiently. 
To confirm that the BeYDV Rep was initiating the replication of the synthetic BFDV DNA molecular 
clone, the BFDV clone with a mutated nonanucleotide motif was tested (Figure 5.7B). Unexpectedly, 
no difference was observed between synthetic BFDV DNA molecular clone and the altered clone (5ʹ-
TAGgATcgg-3ʹ): the BeYDV Rep could apparently recognise the altered nonanucleotide motif. A 
possible explanation for this is that the changes to the BFDV sequence were based on lethal 
mutations observed in PCV-2, and did not account for allowed variations in the nonanucleotide motif 
of geminiviruses (Cheung, 2004). For example, Laufs et al. (1995) demonstrated that changing the 
nonanucleotide motif (5ʹ-TAATATTAC-3ʹ) for geminiviruses at position 7 or 8 (underlined) resulted 
replication efficiency that remained above 50 %; however, mutations at position 9 reduced 
replication efficiency to below 25 %. It could be suggested the changes to the BFDV nonanucleotide 
motif in this study may allow replication due to the heterologous Rep. 
To confirm that the increase in copy number observed was from the BFDV genome and not the 
BeYDV plant vector, RCA and qPCR amplifications were performed on the plant total DNA extracts. 
The RCA analysis confirmed that the synthetic BFDV DNA molecular clone did not replicate in the 
absence of the BeYDV plant vector (Figure 5.8). However, it was apparent that the RCA reaction 
involving the amplification of the BeYDV replicon out-competed that of the BFDV genome, as only a 
2.5-kb linear BeYDV replicon was detected. This could be due to the much greater replication 
efficiency of the BeYDV replicon versus the BFDV genome before DNA extraction. As is also the case 
with PCR, the RCA reaction would preferentially amplify the DNA species having the highest 
concentration. 
To determine the copy number of the BeYDV replicon, synthetic BFDV DNA molecular clone was 
tested in the presence of an empty BeYDV plant vector and a vector containing a cloned cp. Analysis 
of copy number specifically measuring the cp was performed using qPCR (Figure 5.8B). In the 
absence of the cloned BFDV cp the copy number of the BFDV genome increased by approximately 
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two orders of magnitude, as has previously been shown. This reflects the replication of the BFDV 
genome and does not detect the BeYDV replicon. On day 4 of the experiment with both the BFDV 
genome, and the BeYDV replicon containing cp, the cp copy number increased by three orders of 
magnitude which is similar to that reported for other heterologous genes cloned into the BeYDV 
plant vector (Regnard et al., 2010). This increase in cp copy number is almost certainly due mainly to 
the BeYDV amplification, as the contribution of the BFDV genome to the increase in cp copy number 
is expected to be marginal considering the BFDV genome alone increases by only two orders of 
magnitude compared to three for BeYDV. This would support the observations seen for the RCA 
amplification. Analysis of copy number specifically measuring the rep was performed using qPCR and 
served as a control (Figure 5.8C). The qPCR reaction would only be able to detect replication of BFDV 
genome irrespective of whether the BeYDV plant vector contained cp. The increase in BFDV genome 
copy number was lower in the presence of the BeYDV replicon containing cp. This could be explained 
by the downstream translation of the cp that would compete for cell resources. There is also the 
possibility that the expressed CP was interfering in genome amplification by encapsidating the 
ssDNA form of the genome. This possibility was not tested, however. These results could be further 
supported by determining the copy number of the BeYDV replicon based qPCR specific to the BeYDV 
replicon and not the BFDV cp. 
Further analysis of purified BFDV virions and the synthetic BFDV DNA molecular clone would involve 
testing of infectivity in embryonated eggs. Considering the BFDV isolate used in this study was 
isolated from Budgerigars, eggs from this host would probably be suitable. However, the unexpected 
finding of the replication of BFDV in 293TT cells presents an opportunity for the development of a 
replicating vector for use in gene delivery. Similarly, the replication of the BFDV genome in N. 
benthamiana coupled with the expression of the BFDV CP could provide an alternative gene delivery 
vector or vaccine that can generate a strong humoral and cellular response for psittacines. 
In conclusion, I found that the BFDV virions could be successfully purified from whole tissue of parrot 
internal organs, and that a synthetic BFDV DNA molecular clone was able to replicate once 
transfected into HEK 293 TT cells and is moreover capable of the replicating in N. benthamiana in the 
presence of BeYDV replication elements. This is the first reported instance of BFDV replicating in 
mammalian cells and the first report of a circovirus replicating with the aid of a geminivirus in N. 
benthamiana. Both these developments could significantly open up possibilities for making reagents 
and vaccines for BFDV, and possibly even sophisticated virion-based vaccines containing artificial 
genomes. 
 125 
Chapter 6: General conclusion 
At present, there is no commercial treatment or vaccine available against PBFD (Patterson et al., 
2013b). The development of subunit vaccines is seen as being preferable to inactivated vaccines, as 
the virion is extremely stable, making incomplete inactivation a potential risk (Raidal and Cross, 
1994a). The BFDV CP has previously been expressed in various systems, including bacterial 
fermentations; however expression of the full-length protein was unsuccessful as the protein was 
insoluble (Heath, 2006; Patterson et al., 2013b). Thus far, only one challenge trial of a BFDV subunit 
vaccine has been conducted: this tested insect cell-produced CP against purified infectious virions 
derived from whole tissue (Bonne et al., 2009). The trial was successful in that an immune response 
was produced in the vaccinated fledglings; however, the vaccine was unable to prevent viral 
replication and the challenge material was prepared more than a decade ago. Improvements to the 
current subunit vaccine are therefore needed, together with the development of a reliable 
alternative to purified virus as challenge material. 
To this end, the aim of this study was to understand the current status of BFDV diversity in South 
Africa, with particular focus on the endangered wild Cape parrot population. Understanding the 
regional diversity would thereby direct the development of an experimental subunit vaccine to be 
produced in plants. This would be accompanied by parallel development of a suitable infectious 
virus-derived molecular DNA clone challenge model. 
Investigation of a recent outbreak of BFDV in endangered Cape parrots endemic to South Africa 
revealed that wild and captive birds were infected independently, which could result in raising the 
risk of introducing new virus strains upon successful rehabilitation and release of the captive birds. 
Developing a challenge model based on Cape parrots would be unfeasible, as the birds are 
endangered due to dwindling populations and therefore protected (Martin et al., 2014). BFDV 
isolates from captive Cape parrots were seen to cluster phylogenetically with South African isolates 
from Budgerigars previously described (Varsani et al., 2010). The development of a suitable 
challenge model based on Budgerigars is therefore a feasible alternative, considering its relative 
abundance as a companion species (Parr and Juniper, 2010). 
As part of the conservation strategy of the Cape parrot, the relationship between clinical signs of the 
disease to the BFDV viral load in the blood was characterised, with the aim of developing a reliable 
tool for use in the field for differentiating diseased and healthy birds. A direct correlation between 
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viral load in the blood and an increase in clinical signs was shown, allowing researchers to monitor 
disease spread in wild birds indirectly. 
The development of a subunit vaccine focused on plant-based production of CP from a Budgerigar 
isolate described by Varsani et al. (2010). The plant expression platform has been shown to be 
favourable for the production of region-specific and niche market products (Stoger et al., 2014). This 
made it viable for a vaccine against BFDV, which would be considered a niche market. The CP was 
expressed in plants and accumulation could be increased with a variety of optimisations; however, 
the overall yield was still insufficient to make production commercially viable. This could be due to 
problems associated with solubility, as has previously been reported. Tentative evidence suggested 
that the CP was able to form assemble into pentameric subunits, even under SDS denaturation, 
leading the possibility of the CP forming plant-produced VLPs. The assembly of insect cell produced 
CP into VLPs has been demonstrated, suggesting that the same could be true for plant-produced CP 
(Stewart et al., 2007). 
Plant-produced BFDV VLPs were demonstrated using purification methods based on the extraction 
of virions. The VLPs were similar in size and morphology to the genuine virions and insect cell 
produced VLPs, and it was possible that the VLPs were incorporating geminivirus-derived replicons 
expressed from the BeYDV-based replicating plant expression vector (Crowther et al., 2003; Regnard 
et al., 2010; Stewart et al., 2007). The production of VLPs and the inclusion of episomal DNA has the 
potential to create a potent vaccine capable of eliciting a strong humoral and cellular response, 
should the cp be included and expressed in the host cell. This could overcome the problem of 
continued viral replication and transient viraemia present in vaccinated birds challenged with live 
virus. 
Parallel development of the challenge vector involved testing of a potentially infectious molecular 
DNA clone in mammalian cell culture and N. benthamiana. The clone, based on the described 
Budgerigar isolate, was seen to replicate in transfected mammalian 293TT cells. This confirmed that 
the replication elements used to develop the clone were functional and capable of producing intact 
BFDV genomes. This would be critical to starting an infection in host cells during challenge. The study 
explored the possibility of the BFDV clone replicating in plants. Replication was seen only in the 
presence of a BeYDV replicating vector, suggesting the BFDV Rep was not expressed and therefore 
RCR was initiated in trans by the BeYDV Rep. Successful replication on the BFDV genome in plants in 
combination with plant expression of the CP could potentially lead to the packaging of infectious 
plant-produced virions. These virions would be free of bird pathogens, and could be readily 
quantified and used in a challenge trial. These aspects will be addressed in future studies. 
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This study was established to investigate the prevalence and diversity of BFDV in the endangered 
Cape parrot, and if possible to develop a robust challenge model and vaccine for BFDV. I can 
conclude that I have successfully studied the virus in Cape parrots, and I have produced a potential 
subunit vaccine in plants, and I have tested replication of a ‘live challenge’ vector in mammalian 
tissue culture and in plants. 
The present study expands significantly on the current state of knowledge of BFDV. The elucidation 
of the genetic diversity of BFDV in wild Cape parrots in South Africa can assist further in 
understanding of BFDV global movement (Harkins et al., 2014). In addition, these data can be used 
by conservation agencies to trace the illegal capture of wild Cape parrots through analysis of virus 
isolates (Massaro et al., 2012). Knowledge of BFDV isolates infecting Cape parrots could also advise 
conservation policies, especially with regards to introducing rehabilitated birds back into the wild 
population. The insights provided through analysis of viral load in the blood provides a better 
understanding of viraemia, and is a useful addition in defining the upper and lower limits of virus 
presence in the blood (Katoh et al., 2008; Shearer et al., 2009b). The correlation between increasing 
viral load and deteriorating clinical signs can be readily applied in the conservation of wild Cape 
parrots. Here too, knowledge of the lower limits of viral load found in healthy birds could assist in 
the diagnosis of PBFD. 
Plant-produced BFDV CP and VLPs provide an alternative to CP produced in insect cell culture and 
bacterial fermentations. As has been demonstrated, the CP can be readily expressed in plants, albeit 
fused to a large purification/aggregation tag such as the elastin-like polypeptide (ELP)(Duvenage et 
al., 2013). The present study is the first reported production of BFDV VLPs in plants. This could form 
the basis of a viable vaccine, and if combined with DNA capable of being packaged by CP, could 
potentially result in pseudovirions. These would probably elicit a potent humoral and cellular 
immune response. The synthesis and successful preliminary testing of a BFDV dsDNA molecular 
clone was based on similar successes shown for PCV (Fenaux et al., 2002; Liu et al., 2001). Not only 
does the study put forward a convenient challenge vector, it expands the tools available with which 
to study the replication of BFDV and circoviruses at large. There is potential in creating defective 
virion particles, opening up a BFDV attenuated vaccine alternative to be explored. 
Exploring the following as future research may further develop on these reported findings. 
Continued monitoring and sampling of the Cape parrot population would provide invaluable data 
regarding virus genetic evolution and bottlenecks, as well as temporal data on genetic diversity and 
viral load within the wild bird population. Purification of sufficient quantities of plant-produced CP 
for testing of immunogenicity in Budgerigars should be done as a matter of urgency. The production 
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of pseudovirions in plants should be further explored. Combinations of BFDV and BeYDV replication 
elements together with a genome-sized replicon may allow for packaging and assembly. The replicon 
design could introduce additional disease antigens, thus allowing for the vaccine to protect against 
more than one disease. Future work with the BFDV dsDNA infectious molecular clone should focus 
on testing in embryonated eggs together with exploring plant-produced virion particles. The 
production of virus particles can be used to test knockout mutants and provide empirical evidence 
for the mechanism of BFDV replication. Due to the simple replication strategy, the BFDV sequence 
elements used in this study could be deconstructed and optimised for use as a potential replicating 
component for gene therapy. 
A successful vaccine against BFDV could be integrated into the conservation of wild Cape Parrots 
during routine capture and release of birds for monitoring of BFDV. The vaccine could be 
administered either as a subcutaneous injection during handling or the possibility exists to introduce 
the vaccine via feed however dosage would be unregulated. 
There were a number of limitations that were encountered during this study. Sampling of Cape 
parrots favoured the capture of diseased parrots over healthy ones, as it was observed in the field 
that these struggled during flight to gain enough height, and thus were more often caught. This may 
have excluded samples that may have tested positive for BFDV while having no clinical signs of PBFD. 
Moreover, the isolation of BFDV genomic DNA through RCA may have overlooked samples 
containing multiple infections with different isolates. Identifying samples with multiple infections 
would have been a time-consuming exercise, but should however be explored in the future, with the 
possibility of detecting recombination events. The yield of plant-produced CP was determined to be 
low in comparison to other proteins. Various optimisations were undertaken to increase expression, 
with mixed results being achieved. Plant codon-optimisation had little effect on expression; however 
the overall G+C content of the gene remained unchanged. Increasing the G+C content as opposed to 
optimising codon usage could possibly increase the expression of CP. The low yield prompted us to 
explore VLP formation, as a possible explanation. 
This study contributes considerably to the overall understanding of BFDV. The virus diversity present 
in a recent outbreak of BFDV was defined for a wild population of Cape parrots. This was 
accompanied by the first described assessment of BFDV viral load in a wild psittacine population, 
and the verification of a field guide for estimation of disease status. This study also considerably 
furthered the development of a plant-produced BFDV CP vaccine. The expression of CP in N. 
benthamiana was optimised, and thereafter purification of CP VLPs was successful. This is the first 
report of BFDV VLP production in plants. In parallel to vaccine development, a suitable challenge 
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vector was explored. A BFDV dsDNA molecular clone was synthesised and demonstrated to replicate 
in mammalian tissue culture and plants. This is the first report of successful BFDV replication in a 
tissue culture system. It is to be hoped that others can build on this to complete our team’s goal of 
making a viable BFDV vaccine, together with a reliable challenge model.  
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Appendix A: Minimum information for publication of quantitative 
real-time PCR experiments 
Table A.1: MIQE checklist for authors, reviewers and editors. All essential information (E) must be submitted. 
Desirable information (D) should be submitted if available. If using primers obtained from RTPrimerDB, 
information on qPCR target, oligonucleotides, protocols and validation is available from that source. 
Item to check ! Checklist 
Experimental design 
 
  
Definition of experimental and control 
groups E See Section 2.2.5 
Number within each group E A total of 49 samples 
Assay carried out by core lab or investigator's 
lab? D 
 Acknowledgement of authors' contributions  D 
 Sample 
 
  
Description E Blood on FTA™ Classic Card (Whatman) 
Volume/mass of sample processed D 
 Microdissection or macrodissection E Not applicable 
Processing procedure E Not applicable 
If frozen - how and how quickly? E Not applicable 
If fixed - with what, how quickly? E Not applicable 
Sample storage conditions and duration 
(especially for FFPE samples) E Storage at 4 °C 
Nucleic acid extraction 
 
  
Procedure and/or instrumentation E DNA extraction from nucleated blood samples 
Name of kit and details of any modifications E DNeasy® Blood & Tissue Kit (Qiagen) 
Source of additional reagents used  D 
 Details of DNase or RNAse treatment E Not applicable (Measurement of virus particles in blood) 
Contamination assessment (DNA or RNA) E Not applicable 
Nucleic acid quantification  E Spectrophotometric analysis 
Instrument and method E NanoDrop ND-1000 Spectrophotometer V3.1.0 
Purity (A260/A280)  D 
 Yield D 
 RNA integrity method/instrument E Not applicable 
RIN/RQI or Cq of 3' and 5' transcripts  E Not applicable 
Electrophoresis traces D 
 Inhibition testing (Cq dilutions, spike or 
other)  E No inhibition testing was performed 
Reverse transcription 
 
  
Complete reaction conditions E Not applicable 
Amount of RNA and reaction volume E Not applicable 
Priming oligonucleotide (if using GSP) and 
concentration E Not applicable 
Reverse transcriptase and concentration E Not applicable 
Temperature and time E Not applicable 
Manufacturer of reagents and catalogue 
numbers D 
 Cqs with and without RT D 
 Storage conditions of cDNA D 
 qPCR target information 
 
  
If multiplex, efficiency and LOD of each 
assay. E Not applicable 
Sequence accession number E GQ165756 EU660286 
Location of amplicon D 
 Amplicon length E 97-bp 97-bp 
In silico specificity screen (BLAST, etc) E BLAST analysis performed 
Pseudogenes, retropseudogenes or other 
homologs? D 
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Sequence alignment D 
 Secondary structure analysis of amplicon D 
 Location of each primer by exon or intron (if 
applicable) E Not applicable 
What splice variants are targeted? E Not applicable 
qPCR oligonucleotides 
 
  
Primer sequences E 
5'-CAGTTAAGGGCGCTTTTGTGGAG-3' 
5'-TTCGGGTCACAGTCCTCCTTG-3' 
5'-TCCCATCTGGCACTGTCTCTG-3' 
5'-ACAGAGCTTTCACCCTCATTTATGG-3' 
RTPrimerDB Identification Number  D 
 Probe sequences D 
 Location and identity of any modifications E Not applicable 
Manufacturer of oligonucleotides D 
University of Cape Town, Molecular and Cell Biology Department, Synthetic DNA 
Laboratory 
Purification method D Post-synthesis desalting 
qPCR protocol 
 
  
Complete reaction conditions E See below 
Reaction volume and amount of cDNA/DNA E 20 μL and 1 μL DNA 
Primer, (probe), Mg++ and dNTP 
concentrations E 200 μM each, N/A, manufacturer, manufacturer 
Polymerase identity and concentration  E JumpStartTM Taq DNA Polymerase (Sigma-Aldrich); concentration unknown 
Buffer/kit identity and manufacturer  E LuminoCT SYBR Green qPCR ReadyMix; Sigma-Aldrich 
Exact chemical constitution of the buffer D 
Tris-HCl, pH 8.3, KCl, dNTPs (dATP, dCTP, dGTP, TTP), stabilizers, MgCl2, SYBR Green I 
and JumpStartTM Taq DNA Polymerase 
Additives (SYBR Green I, DMSO, etc.) E None 
Manufacturer of plates/tubes and catalogue 
number D Corbet Research 0.1 ml Tubes & Caps 3001-002 
Complete thermocycling parameters E 
Hold @ 95 °C (10 minutes), cycling (40 repeats) step 1 @ 95 °C (hold 15 s), step 2 @ 
55 °C (hold 15 s), step 3 @ 60 °C (hold 15 s) 
Reaction setup (manual/robotic) D Manual 
Manufacturer of qPCR instrument E Qiagen 
qPCR validation 
 
  
Evidence of optimisation (from gradients)  D 
 Specificity (gel, sequence,  melt, or digest) E Melt (See Section A.1) 
For SYBR Green I, Cq of the NTC E See Table A.2 
Standard curves with slope and y-intercept E See Section A.1 
PCR efficiency calculated from slope E See Table A.2 
Confidence interval for PCR efficiency or 
standard error D 
 r2 of standard curve E See Table A.2 
Linear dynamic range E See Section A.1 
Cq variation at lower limit E See Table A.2 
Confidence intervals throughout range D 
 Evidence for limit of detection E See Section A.1 
If multiplex, efficiency and LOD of each 
assay. E Not applicable 
Data analysis 
 
  
qPCR analysis program (source, version) E Rotor-Gene 6000 real-time rotary analyzer, Software version 1.7 (Build 87) 
Cq method determination E Rotor-Gene 6000 real-time rotary analyzer, Software version 1.7 (Build 87) 
Outlier identification and disposition E Outliers due to pipetting error were removed 
Results of NTCs E See Section A.1 
Justification of number and choice of 
reference genes E See Section 2.2.5 
Description of normalisation method E See Section 2.2.5 
Number and concordance of biological 
replicates D 
 Number and stage (RT or qPCR) of technical 
replicates E 3 qPCR technical repeats 
Repeatability (intra-assay variation) E See Section A.1 
Reproducibility (inter-assay variation, %CV) D 
 Power analysis D 
 Statistical methods for result significance E See Section 2.2.5 
Software (source, version) E StatSoft, Inc. (2011). STATISTICA (data analysis software system), version 10. 
Cq or raw data submission using RDML D 
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Table A.2: MIQE qPCR validation. Essential information submitted for each qPCR run: Cq of the NTC, PCR 
efficiency, r
2
 of standard curve and Cq variation at lower limit. 
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rep (mean) (0.990) (0.997) 
 
Run 1 32.49 0.970 0.999 1.34 
Run 2 34.88 1.06 0.993 1.08 
Run 3 31.9 0.950 0.999 1.21 
Run 4 32.78 0.970 0.999 1.23 
Run 5 33.8 0.960 0.999 1.18 
Run 6 32.05 0.960 0.999 1.19 
Run 7 35.69 0.990 0.996 1.20 
Run 8 37.33 1.06 0.996 1.33 
Run 9 35.67 0.990 0.994 1.21 
     
TGFB2 (mean) (1.01) (0.996) 
 
Run 10 31.67 1.06 0.990 1.31 
Run 11 31.97 0.940 0.998 1.28 
Run 12 33.39 0.950 0.997 1.28 
Run 13 31.52 0.980 0.997 1.16 
Run 14 28.24 1.08 0.998 1.45 
Run 15 33.68 1.06 0.995 1.41 
Run 16 35.67 1.04 0.997 1.22 
 
A.1. qPCR runs. Essential information submitted for each qPCR run: standard curves (blue) with 
slope and y-intercept, linear dynamic range, evidence for limit of detection, results of NTCs 
(red), repeatability and specificity. 
qPCR run 1 
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qPCR run 2 
 
qPCR run 3 
 
qPCR run 4 
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qPCR run 5 
 
 
qPCR run 6 
 
qPCR run 7 
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qPCR run 8 
 
qPCR run 9 
 
qPCR run 10 
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qPCR run 11 
 
qPCR run 12 
 
qPCR run 13 
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qPCR run 14 
 
qPCR run 15 
 
qPCR run 16 
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Appendix B: PCR thermocycling parameters 
B.1. PCR amplification of 97-bp 6xHis TEV 
Temperature (°C) Time (s) Cycles 
95 90 1 
95 30  
59 30 5 
72 60  
95 30  
67 30 25 
72 30  
72 300 1 
B.2. PCR amplification of 781-bp BFDV AFG3-ZA cp, 658-bp BFDV AFG3-ZA ΔN40 cp and 673-bp 
BFDV tco AFG3-ZA ΔN40 cp 
Temperature (°C) Time (s) Cycles 
95 90 1 
95 30  
55 30 5 
72 120  
95 30  
61 30 25 
72 120  
72 300 1 
B.3. PCR amplification of 796-bp BFDV BKS1ZA_84 cp 
Temperature (°C) Time (s) Cycles 
95 180 1 
95 15  
50 15 5 
72 120  
95 15  
56 15 25 
72 120  
B.4. PCR amplification of 959-bp rcbs1-cTP BFDV BKS1ZA_84 cp 6xHis 
Temperature (°C) Time (s) Cycles 
95 180 1 
95 15  
52 15 30 
72 120  
B.5. PCR amplification of 814-bp BFDV BKS1ZA_84 cp 6xHis SEKDEL, 860-bp LPH BFDV 
BKS1ZA_84 cp 6xHis SEKDEL and an 840-bp LPH BFDV BKS1ZA_84 cp 6xHis 
Temperature (°C) Time (s) Cycles 
95 180 1 
95 15  
55 15 30 
72 120  
B.6. PCR amplification of 1-kb BeYDV gene fragment 
Temperature (°C) Time (s) Cycles 
95 90 1 
95 30  
 139 
54 30 30 
72 60  
B.7. PCR amplification of 900-bp BFDV rep fragment 
Temperature (°C) Time (s) Cycles 
94 300 1 
94 30  
65 30 30 
72 60  
72 300 1 
B.8. PCR amplification of 421-bp BK1ZA_84 N9 PstI mutant 
Temperature (°C) Time (s) Cycles 
95 180 1 
95 30  
55 30 30 
72 120  
B.9. PCR amplification of 265-bp BFDV BKS1ZA_84 rep SacI mutant and 239-bp BFDV BKS1ZA_84 
rep PstI mutant 
Temperature (°C) Time (s) Cycles 
95 180 1 
95 15  
55 15 30 
72 45  
B.10. PCR amplification of 504-bp BFDV BKS1ZA_84 rep SpeI mutant 
Temperature (°C) Time (s) Cycles 
95 180 1 
95 15  
55 15 30 
72 60  
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